Clinical Practice Guideline

Number 18

Smoking Cessation



Clinical Practice Gu

Smoking Cessation

U.S. Department of Health and Human Services
Public Health Service
Agency for Health Care Policy and Research
Centers for Disease Control and Prevention

The Agency for Health Care Policy and Research (AHCPR) was established in December 1989 under Public Law 101–239 (Omnibus Budget Reconciliation Act of 1989) to enhance the quality, appropriateness, and effectiveness of health care services and access to these services. AHCPR carries out its mission by conducting and supporting general health services research, including medical effectiveness research, facilitating development of clinical practice guidelines, and disseminating research findings and guidelines to health care providers, policymakers, and the public.

The legislation also established within AHCPR the Office of the Forum for Quality and Effectiveness in Health Care (the Forum). The Forum has primary responsibility for facilitating the development, periodic review, and updating of clinical practice guidelines. The guidelines will assist practitioners in the prevention, diagnosis, treatment, and management of clinical conditions.

The Centers for Disease Control and Prevention (CDC) promotes health and quality of life by preventing and controlling disease, injury, and disability. In acknowledgment of the important role clinical practice guidelines can play in reduction of tobacco use, CDC has collaborated with AHCPR as a partner in the development of this *Clinical Practice Guideline*.

Guidelines are available in formats suitable for health care practitioners, the scientific community, educators, and consumers. AHCPR invites comments and suggestions from users for consideration in development and updating of future guidelines. Please send written comments to Director, Office of the Forum for Quality and Effectiveness in Health Care, AHCPR, Willco Building, Suite 310, 6000 Executive Boulevard, Rockville, MD 20852.

Clinical Practice Guideline

Number 18

Smoking Cessation

Smoking Cessation Guideline Panel

Michael C. Fiore, MD, MPH (Panel Chair)
William C. Bailey, MD
Stuart J. Cohen, EdD
Sally Faith Dorfman, MD, MSHSA
Michael G. Goldstein, MD
Ellen R. Gritz, PhD
Richard B. Heyman, MD
John Holbrook, MD
Carlos Roberto Jaen, MD, PhD
Thomas E. Kottke, MD, MSPH
Harry A. Lando, PhD
Robert Mecklenburg, DDS, MPH
Patricia Dolan Mullen, DrPH
Louise M. Nett, RN, RRT
Lawrence Robinson, MD, MPH
Maxine L. Stitzer, PhD
Anthony C. Tommasello, MS
Louise Villejo, MPH, CHES
Mary Ellen Wewers, PhD, RN

U.S. Department of Health and Human Services
Public Health Service
Agency for Health Care Policy and Research
Centers for Disease Control and Prevention

AHCPR Publication No. 96-0692
April 1996

Guideline Development and Use

Guidelines are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical conditions. This guideline was developed by a private-sector panel convened by the Agency for Health Care Policy and Research (AHCPR) and the Centers for Disease Control and Prevention (CDC). The panel employed an explicit science-based methodology and expert clinical judgment to develop specific statements on smoking cessation.

Extensive literature searches were conducted, and critical reviews and syntheses were used to evaluate empirical evidence and significant outcomes. Peer review was undertaken to evaluate the reliability and utility of the guideline in clinical practice. The panel's recommendations are primarily based on the published scientific literature. When the scientific literature was incomplete or inconsistent in a particular area, the recommendations reflect the professional judgment of panel members and consultants.

The guideline reflects the state of knowledge, current at the time of publication, on effective and appropriate care. Given the inevitable changes in the state of scientific information and technology, periodic review, updating, and revision will be done.

We believe that this AHCPR and CDC-assisted clinical practice guideline will make positive contributions to the quality of care in the United States. We encourage practitioners and patients to use the information provided in the guideline. The recommendations may not be appropriate for use in all circumstances. Decisions to adopt any particular recommendation must be made by the practitioner in light of available resources and circumstances presented by individual patients.

Clifton R. Gaus, ScD
Administrator
Agency for Health Care Policy and Research

David Satcher, MD, PhD
Director
Centers for Disease Control and Prevention

Publication of this guideline does not necessarily represent endorsement by the U.S. Department of Health and Human Services.

For sale by the U.S. Government Printing Office
Superintendent of Documents, Mail Stop: SSOP, Washington, DC 20402-9328
ISBN 0-16-048610-6

Abstract

This guideline contains strategies and recommendations designed to assist clinicians, smoking cessation specialists, and health care administrators/insurers/purchasers in identifying tobacco users and supporting and delivering effective smoking cessation interventions. These recommendations were made as a result of an exhaustive and systematic review and analysis of the scientific literature. The primary analytic technique used was meta-analysis. The strength of evidence that served as the basis for each recommendation is clearly indicated in the guideline. Public testimony and a peer review were also part of the guideline's development process, as well as a notice in the *Federal Register* inviting review. The guideline's principal findings are:

- Every person who smokes should be offered smoking cessation treatment at every office visit.
- Clinicians should ask and record the tobacco-use status of every patient.
- Cessation treatments even as brief as 3 minutes a visit are effective.
- More intense treatment is more effective in producing long-term abstinence from tobacco.
- Nicotine replacement therapy (nicotine patches or gum), clinician-delivered social support, and skills training are particularly effective components of smoking cessation treatment.[a]
- Health care systems should make institutional changes that result in the systematic identification of, and intervention with, all tobacco users at every visit.

The guideline proposes strategies for carrying out each of its specific recommendations. For clinicians, these recommendations are (1) systematically identify tobacco users and document their status; (2) strongly urge all smokers to quit; (3) identify smokers willing to make a quit attempt; (4) aid the patient in quitting by helping with a quit plan, offering nicotine replacement therapy, giving advice, and providing supplementary information; and (5) schedule followup contact. Recommendations for smoking cessation specialists are (1) assess the smoker who has entered an intervention program; (2) use a variety of clinical specialists; (3) ensure that the program is sufficiently intensive; (4) use a variety of program formats; (5) include effective counseling techniques; (6) target the smoker's motivation to quit; (7) provide relapse prevention intervention; (8) offer nicotine replacement therapy; and (9) arrange followup contact. Recommendations for health insurance purchasers and health care

[a] As this guideline went to press, nicotine nasal spray was approved for use in the United States by the Food and Drug Administration, joining the nicotine patch and gum as effective available interventions.

administrators are (1) consider making tobacco assessment, counseling, and treatment a contractual obligation of the insurers and providers that sell services; and (2) ensure that institutional changes to promote smoking cessation interventions are universally implemented.

Fiore MC, Bailey WC, Cohen SJ, et al. *Smoking Cessation.* Clinical Practice Guideline No 18. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 96-0692. April 1996.

Acknowledgments

Many organizations and individuals made significant contributions during the development of this guideline. Although they are too numerous to mention here, the Contributors section lists individual consultants, peer reviewers, and support staff. This guideline would not have been possible without their collaborative efforts.

All persons, organizations, and agencies with an interest in the smoking cessation guideline were invited to participate at a public meeting held in Bethesda, Maryland, on November 9, 1994. The panel gratefully acknowledges the valuable input received during that session.

The panel gratefully acknowledges the extraordinarily supportive efforts of Ernestine W. Murray, RN, MAS, panel project officer from the Office of the Forum for Quality and Effectiveness in Health Care, Agency for Health Care Policy and Research (AHCPR). We also wish to thank Cheryl Campbell of Technical Resources International, Inc., and Sharon Sokoloff, PhD, of Mikalix and Company for their collaboration and cooperation with this project.

The panel particularly thanks the three key consultants in this project: Timothy Baker, PhD, Senior Scientific Advisor; Victor Hasselblad, PhD, Statistical Methodologist; and David Schriger, MD, MPH, Methodologist.

Finally, the panel extends its gratitude and appreciation to the Wisconsin and Alabama staff members for their tireless efforts in bringing this project to completion. In particular, we thank David Wetter, PhD, Project Director; Connie Kohler, PhD, Project Co-Director; Lisa Wetter, Project Manager; Kathleen Reardon, Project Co-Manager; and Sarah Trost, Project Co-Manager.

Contents

Executive Summary 1

1. Overview 5
Rationale for Guideline Development 5
Organization of the Guideline and Other Products 6
Guideline Development Methodology 8
Introduction 8
Topics Included in the Guideline 9
Guideline Development Process 9
Search and Review of the Literature 9
Meta-Analytic Techniques 12
Strength of Evidence 13
Interpretation of Meta-Analysis Results 13
How To Read the Data Tables 14
Caveats to Recommendation Use 16
Eliciting and Addressing Public Opinion 17
External Review of the Guideline 17

2. Recommendations for Three Target Audiences 19
Primary Care Clinicians 19
Background 19
Training Clinicians To Intervene With Their Patients Who Smoke . . 20
Recommendations for Primary Care Clinicians 21
Tobacco Cessation Specialists and Programs 23
Background 23
Recommendations for Tobacco Cessation Specialists and Programs 26
Health Care Administrators, Insurers, and Purchasers 26
Background 26
Cost-Effectiveness of Smoking Cessation Interventions 27
Recommendations for Health Care Administrators, Insurers, and Purchasers 29

3. Evidence 35
Background 35
Screen for Tobacco Use 38
Identifying Smokers: Impact on Clinical Intervention 38
Identifying Smokers: Impact on Smoking Cessation 38
Advice To Quit Smoking 40
Specialized Assessment 40
Interventions 42
Type of Clinician 42

Treatment Formats 43
Efficacy of Self-Help Treatment Alone 44
Intensity of Person-to-Person Clinical Intervention 46
Content of Smoking Cessation Interventions 47
Person-to-Person Treatment: Duration and Number of Sessions . . . 50
Smoking Cessation Pharmacotherapy 52
Followup Assessment and Procedures 60
Reimbursement for Smoking Cessation Treatment 61

4. Promoting the Motivation To Quit and Preventing Relapse 63
Promoting the Motivation To Quit 63
Relapse Prevention 63
Minimal Practice 64
Prescriptive Interventions 65

5. Special Populations and Topics 67
Background 67
Gender 67
Racial and Ethnic Minorities 67
Pregnancy 69
Hospitalized Smokers 71
Efficacy of Inpatient Hospital Smoking Cessation Treatment 72
Smokers With Psychiatric Comorbidity 72
Weight Gain After Smoking Cessation 74
Recommendations To Address Weight Gain 75
Smokeless Tobacco Use 76
Children and Adolescents: Primary Prevention of Tobacco Addiction . 77
Prevention of Tobacco Use 77
Tobacco Use Cessation in Children and Adolescents 79

References 81

Glossary 91

Contributors 97

Attachment 113

Index 123

Tables

1. Relation between maternal smoking and low birth weight in infants 14
2. Efficacy of and cessation rates for various durations of treatment 15
3. Analyzed treatment and assessment strategies 36

4. Impact of having a smoking status identification system in place on rates of clinician intervention with their patients who smoke 39
5. Impact of having a smoking status identification system in place on the rates of cessation among patients who smoke..... 39
6. Efficacy of advice to quit by a clinician..... 41
7. Variables associated with lower cessation rates 41
8. Efficacy of and estimated cessation rates for interventions delivered by various types of providers 43
9. Efficacy of and estimated cessation rates for various formats 44
10. Efficacy of and cessation rates for various types of self-help formats when used alone 45
11. Efficacy of multiple types of self-help materials 46
12. Efficacy of and cessation rates for various intensity levels of person-to-person contact 47
13. Efficacy of and cessation rates for various types of content relative to no-contact arms 49
14. Efficacy of and cessation rates for various durations of person-to-person treatment 52
15. Efficacy of and cessation rates for number of person-to-person treatment sessions 52
16. Summary of nicotine patch meta-analyses efficacy results 54
17. Summary of nicotine gum meta-analyses 57
18. Efficacy of counseling intervention with pregnant smokers 71
19. Efficacy of inpatient smoking cessation treatment 73

Strategies

Strategies for the Primary Care Clinician

1 Ask—systematically identify all tobacco users at every visit..... 22
2. Advise—strongly urge all smokers to quit..... 22
3. Identify smokers willing to make a quit attempt 23
4. Assist—aid the patient in quitting 24
5. Arrange—schedule followup contact..... 25

Strategies for the Tobacco Cessation Specialist

1. Findings relevant to the specialist's implementation of intensive cessation programs..... 27
2. Recommendations regarding intensive smoking cessation programs..... 28

Strategies for Health Care Administrators, Insurers, and Purchasers

1. Implement a tobacco-user identification system in every ..... clinic..... 30

2. Provide education, resources, and feedback to promote provider intervention . . . 31
3. Dedicate staff to provide smoking cessation treatment and assess the delivery of this treatment in staff performance evaluations. . . . 31
4. Promote hospital policies that support and provide smoking cessation services . . . 32
5. Include smoking cessation treatments (both pharmacotherapy and counseling), identified as effective in this guideline, as paid services for all subscribers of health insurance packages . . . 32
6. Reimburse fee-for-service clinicians for delivery of effective smoking cessation treatments and include these interventions among the defined duties of salaried clinicians . . . 33

General Strategies

1. Common elements of problem-solving/skills-training smoking cessation treatments . . . 50
2. Common elements of supportive smoking cessation treatments . . . 51
3. Suggestions on the clinical use of the nicotine patch . . . 55
4. Clinical guidelines for prescribing nicotine replacement products . 56
5. Suggestions for the clinical use of nicotine gum . . . 58
6. Components of clinical interventions designed to enhance motivation to quit smoking: the "4 Rs" . . . 64
7. Components of minimal practice relapse prevention interventions . . . 65
8. Components of prescriptive relapse prevention interventions . . . 66
9. Clinical issues when assisting a pregnant patient in smoking cessation . . . 71
10. Clinician statements to help a patient prepare for, and cope with, postcessation weight gain . . . 76
11. Suggested interventions for clinicians to prevent the initiation of tobacco use . . . 78

Figures

1. Model for tobacco cessation evidence . . . 7
2. Guideline development process . . . 10

Executive Summary

Smoking cessation interventions offer clinicians and health care providers their greatest opportunity to improve the current and future health of all Americans (U.S. Department of Health and Human Services [DHHS], 1989). It is essential, therefore, that clinicians, smoking cessation specialists, health care administrators, and health care purchasers take an active role in reducing the prevalence of tobacco use. One way to do this is through the support and delivery of effective smoking cessation interventions.

This guideline is a product of the Smoking Cessation Guideline Panel (the "panel"), which was charged by AHCPR to identify effective, experimentally validated smoking cessation treatments and practices. Through a systematic and exhaustive review and analysis of the available scientific research literature, the panel developed practice recommendations that address three principal audiences: the broad range of primary care clinicians, for whom smoking cessation is just one of many clinical activities; smoking cessation specialists, for whom smoking cessation treatment is a major professional activity; and health care administrators/insurers/purchasers. The last group can influence smoking cessation by supporting the implementation and reimbursement of effective cessation activities.

Major findings and recommendations of this guideline can be summarized in six points:

1. Effective smoking cessation treatments are available, and every patient who smokes should be offered one or more of these treatments.

2. It is essential that clinicians determine and document the tobacco-use status of every patient treated in a health care setting.

3. Brief cessation treatments are effective, and at least a minimal intervention should be provided to every patient who uses tobacco.

4. A dose–response relation exists between the intensity and duration of a treatment and its effectiveness. In general, the more intense the treatment, the more effective it is in producing long-term abstinence from tobacco.

5. Three treatment elements, in particular, are effective, and one or more of these elements should be included in smoking cessation treatment:

   - Nicotine replacement therapy (nicotine patches or gum)

   - Social support (clinician-provided encouragement and assistance)

- Skills training/problem solving (techniques on achieving and maintaining abstinence)

6. Effective reduction of tobacco use requires that health care systems make institutional changes that result in systematic identification of, and intervention with, all tobacco users at every visit.

The vast majority of data available to the panel came from studies of interventions with smokers. Therefore, in most sections of the guideline, the panel specifically refers to "smoking" or "smoking cessation." However, panel consensus is that many, if not all, recommendations in this guideline pertain to assessment and treatment of all tobacco users. Therefore, the panel encourages clinicians and other individuals providing cessation services to use these recommendations to guide their treatment of smokeless tobacco users as well as cigar and pipe users.

The six major findings listed above should be important for all three professional target audiences. However, some findings have special relevance to certain audiences, and Chapter 2 of this guideline distills findings for the three audiences. For instance, the smoking cessation specialist is directed to the section entitled Tobacco Cessation Specialists and Programs, where findings regarding the effective constituents of intensive cessation treatments are summarized.

Many guideline findings are highly relevant to primary care and other clinicians. One important finding for this audience is that virtually all types of clinicians—physicians, nurses, nurse practitioners, dentists, psychologists, pharmacists, respiratory and physical therapists, physician assistants, and many others—can effectively deliver tobacco cessation treatments (Cohen, Stookey, Katz, et al., 1989; Dix Smith, McGhan, Lauger, 1995; Hall, Tunstall, Rugg, et al., 1985; Hollis, Lichtenstein, Vogt, et al., 1993; National Heart, Lung, and Blood Institute, 1991; Ockene, Kristeller, Goldberg, et al., 1991; Wewers, Bowen, Stanislaw, et al., 1994). Also emphasized is the fact that very brief treatments, such as firm advice to quit smoking, can effectively boost long-term cessation. In addition, clinicians are offered a series of specific steps to follow to intervene effectively with their patients who use tobacco (see the first section in Chapter 2, Primary Care Clinicians).

The attention of health care administrators/insurers/purchasers is directed to the third section of Chapter 2, which highlights the importance of institutional changes that ensure that health care systems identify and intervene with every patient who uses tobacco. This unique emphasis reflects panel recognition of the increasing role of managed care in health care delivery. This recognition requires the guideline to move beyond a traditional focus on the clinician and to address the potential of health care delivery organizations to ensure that tobacco users are reliably identified and treated.

The most significant message of this guideline has great relevance to anyone concerned with health care. This guideline challenges clinicians and others to change the nature of clinical practice to address universally and systematically the leading preventable cause of illness and death in our society (DHHS, 1988; 1989).

Tobacco use has an enormous impact on health in the United States. Approximately 25 percent of adult Americans smoke cigarettes, yet smokers enter and exit the health care system each day without receiving treatment for this important health risk. Clinicians have unique access to individuals who use tobacco—more than 70 percent of smoking Americans visit a clinician each year. Yet half of these individuals report having never been urged to quit by a clinician, and more than 70 percent now say they want to quit and have made at least one unsuccessful prior quit attempt. American clinicians are missing a unique opportunity to help their patients who use tobacco. This guideline offers a simple and flexible set of strategies that ensure that all patients who use tobacco are offered motivational interventions and effective treatments to overcome this powerful addiction.

1 Overview

Rationale for Guideline Development

The Agency for Health Care Policy and Research (AHCPR) convenes expert panels to develop clinical guidelines for health care practitioners. AHCPR determines the need for guidelines for a given condition based on several factors, including prevalence, related morbidity and mortality, economic burden imposed by the condition, variation in clinical practice related to the condition, availability of methods for improvement of care, and availability of data on which to base recommendations for care.

Tobacco use has been cited as the chief avoidable cause of illness and death in our society, responsible for more than 400,000 deaths in the United States each year. Smoking is a known cause of cancer, heart disease, stroke, and chronic obstructive pulmonary disease (Centers for Disease Control [CDC], 1993a). Tobacco use is surprisingly prevalent, given the health dangers it presents and the public's awareness of those dangers (DHHS, 1989). Recent estimates are that 25 percent of Americans smoke (CDC, 1994). Moreover, smoking prevalence among adolescents appears to be rising, with more than 3,000 children and adolescents becoming regular users of tobacco each day. This ensures that a new generation of Americans will be addicted to nicotine and at risk for the host of harmful consequences of tobacco use. Tobacco use is not only dangerous to individuals, it yields staggering societal costs as well. The estimated smoking-attributable cost for medical care in 1993 is $50 billion, and the cost of lost productivity and forfeited earnings due to smoking-related disability is estimated at $47 billion per year (Herdman, Hewitt, and Laschober, 1993).

Despite the tragic health consequences of smoking, physicians and other health care clinicians often fail to assess and treat tobacco use consistently and effectively. For instance, only half of smokers seeing a primary care physician in the past year report being asked about their smoking (Robinson, Laurent, and Little, 1995), and only a minority of smokers report being advised to quit (CDC, 1993b). This failure to assess and intervene exists in the face of substantial evidence that even brief smoking cessation treatments can be effective (e.g., Fiore, Smith, Jorenby, et al., 1994, Glynn and Manley, 1990; Russell, Wilson, Taylor, et al., 1979).

The evidence reviewed above suggests that tobacco use presents a rare confluence of circumstances: (1) a highly significant health threat, (2) a disinclination among clinicians to intervene consistently, and (3) the presence of effective, preventive interventions. The last point is buttressed by overwhelming evidence that smoking cessation interventions, if delivered in a timely and effective manner, greatly reduce the smoker's risk of suffering from smoking-related disease (DHHS, 1990). Indeed, it is difficult to

identify a condition in developed countries that presents such a mix of lethality, prevalence, and neglect, despite effective and readily available interventions.

Clinicians know that tobacco use is a serious health problem. But significant barriers exist that interfere with clinicians' assessment and treatment of smokers. Many clinicians lack knowledge about how to identify smokers quickly and easily, which treatments are efficacious, how such treatments can be delivered, and the relative efficacies of different treatments. Clinicians may fail to intervene because they are unaware of the availability of efficacious, brief treatments that are ideal for clinical settings. Or, clinicians may fail to intervene because of inadequate clinic or institutional support for routine assessment and treatment of tobacco use.

This guideline addresses these barriers on the basis of a careful evaluation and synthesis of relevant existing scientific literatures. The guideline comprises specific evidence-based recommendations to guide clinicians and smoking cessation specialists in their tobacco intervention efforts. Additional specific recommendations guide insurers, managed care providers, and other health care administrators in their efforts to develop and implement institutional supports for reliable assessment and treatment of tobacco use. The National Cancer Institute (NCI) projects that if 100,000 physicians were to help 10 percent of their patients who smoke to stop each year, the number of smokers in the United States would drop by an additional 2 million people annually (Fiore, Pierce, Remington, et al., 1990). Even greater cessation would occur if other types of health care clinicians (e.g., nurses) would also intervene with their patients who smoke. This guideline, therefore, is a potentially powerful tool in the mission to curtail the greatest preventable cause of death and disability in the United States today.

Organization of the Guideline and Other Products

This guideline is divided into five chapters. Chapter 1, Overview, provides an overview and rationale for the guideline, as well as a detailed description of the methodology used to review the scientific literature and develop the guideline.

Chapter 2, Recommendations for Three Target Audiences, is directed at the three key audiences for this guideline—primary care clinicians, smoking cessation specialists, and health care delivery administrators, insurers, and purchasers. These sections are designed as stand-alone guides for implementing the relevant components of the guideline.

Chapter 3, Evidence, presents the evidentiary basis for the guideline recommendations. The sections within this chapter are organized around the Model for Tobacco Cessation Evidence (Figure 1); each section describes the scientific data that support the components of the evidence model. The section on Screen for Tobacco Use provides the scientific evidence that forms the basis for recommendations regarding the identification of tobacco users. This section corresponds to the "Screen for Tobacco Use" box in Figure 1.

Figure 1. Model for tobacco cessation evidence



The section on Advice to Quit Smoking characterizes the evidence that supports the importance of clinicians advising every tobacco user to quit. This section corresponds to the "Advise" box in Figure 1. For those smokers who are willing to make a quit attempt, the section on Specialized Assessment addresses the formal assessment of smokers prior to a cessation attempt. This section corresponds to the "Assess" box of Figure 1. The section on Interventions, the longest section of the chapter, provides the scientific evidence evaluating various characteristics and types of tobacco cessation interventions. This corresponds to the "Intervene" box of Figure 1. Finally, the evidence supporting the importance of followup interventions after a smoker has quit is described in the section on Followup Assessment and Procedures. This corresponds to the "Followup Procedures" box in Figure 1.

Chapter 4 of the guideline, Promoting the Motivation to Quit and Preventing Relapse, addresses two issues not covered in the previous chapters. The first section addresses strategies to motivate smokers not willing to make a quit attempt at this time. The second section provides recommendations to prevent relapse among individuals trying to quit.

Chapter 5, Special Populations and Topics, provides specific information on specific populations (women, racial and ethnic minorities, hospitalized patients, children and adolescents) and special topics (weight gain upon quitting, smokeless tobacco use) not otherwise addressed in the guideline. These special populations and topics are not identified in Figure 1.

In addition to this *Clinical Practice Guideline*, a larger document, the *Smoking Cessation Guideline Technical Report* (the "technical report"), contains more detailed information on the methodology employed in developing this guideline. This technical report may be obtained by contacting the National Technical Information Service. Additionally, two quick reference guides are available, as well as a consumer guide.

Guideline Development Methodology

Introduction

The panel attempted, through the recommendations in the guideline, to provide clinicians with effective strategies to assist patients who use tobacco. Recommendations were influenced by two goals. The first was to be as clear as possible in identifying those treatment strategies found to be efficacious. The second was that recommendations be made in such a way that they could be implemented across diverse clinical settings and patient populations.

The guideline is based on systematic reviews of the available scientific literature. The reviews involved a comprehensive examination of literature published from 1976 through 1994. The panel identified randomized controlled trials as the strongest level of evidence for evaluation of treatment efficacy. Thus, evidence derived from randomized controlled trials serves as the basis for almost all recommendations contained in this guideline. However, the panel occasionally made recommendations in the absence of randomized controlled

trials. It did so when faced with an important clinical practice issue for which considerable suggestive evidence existed. The panel clearly identified the level or strength of evidence that served as the basis for each of its recommendations.

Topics Included in the Guideline

The panel identified tobacco use as the targeted condition and all tobacco users as the clinical population of interest. All tobacco cessation interventions were examined, as well as interventions aimed at modifying both clinician and health care delivery system behavior.

Interventions for the primary prevention of tobacco use were not examined in detail (see the Section in Chapter 5, Children and Adolescents: Primary Prevention of Tobacco Addiction) with the exception of interventions directly relevant to clinical practice. Because of the importance and complexity of the primary prevention of tobacco initiation, the panel recommended that primary prevention be addressed in a separate clinical practice guideline. In addition, community-level interventions (e.g., mass media campaigns) that were not directly relevant to primary care practice settings were not addressed.

This guideline was designed for three primary audiences: primary care clinicians, smoking cessation specialists, and health care administrators/ insurers/purchasers. The guideline was also designed to be appropriate for use in a wide variety of practice settings including private practice, health maintenance organizations, public health department clinics, hospitals, school or work site clinics, and so on.

Guideline Development Process

This guideline was developed over 2 years beginning in late 1993. A distillation of the guideline development process is illustrated in Figure 2.

Search and Review of the Literature

The literature was reviewed systematically by (a) establishing a priori criteria for relevant studies, (b) reviewing abstracts and articles selected by computer searches and by scanning bibliographies, (c) compiling and reviewing the full articles, (d) compiling evidence tables summarizing these articles, and (e) conducting meta-analyses where possible.

Inclusion Criteria. Approximately 3,000 articles were reviewed to identify the literature appropriate for evaluation. The appropriateness of an article was determined by applying the criteria for inclusion established a priori by the panel. The criteria were that the article (a) reported the results of a randomized, controlled trial of a tobacco-use cessation intervention, (b) provided followup results at a timepoint at least 5 months after the quit date, (c) was published in a peer-reviewed journal, (d) was published between 1975 and 1994, and (e) was published in English. As a result of this review, more than 300 articles were included in our final database. A list of these references

Figure 2. Guideline development process



may be obtained by contacting AHCPR and is available for online retrieval (see Availability of Guidelines on inside back cover for more information).

When individual authors produced multiple articles meeting inclusion criteria, each article was carefully screened to ensure that it, in fact, represented an independent trial. Where two articles appeared to report data from the same group of subjects, only the most complete article was used to generate data for the analyses.

In some cases, panel conclusions were based partly on the results of previously published meta-analyses. Published meta-analyses were used when they (a) synthesized data from related sets of randomized clinical trials of smoking cessation methods, (b) were published in peer-reviewed journals, (c) were published between 1975 and 1994, and (d) were published in English.

Selection of Evidence. Only published, peer-reviewed randomized controlled trials were considered to provide strong evidence in support of guideline recommendations. This decision was based on the judgment that randomized controlled trials are the clearest scientific method for judging comparative efficacy. The panel made this decision recognizing the limitations of randomized controlled trials, particularly considerations of generalizability with respect to patient selection and treatment quality.

Preparation of Evidence Tables. To evaluate the literature systematically, three literature reviewers independently read and scored each article that met inclusion criteria. The reviewers then met and compared coding. Any discrepancies that could not be resolved were adjudicated by the project director, panel chair, and/or senior scientific consultant. The data were then compiled and used in relevant analyses.

Analysis of Treatment Effect. The success of a treatment studied in a randomized controlled trial can be reported in a number of ways. For instance, what percentage of patients randomized to a treatment successfully quit? This question can be answered by an intent-to-treat analysis that uses the number of patients who quit smoking (regardless of whether they remained in the study) as the numerator and the number randomized to the treatment as the denominator.

A modified intent-to-treat analysis was generally used in this guideline. The denominator for this analysis was the number of patients randomized to the treatment, but in most studies, the numerator was the number of abstinent patients who were contacted at followup. In other words, smokers who could not be contacted at followup were not considered abstinent and were not included in the numerator. This modification was made because few studies presented sufficient data to permit calculation of true intent-to-treat numbers, whereas many provided enough information to permit calculation of the modified percentage.

Outcome Data. A study was required to provide outcome data with followup at least 5 months after the designated quit day. Five months was chosen to balance the needs for (a) a large pool of studies for meta-analyses and (b) the desire to examine only clinically important outcomes (i.e., long-term cessation). These long-term outcome data provided the basis of virtually all cessation analyses contained in this guideline. (The one exception is that the

meta-analysis of cessation treatments in pregnant women contained somewhat shorter followup periods.) Panel staff also coded the presence of biochemical confirmation of self-reported abstinence. In most major meta-analyses, panel staff investigated whether studies using biochemical confirmation yielded different results than did studies without this design feature. Including or excluding studies that lacked biochemical verification had little impact on meta-analysis results. Therefore, meta-analyses presented in the guideline reflect a pooling of studies with and without biochemical confirmation.

Meta-Analytic Techniques

Methodology and Limitations. The principal analytic technique used in this guideline was meta-analysis. This statistical technique estimates the impact of a treatment or variable across a set of related investigations. A complete and detailed review of the meta-analytic methods used in the guideline can be found in the technical report. The primary meta-analytic model used in the guideline was logistic regression using random effects modeling. The panel methodologists chose to employ random effects modeling, assuming that both the subject populations and the treatment elements analyzed would vary from study to study (e.g., "general problem-solving" counseling might be done somewhat differently at two different sites). Random effects modeling is well suited to accommodate such variation among studies (DerSimonian and Laird, 1986).

The initial step in meta-analysis was the selection of studies that were relevant to the treatment characteristic being evaluated. After relevant studies were identified (e.g., those that contained a self-help intervention if self-help treatments were being evaluated), panel staff reviewed the studies to ensure that they passed screening criteria. Some screening criteria were general (e.g., appropriate randomization), whereas other criteria were specific to the type of treatment characteristic evaluated (e.g., in the analysis of clinicians, screening ensured that differences in clinicians were not confounded by differences in pharmacotherapy status). The technical report contains lists and descriptions of all screening criteria.

Several factors can compromise the internal validity of the meta-analyses. For example, publication biases (particularly the tendency to publish only those studies with positive findings) may result in biased summary statistics. In addition, either the magnitude or the significance of the findings of the meta-analyses may be influenced by factors such as the frequency with which treatments occurred in the data set, and by the extent to which treatments co-occurred with other treatments. All else being equal, a treatment that occurs infrequently in the data set is less likely to be found significant than a more frequently occurring treatment. And, when two treatments co-occur frequently in the same groups of subjects, it is difficult to apportion statistically the impact of each.

Threats to the external validity of the meta-analysis relate primarily to the generalizability of the study populations. However, conducting separate meta-analyses based on the populations under study yielded generally similar

results across a variety of treatment dimensions. For instance, meta-analyses that involved subjects seeking out smoking cessation treatment ("self-selected") yielded results similar to meta-analyses in which subjects received treatment without taking steps to seek it, such as when it is an integral part of a health care visit ("all-comers"). No other population characteristics (e.g., years smoked, packs per day) were explored in meta-analyses.

In summary, with the exception of the caveats discussed above, the meta-analytic techniques provide a valid synthesis of smoking cessation treatment outcome data and identify treatment features or elements that are effective across a group of related investigations.

Strength of Evidence

Every recommendation made by the panel bears a strength-of-evidence rating that indicates the quality and quantity of empirical support for the recommendation. The three ratings are described below:

A Multiple well-designed randomized clinical trials, directly relevant to the recommendation, yielded a consistent pattern of findings.

B Some evidence from randomized clinical trials supported the recommendation, but the scientific support was not optimal. For instance, either few randomized trials existed, the trials that did exist were somewhat inconsistent, or the trials were not directly relevant to the recommendation. An example of the last point would be the case where trials were conducted using a study population that differed from the target population of the recommendation.

C Reserved for important clinical situations where the panel achieved consensus on the recommendation in the absence of relevant randomized controlled trials.

The panel declined to make recommendations when there was no relevant evidence or the evidence considered was too weak or inconsistent.

Not every evidence statement is used to support a recommendation. Therefore, a recommendation may be directly relevant to only a subset of the evidence statements in the same guideline section. Thus, within a section, some evidence statements may carry different strength ratings than does a particular recommendation.

Interpretation of Meta-Analysis Results

The meta-analyses yielded logistic regression coefficients that were converted to odds ratios. The meaning or interpretation of an odds ratio can be seen most easily by means of an example depicted in a 2 x 2 table. Table 1 contains data showing the relation between maternal smoking and low birth weight in infants. Data are extracted from Hosmer and Lemeshow (1989).

Table 1. Relation between maternal smoking and low birth weight in infants

		Maternal smoking: Yes	Maternal smoking: No	
Low birth weight	Yes	30	29	59
	No	44	86	130
		74	115	189

The odds of a low birth weight infant if the mother smokes are 30:44, or 0.68 to 1. The odds of a low birth weight infant if the mother does not smoke are 29:86, or 0.34 to 1. The odds ratio is thus (30/44)/(29/86) = 2.02 to 1.

Therefore, the odds ratio can be seen roughly as the odds of an outcome on one variable, given a certain status on another variable(s). In the case above, the risk of a low birth weight infant is about double for women who smoke compared with those who do not.

Once odds ratios were obtained from meta-analyses, the statistical methodologist estimated 95 percent confidence intervals around the odds ratios. An odds ratio is only an estimate of a relation between variables. The 95 percent confidence interval presents an estimate of the accuracy of the particular odds ratio obtained. If the confidence interval for a given odds ratio does not include "1," then the odds ratio represents a statistically significant effect at the .05 level. The confidence intervals will generally not be perfectly symmetrical around an odds ratio because of the distributional properties of the odds ratio.

After computing the odds ratios and their confidence intervals, the statistical methodologist then converted the odds ratios to cessation percentages and their 95 percent confidence intervals. Cessation percentages indicate the estimated long-term smoking cessation rate achieved under the tested treatment or treatment characteristic. The cessation percentage results are approximate estimates derived from the odds ratio data (Eddy and Hasselblad, 1992). Therefore, they essentially duplicate the odds ratio results but are presented because their meaning may be clearer for some readers.

How To Read the Data Tables

Table 2 depicts a table of results from one of the meta-analyses reported in this guideline. This table presents results from the analysis of the effects of different durations of treatment (in weeks) on outcome (see the section in Chapter 3, Interventions). In this table, the comparison condition, or "reference group," for determining the impact of different treatment durations, was smokers given brief cessation interventions—ones lasting less than 2 weeks (all sessions were delivered within a 2-week period). The "Estimated odds

Table 2. Efficacy of and cessation rates for various durations of treatment (n = 55 studies)

Duration	Number of arms	Estimated odds ratio (95% C.I.)	Estimated cessation rate (95% C.I.)
< 2 weeks (reference group)	101	1.0	10.4
2 to < 4 weeks	14	1.6 (1.3–2.0)	15.6 (12.9–18.3)
4–8 weeks	12	1.6 (1.2–2.1)	16.1 (12.4 –19.7)
> 8 weeks	15	2.7 (2.2–3.2)	23.8 (20.6–27.1)

ratio" column reveals that treatment groups receiving treatments lasting either 2–4 weeks or 4–8 weeks both had odds ratios of 1.6. In both cases, the odds ratio indicates a significant effect, because the lower boundary of the confidence interval did not include "1." Treatments lasting more than 8 weeks had the largest odds ratio (2.7). This odds ratio means that when a smoker receives long-duration treatments (greater than 8 weeks), in contrast to treatments lasting fewer than 2 weeks, the likelihood is more than doubled that he or she will quit smoking. This effect is significant, because the lower confidence interval boundary (2.2) does not include "1."

The column labeled "Estimated cessation rate" shows the cessation percentages for the various treatment durations. For instance, the reference group conditions (duration less than 2 weeks) in the analyzed data set were associated with a smoking cessation abstinence rate of 10.4 percent. As suggested by the odds ratio data reviewed above, treatment durations lasting 2–8 weeks produced moderate increases in cessation rates (to about 16 percent), whereas the longest treatments (greater than 8 weeks) produced substantial increases (to over 23 percent). The statistical significance of the three longer treatment durations is indicated by the fact that their confidence intervals do not overlap the cessation rate produced by the less-than-2-week (reference group) condition.

The column labeled "Number of arms" lists the number of treatment conditions or groups across all analyzed studies that fell within the various treatment duration categories (e.g., in 15 treatment arms, treatment exceeded 8 weeks). Therefore, this column depicts the number of treatment conditions or groups relevant to each analyzed category.

Two additional factors deserve to be highlighted regarding the data tables in this guideline. First, all outcome data (both odds ratios and cessation rates) are based exclusively on studies that provided long-term followup, defined as quit rates at 5 months or greater followup points. When quit rates were provided for multiple long-term endpoints, efficacy data from the endpoint closest to 6 months were used. Second, all outcome data are based on all studies that met inclusion criteria (see Methodology

and Limitations subsection above). Therefore, the outcome data in the tables include studies with "all-comers" (individuals who did not choose to be part of a smoking cessation intervention) and "self-selected" populations, as well as studies with and without biochemical confirmation. As previously mentioned, there were essentially no differences identified when these comparison populations, or studies with different biochemical confirmation statuses, were analyzed separately. Despite the present results, biochemical confirmation may contribute to the internal validity of controlled clinical trials.

Caveats to Recommendation Use

In applying these guideline recommendations, the reader should note some caveats. First, an absence of studies should not be confused with a proof of lack of efficacy. In certain situations, there was little direct evidence regarding the efficacy of various treatments, and in these cases the panel usually rendered no opinion.

Moreover, the emphasis of this guideline was to identify efficacious interventions, not to rank-order interventions in terms of efficacy. The panel chose not to emphasize comparisons among efficacious interventions for several reasons. First, the most important goal of the analytic process was to identify all of those interventions that are efficacious. Second, selection or use of particular intervention techniques or strategies is usually a function of practical influences: time available, training of the clinician, patient preference, cost, and so on. The panel believed that clinicians should choose from among the efficacious interventions those that are feasible given existing circumstances. An excessive emphasis on relative efficacy might discourage clinicians from using interventions that have a small, but reliable, impact on smoking cessation. Finally, data were often inadequate or unavailable to make adequate statistical comparisons of different types of interventions. For example, although numerous studies have investigated the efficacy of both the nicotine patch and nicotine gum relative to placebo treatments, no published randomized trials directly compared the efficacy of these two pharmacotherapies.

Despite a lack of emphasis on the rank-ordering of interventions, some interventions were so superior to control or no-treatment conditions that the panel clearly identified them as superior to other intervention. For instance, although even minimal person-to-person contact can increase smoking cessation rates over no-treatment conditions, there is little doubt that longer person-to-person interactions have an even greater impact.

Eliciting and Addressing Public Opinion

At the start of the second panel meeting, an open forum was held in Washington, DC, on November 9, 1994, to receive input from the general public. This open forum meeting was publicized in the *Federal Register*. A variety of issues were raised by individuals from many disciplines, including physicians, nurses, and psychologists; professional groups; individual medical consumers; and other concerned parties. Suggestions from the public forum were reviewed and incorporated into the guideline when appropriate.

External Review of the Guideline

The panel and AHCPR invited 155 outside reviewers to peer review the guideline draft. In addition, AHCPR placed a notice in the *Federal Register* inviting individuals to review and comment on the draft guideline. A total of 71 reviewers provided comments. Peer reviewers included clinicians, health care program directors, social workers, counselors, health educators, researchers with clinical experience, consumers, and key personnel at selected Federal agencies (CDC, National Institute on Drug Abuse, NCI, Food and Drug Administration [FDA]) among others. Reviewers were asked to evaluate the guideline based on five criteria: validity, reliability, clarity, clinical applicability, and utility. The reviewers were encouraged to provide additional comments. Comments of the peer reviewers were evaluated by the panel and panel staff and were incorporated into the guideline when appropriate.

2 Recommendations for Three Target Audiences

Primary Care Clinicians

Background

Primary care and other clinicians are uniquely poised to assist patients who smoke, in that they have extraordinary access to this population. At least 70 percent of smokers see a physician each year and more than 50 percent see a dentist (Hayward, Meetz, Shapiro, et al., 1989; Tomar, Husten, and Manley, 1996). Moreover, 70 percent of smokers report that they want to quit and have made at least one self-described serious attempt to quit (CDC, 1994). Finally, smokers cite a physician's advice to quit as an important motivator for attempting to stop (NCI, 1994; Ockene, 1987; Pederson, 1982). The importance of clinical intervention with patients who use tobacco is highlighted by its inclusion as a national health goal in *Healthy People 2000: National Health Promotion and Disease Prevention Objectives* (DHHS, 1991).

Unfortunately, clinicians are not capitalizing fully on this unique opportunity. Only about half of current smokers report having ever been asked about their smoking status or urged to quit (Anda, Remington, Sienko, et al., 1987; CDC, 1993b; Frank, Winkleby, Altman, et al., 1991). Fewer still have received specific advice on how to quit smoking successfully.

Why don't clinicians consistently confront tobacco use among their patients? Some clinicians' reluctance to intervene may be attributed, in part, to time constraints, a perceived lack of skills to be effective in this role, frustration owing to low success rates, or even a belief that smoking cessation is not an important professional responsibility (Jaen, Stange, and Nutting, 1994). Several changes have been proposed to increase clinicians' intervention with smokers: (a) health care delivery practices must change so that smoking cessation interventions are institutionalized, (b) clinicians and their patients must be reimbursed by insurers for smoking cessation counseling and pharmacotherapy, (c) clinicians must adjust their goals so that motivational interventions are offered to smokers who are not yet committed to quitting (Biener and Abrams, 1991; Curry, Wagner, and Grothaus, 1990; Prochaska and Goldstein, 1991), and (d) standards of health care delivery must reflect the health care system's obligation to intervene in a timely and appropriate manner with patients who smoke (Fiore and Baker, 1995; Kottke and Solberg, 1995).

In this section of the guideline, specific recommendations relevant to primary care clinicians (physicians, nurses, dentists, respiratory therapists, etc.) are presented. The goals of these recommendations are clear: to change clinical culture and practice patterns to ensure that every patient who smokes is offered treatment. The recommendations in this section are selected from

among the findings presented in Chapter 3. The recommendations underscore a central theme: It is essential to provide a brief but effective cessation intervention for all tobacco users at each clinical visit. Several observations are relevant to this theme. First, institutional changes in clinical practice are necessary to ensure that all patients who smoke are identified for intervention (see section below on Health Care Administrators, Insurers, and Purchasers). Second, the compelling time limitations on practicing primary care physicians in the United States today (median visit = approximately 12 minutes; Gilchrist, Miller, Gillanders, et al., 1993) often require brief interventions, although more intensive interventions produce greater success. Third, although many smokers are reluctant to seek out intensive cessation programs (Lichtenstein and Hollis, 1992), they nevertheless can receive treatment every time they visit any type of clinician.

Training Clinicians To Intervene With Their Patients Who Smoke

Clinicians must be trained in effective smoking cessation interventions if these guideline recommendations are to be implemented. The importance of training is clear in that clinicians report lack of relevant knowledge as a significant barrier to intervening with their patients who smoke (Cummings, Giovino, Sciandra, et al., 1987; Scott and Neighbor, 1985; Wechsler, Levine, Idelson, et al., 1983).

Training should be directed at clinicians-in-training as well as practicing clinicians. For clinicians-in-training, most disciplines do not currently provide training, or require competency, in smoking cessation interventions. For example, a recent NCI expert panel found that medical schools do not consistently train students in effective smoking cessation interventions (Fiore, Epps, and Manley, 1994). The panel recommended that a specific curriculum devoted to smoking cessation be included as part of each medical student's education. Similar recommendations would be relevant to virtually all other clinical disciplines. Training in smoking inter- vention should not only transmit essential treatment skills but also inculcate the belief that smoking cessation treatment is a standard of good practice (Kottke, Solberg, Brekke, et al., 1992).

Practicing clinicians would also benefit from continuing education that addresses smoking cessation. This guideline recommends that clinicians be reimbursed for smoking cessation treatment and that their intervention activities be tracked. Either of these policies should foster increased interest in smoking cessation training among practicing clinicians.

Several factors would promote the training of clinicians to intervene in smoking cessation activities:

- Inclusion of smoking cessation interventions in the required curricula of all clinical disciplines.

- Inclusion of questions on effective smoking cessation interventions in licensing and certification exams for all clinical disciplines.
- Adoption by specialty societies of a uniform standard of competence in smoking cessation intervention for all members.

Finally, clinicians who smoke should participate in an additional type of education or training—they should enter smoking cessation treatment programs in order to stop smoking permanently. Clinicians have an important role as nonsmoking models for their patients. An encouraging finding has been the dramatic decrease in smoking rates reported among many types of clinicians. In a recent report on tobacco-use prevalence by occupation, the rate of smoking was noted to be 5.5 percent among physicians, 7.4 percent among dentists, 8.7 percent among physical therapists, and 22.0 percent among registered nurses (Nelson, Emont, Brackbill, et al., 1994). All of these prevalence rates are lower than tobacco-use rates in the general population. All clinicians who currently smoke should seek out effective smoking cessation treatments recommended in this guideline.

Recommendations for Primary Care Clinicians

Recommendations for primary care clinicians are based on the evidence described in the first four sections of Chapter 3, as well as on panel opinion. These recommendations assume that office systems will be implemented to institutionalize smoking cessation assessment and intervention (see section on Health Care Administrators, Insurers, and Purchasers). They also are designed to be brief, requiring 3 minutes or less of direct clinician time. Finally, these recommendations are consistent with those produced by NCI (Glynn and Manley, 1990) and the American Medical Association (AMA) (American Medical Association, 1994), as well as others (e.g., Kottke, Solberg, and Brekke, 1990; Mecklenburg, Christen, Gerbert, et al., 1991).

The AHCPR guideline recommendations emphasize the importance of systematically identifying all smokers (see For the Primary Care Clinician: Strategy 1), strongly advising all smokers to quit (see For the Primary Care Clinician: Strategy 2), and determining patients' willingness to make a quit attempt (see For the Primary Care Clinician: Strategy 3). The patient not willing to commit to quitting should receive a motivational intervention to promote subsequent quit attempts (see Chapter 4, Promoting the Motivation to Quit). When the patient is willing to make a quit attempt, primary care clinicians may assist by asking the patient to set a quit date, preparing the patient for the quit date, encouraging nicotine replacement therapy, providing self-help materials, and providing key advice (see For the Primary Care Clinician: Strategy 4). The clinician should refer the patient to intensive treatments when the clinician views such treatments as appropriate (e.g., if the patient has relapsed repeatedly following minimal interventions) or if the patient prefers such treatments (see next section). All patients attempting quitting should have followup contact scheduled (see For the Primary Care Clinician: Strategy 5).

For the primary care clinician:
Strategy 1. Ask—systematically identify all tobacco users at every visit

Action	Strategies for implementation
Implement an office-wide system that ensures that, for EVERY patient at EVERY clinic visit, tobacco-use status is queried and documented.[a]	Expand the vital signs to include tobacco use. ■ Data collected by health care team. ■ Implemented using preprinted progress note paper that includes the expanded vital signs, a vital signs stamp, or, for computerized records, includes an item assessing tobacco-use status. **VITAL SIGNS** Blood Pressure:_____ Pulse:_____ Weight:_____ Temperature:_____ Respiratory Rate:_____ Tobacco Use: Current Former Never (*circle one*) Alternatives to the vital sign stamp are to place tobacco-use status stickers on all patient charts or to indicate smoking status using computer reminder systems.

[a] Repeated assessment is not necessary in the case of the adult who has never smoked or not smoked for many years, and for whom this information is clearly documented in the medical record.

For the primary care clinician:
Strategy 2. Advise—strongly urge all smokers to quit

Action	Strategies for implementation
In a *clear*, *strong*, and *personalized* manner, urge every smoker to quit.	Advice should be: ■ *Clear*—"I think it is important for you to quit smoking now and I will help you." "Cutting down while you are ill is not enough." ■ *Strong*—"As your clinician, I need you to know that quitting smoking is the most important thing you can do to protect your current and future health." ■ *Personalized*—Tie smoking to current health/illness, and/or the social and economic costs of tobacco use, motivation level/readiness to quit, and/or the impact of smoking on children and others in the household. Encourage clinic staff to reinforce the cessation message and support the patient's quit attempt.

For the primary care clinician:
Strategy 3. Identify smokers willing to make a quit attempt

Action	Strategies for implementation
Ask every smoker if he or she is willing to make a quit attempt at this time.	■ If the patient is willing to make a quit attempt at this time, provide assistance (see Strategy 4 for the Primary Care Clinician). ■ If the patient prefers a more intensive treatment or the clinician believes intensive treatment is appropriate, refer to interventions administered by a smoking cessation specialist and follow up with the patient regarding quitting (see Strategy 5 for the Primary Care Clinician and Chapter 2, second section). ■ If the patient clearly states he/she is not willing to make a quit attempt at this time, provide a motivational intervention (see Chapter 4, first section). Also, if the patient is a member of a special population (e.g., adolescent, pregnant smoker, racial/ethnic minority), additional information is provided in Chapter 5.

Tobacco Cessation Specialists and Programs

Background

Smoking cessation specialists are not defined by their professional affiliation or by the field in which they trained. Rather, the specialist views smoking cessation as a critical professional role, possesses skills relevant to cessation activities, and is often affiliated with programs offering intensive cessation interventions or services (programs with staff dedicated to smoking interventions, where treatment involves multiple counseling sessions, and so on).

Specialists are a vital resource in smoking cessation efforts. For example, many effective smoking cessation strategies now widely disseminated (e.g., skills for coping with urges to smoke) were developed by specialists conducting intensive intervention programs. As major contributors to cessation research, specialists exert a cumulative effect greater than their number.

Also, specialists play an important role in service delivery—especially through the provision of intensive cessation interventions. Some smokers seek out and prefer the intensive interventions offered by specialists. There is substantial evidence that such programs produce higher success rates than do less intensive interventions (as indicated by several findings of the present guideline). In addition, the cessation interventions offered by specialists are important because many nonspecialists do not consistently and reliably intervene with smokers.

Although the specialist definitely contributes greatly to smoking cessation efforts, constraints limit the impact of the specialist's service delivery activities. Only a minority of smokers participate in the intensive programs

For the primary care clinician:
Strategy 4. Assist—aid the patient in quitting

Action	Strategies for implementation
Help the patient with a quit plan.	Set a *quit date* — Ideally, the quit date should be within 2 weeks, taking patient preference into account. *A patient's preparations for quitting:* ■ *Inform* family, friends, and co-workers of quitting and request understanding and support. ■ *Remove* cigarettes from your environment. Prior to quitting, avoid smoking in places where you spend a lot of time (e.g., home, car). ■ *Review* previous quit attempts. What helped you? What led to relapse? ■ *Anticipate* challenges to planned quit attempt, particularly during the critical first few weeks. These include nicotine withdrawal symptoms.
Encourage nicotine replacement therapy except in special circumstances.	Encourage the use of nicotine patch or nicotine gum therapy for smoking cessation (see General Strategies 3 and 5 for specific instructions and precautions).
Give key advice on successful quitting.	*Abstinence* — Total abstinence is essential. "Not even a single puff after the quit date." *Alcohol* — Drinking alcohol is highly associated with relapse. Those who stop smoking should review their alcohol use and consider limiting/abstaining from alcohol during the quit process. *Other smokers in the household* — The presence of other smokers in the household, particularly a spouse, is associated with lower success rates. Patients should consider quitting with their significant others and/or developing specific plans to stay quit in a household where others still smoke.
Provide supplementary materials.	*Sources* — Federal agencies, including AHCPR; nonprofit agencies (ACS, ALA, AHA); or local/State health departments (see Attachment for details). *Type* — Culturally/racially/educationally/age appropriate for the patient. *Location* — Readily available in every clinic office.

For the primary care clinician:
Strategy 5. Arrange—schedule followup contact

Action	Strategies for implementation
Schedule followup contact, either in person or via telephone.	*Timing* — Followup contact should occur soon after the quit date, preferably during the first week. A second followup contact is recommended within the first month. Schedule further followup contacts as indicated. *Actions during followup visit* — Congratulate success. If smoking occurred, review circumstances and elicit recommitment to total abstinence. Remind patient that a lapse can be used as a learning experience. Identify problems already encountered and anticipate challenges in the immediate future. Assess nicotine replacement therapy use and problems. Consider referral to a more intense or specialized program (see Chapter 4, second section).

typically offered by specialists (Fiore, Novotny, Pierce, et al., 1990). Moreover, not enough resources are available to offer intensive programs to all smokers wanting to quit. Such considerations suggest that, in the future, the specialist may contribute to smoking cessation efforts through activities in addition to service delivery per se, such as the following:

- Serving as a resource to nonspecialists who offer smoking cessation services as part of general health care delivery. This might include training nonspecialists in counseling strategies, providing consultation on difficult cases, and providing specialized assessment services.

- Developing and evaluating changes in office/clinic procedures that increase the rates at which smokers are identified and treated.

- Conducting evaluation research to determine the effectiveness of ongoing smoking cessation activities in relevant institutional settings.

- Developing and evaluating innovative treatment strategies that increase the effectiveness of smoking cessation interventions. For example, "treatment matching" (e.g., Hall, Munoz, and Reus, 1994; Zelman, Brandon, Jorenby, et al., 1992), "stepped-care" approaches (Abrams, Orleans, Niaura, et al., 1993, in press; Orleans, 1993), smoking cessation interventions for patients with psychiatric comorbidity (Hughes and Frances, 1995; Hurt, Eberman, Croghan, et al., 1994), the treatment of severely dependent smokers (Hurt, Dale, Offord, et al., 1992), and proactive telephone counseling during followup (Zhu, Stretch, Balabanis, et al., 1996) represent five such innovative approaches.

Recommendations for Tobacco Cessation Specialists and Programs

Given that the specialist may assume diverse roles regarding smoking cessation—treatment, assessment, training of nonspecialists, and program development and evaluation—it is apparent that virtually all of the information in the guideline might be important to the specialist. However, highlighted in For the Specialist: Strategy 1 are guideline findings that seem particularly relevant to the specialist's implementation of intensive cessation programs. The above findings lead to the following recommendations regarding intensive smoking cessation programs (see For the Specialist: Strategy 2). Of course, implementation of these recommendations depends on factors such as resource availability, time constraints, and so on.

Health Care Administrators, Insurers, and Purchasers

Background

Although clinical practice guidelines have traditionally focused on the role of the individual clinician, promoting smoking cessation in the United States requires a broader approach involving health care delivery administrators, insurers, and purchasers. Why broaden the scope of this document beyond the individual clinician? Smoking cessation efforts directed solely at the individual clinician have yielded disappointing results. National data suggest that, in a given visit with a clinician, most smokers are not advised and assisted with cessation (CDC, 1993b). Factors that contribute to this problem include failure to (a) include smoking assessment and cessation in the performance expectations of clinicians and (b) provide clinicians with an environment that supports systematic intervention with smokers. Without supportive systems, policies, and environmental prompts, the individual clinician cannot be counted on to assess and treat tobacco use reliably. In addition, an increasing number of Americans are receiving their health care in managed care settings. The structure of managed care environments provides new opportunities to identify and treat patients who smoke. These factors indicate that responsibility for smoking cessation treatment must be redistributed; just as every clinician has a professional responsibility to assess and treat tobacco users, health care administrators, insurers, and purchasers have a responsibility to craft policies, provide resources, and display leadership in fostering smoking cessation efforts.

It is important to emphasize that smoking cessation treatments (both pharmacotherapy and counseling) are not consistently provided as paid services for subscribers of health insurance packages (Group Health Association of America, 1993), with one survey demonstrating that as few as 11 percent of health insurance carriers provided coverage for treatment of nicotine

For the specialist:
Strategy 1. Findings relevant to the specialist's implementation of intensive cessation programs

- There is a strong dose–response relation between counseling intensity and cessation success. In general, the more intense the cessation intervention, the greater the rate of smoking cessation. Treatments may be made more intense by increasing (a) the length of individual treatment sessions and (b) the number of treatment sessions and number of weeks over which treatment is delivered.
- Valid predictors of outcome are available. For instance, high levels of dependence, psychiatric comorbidity, and low levels of motivation to quit all predict greater likelihood of relapse. These measures might be used to adjust treatment intensity, to match patients with particular types of treatment, or for research purposes.
- Many different types of cessation providers (physicians, nurses, dentists, psychologists, pharmacists, etc.) are effective in increasing rates of smoking cessation, and involving multiple types of providers appears to enhance cessation rates.
- Both individual and group counseling are effective smoking cessation formats.
- Particular counseling contents are especially effective. Problem-solving/skills-training approaches and the provision of intratreatment support are associated with significant increases in cessation rates, as are aversive smoking techniques (e.g., rapid smoking).
- Pharmacotherapy in the form of nicotine patch or nicotine gum therapy consistently increases smoking cessation rates regardless of the level of adjuvant behavioral or psychosocial interventions. Therefore, its use should be encouraged.
- Smoking cessation interventions are effective across diverse populations: across gender, racial, and ethnic groups; across age groups; in pregnant women; etc.

addiction (Gelb, 1985). This lack of coverage is particularly surprising given that studies have shown that physician counseling against smoking is at least as cost-effective as several other preventive medical practices, including the treatment of mild or moderate hypertension or high cholesterol (Cummings, Rubins, and Oster, 1989). These and other findings resulted in the recent addition of a new objective to the national health promotion and disease prevention objectives for the year 2000.

> Increase to 100 percent the proportion of health plans that offer treatment of nicotine addiction (e.g., tobacco use cessation counseling by health care providers, tobacco use cessation classes, prescriptions for nicotine replacement therapies, and/or other cessation services) (DHHS, 1995).

Cost-Effectiveness of Smoking Cessation Interventions

Smoking cessation treatments are not only clinically effective, they have economic benefits as well. It is vital that all three audiences targeted in this

For the specialist:
Strategy 2. Recommendations regarding intensive smoking cessation programs

Assessment	Assessments should determine whether smokers are motivated to quit smoking via an intensive cessation program. Other assessments can provide information useful in counseling (e.g., stress level, presence of comorbidity; see Chapter 3, Specialized Assessment).
Program clinicians	Multiple types of clinicians should be used. One strategy would be to have a medical/health care clinician deliver messages about health risks and benefits, and nonmedical clinicians deliver psychosocial or behavioral interventions.
Program intensity	Because of evidence of a strong dose–response relation, the intensity of the program should be: *Session length* — at least 20–30 min in length[a] *Number of sessions* — at least 4–7 sessions *Length in weeks* — at least 2 w, preferably more than 8 w
Program format	Either individual or group counseling may be used. Use of adjuvant self-help material is optional. Followup assessment procedures should be used (see Chapter 3).
Counseling content	Counseling should involve either or both problem-solving/skills-training content as well as social support delivered during treatment sessions (see Chapter 3, subsection on Content of Smoking Cessation Interventions). In addition, content should target motivation to quit and relapse prevention (see Chapter 4).
Pharmacotherapy	Except in special circumstances, every smoker should be offered nicotine replacement. Encourage the use of nicotine patch or nicotine gum therapy for smoking cessation (see General Strategies 3 and 5 for specific instructions and precautions).
Population	Intensive intervention programs may be used with all smokers willing to enter such programs.

[a] Session length of 20–30 min was recommended because most trials of effective smoking cessation counseling used sessions of at least this length.

guideline recognize that smoking cessation treatments ranging from brief clinician advice to specialist-delivered intensive programs are cost-effective in relation to other sorts of medical interventions. Cost-effectiveness analyses (Cummings, Rubin, and Oster, 1989; Eddy, 1981, 1986; Oster, Huse, Delea, et al., 1986) have shown that smoking cessation treatment compares quite favorably with routine medical interventions such as the treatment of hypertension and hypercholesterolemia and preventive interventions such as

periodic mammography. In fact, Eddy referred to smoking cessation treatment as the "gold standard" of preventive interventions (Eddy, 1992).

Although only a minority of smokers will achieve success in response to a single application of treatment, clinicians, specialists, and administrators should not forget or ignore the significant health and economic benefits of cessation treatments relative to their costs. The cost-effectiveness of guideline recommendations for smoking cessation will be addressed in detail in an ancillary document sponsored by AHCPR.

Recommendations for Health Care Administrators, Insurers, and Purchasers

Health care delivery administrators, insurers, and purchasers can promote tobacco cessation through a systems approach. Purchasers (usually corporations, companies, or other consortia that purchase health care benefits for a group of individuals) should consider making tobacco assessment, counseling, and treatment a contractual obligation of the health care insurers and/or providers that sell them services. In addition, health care administrators and insurers must provide clinicians with assistance to ensure that institutional changes promoting smoking cessation interventions are universally and systematically implemented. A number of institutional policies would facilitate these interventions:

- Implement a tobacco-user identification system in every clinic (see For Health Care Administrators, Insurers, and Purchasers: Strategy 1).
- Provide education, resources, and feedback to promote provider intervention (see For Health Care Administrators, Insurers, and Purchasers: Strategy 2).
- Dedicate staff to provide smoking cessation treatment identified as effective in this document and assess the delivery of this treatment in staff performance evaluations (see For Health Care Administrators, Insurers, and Purchasers: Strategy 3).
- Promote hospital policies that support and provide smoking cessation services (see For Health Care Administrators, Insurers, and Purchasers: Strategy 4).
- Include smoking cessation treatment (both pharmacotherapy and counseling), identified as effective in this guideline, as paid services for all subscribers of health insurance packages (see For Health Care Administrators, Insurers, and Purchasers: Strategy 5).
- Reimburse fee-for-service clinicians for delivery of effective smoking cessation treatments and include these interventions among the defined duties of salaried clinicians (see For Health Care Administrators, Insurers, and Purchasers: Strategy 6).

For health care administrators, insurers, and purchasers:
Strategy 1. Implement a tobacco-user identification system in every clinic

Action	Strategies for implementation
Implement an office-wide system that ensures that, for EVERY patient at EVERY clinic visit, tobacco-use status is queried and documented.	Office system change: Expanding the *Vital Signs* to include tobacco use (see Strategy 1 for the Primary Care Clinician). Responsible staff: Nurse, medical assistant, receptionist, or other individual already responsible for measuring the vital signs—no additional staff requirements. These staff must be instructed regarding the frequency and importance of this activity. Frequency of utilization: Every visit for every patient regardless of the reason that brought the individual to the clinic.[a] In other words, whenever health care staff collect the traditional vital signs data, they also query and document tobacco use. System implementation steps: *Preprint* progress note paper or preprogram computer record for every patient visit to include tobacco use along with the traditional vital signs. A vital sign stamp can also be effective. Alternatives to the vital sign stamp are to place tobacco-use status stickers on all patient charts or to indicate smoking status using computer reminder systems. **VITAL SIGNS** Blood Pressure:_____ Pulse:_____ Weight:_____ Temperature:_____ Respiratory Rate:_____ Tobacco Use: Current Former Never (*circle one*)

[a] Repeated assessment is not necessary in the case of the adult who has never smoked or not smoked for many years, and for whom this information is clearly documented in the medical record.

For health care administrators, insurers, and purchasers:
Strategy 2. Provide education, resources, and feedback to promote provider intervention

Action	Strategies for implementation
Health care systems should ensure that clinicians have the knowledge and training to treat smoking, that clinicians and patients have cessation resources, and that clinicians are given feedback about their cessation practices.	*Educate* — On a regular basis, offer lectures/seminars/ in-services with CME and other credit for smoking cessation treatment. *Resources* — Have patient self-help materials, as well as nicotine replacement "starter kits," readily available in every exam room. *Provide feedback* — Drawing on data from chart audits, electronic medical records, computerized patient databases, and so on, evaluate the degree to which clinicians are identifying, documenting, and treating patients who smoke, and provide feedback to clinicians about their level of intervention.

For health care administrators, insurers, and purchasers:
Strategy 3. Dedicate staff to provide smoking cessation treatment and assess the delivery of this treatment in staff performance evaluations

Action	Strategies for implementation
Clinical sites should communicate to staff the importance of intervening with smokers and should designate one staff person (e.g., nurse, medical assistant, or other clinician) to coordinate and deliver smoking cessation treatments.	*Communicate* to each staff member (e.g., nurse, medical assistant, or other clinician) his or her responsibilities in the delivery of smoking cessation services. *Designate* a smoking cessation treatment coordinator for every clinical site. *Delineate* the responsibilities of the smoking cessation coordinator, including instructing patients on the effective use of cessation treatments (e.g., nicotine replacement therapy, telephone calls to and from prospective quitters, and scheduled followup visits, especially in the immediate post-quit period).

For health care administrators, insurers, and purchasers:
Strategy 4. Promote hospital policies that support and provide smoking cessation services

Action	Strategies for implementation
Provide smoking cessation inpatient consultation services to all smokers admitted to a hospital.	*Implement* a system to identify and document the tobacco-use status of all hospitalized patients. *Offer* cessation treatment to all hospitalized patients who use tobacco *Identify* a clinician(s) to deliver smoking cessation inpatient consultation services for every hospital. *Reimburse* providers for smoking cessation inpatient consultation services. *Expand* hospital formularies to include effective smoking cessation pharmacotherapy such as the nicotine patch and nicotine gum. *Ensure* compliance with JCAHO regulations mandating that all sections of the hospital be entirely smoke-free. *Educate* all hospital staff regarding nicotine withdrawal, including effective treatments such as nicotine replacement therapy and counseling.

For health care administrators, insurers, and purchasers:
Strategy 5. Include smoking cessation treatments (both pharmacotherapy and counseling), identified as effective in this guideline, as paid services for all subscribers of health insurance packages

Action	Strategies for implementation
Provide all insurance subscribers coverage for effective smoking cessation treatments, including pharmacotherapy (nicotine replacement therapy) and counseling.	*Cover* — Include effective smoking cessation treatments (both pharmacotherapy and counseling) as part of the basic benefits package for all individual, group, and HMO insurance packages. *Evaluate* — Include the provision of smoking cessation treatment as part of "report cards" for managed care organizations and other insurers [e.g., Health Plan Employer Data and Information Set (HEDIS)]. *Educate* — Inform subscribers of the availability of covered smoking cessation services and encourage patients to use these services.

For health care administrators, insurers, and purchasers:
Strategy 6. Reimburse fee-for-service clinicians for delivery of effective smoking cessation treatments and include these interventions among the defined duties of salaried clinicians

Action	Strategies for Implementation
Reimburse fee-for-service clinicians for delivery of effective smoking cessation treatments; include smoking cessation treatments in the defined duties of salaried clinicians.	*Include* smoking cessation treatment as a reimbursable activity for fee-for-service providers. *Inform* fee-for-service clinicians that they will be reimbursed for using effective smoking cessation treatments with every patient who uses tobacco. *Include* smoking cessation intervention in the job description and performance evaluation of salaried clinicians.

3 Evidence

Background

The recommendations summarized in Chapter 2 are the result of a review and analysis of the extant tobacco cessation literature. Chapter 3 reports the results of this review and analysis and describes the efficacy of various treatments, assessments, and strategies for their implementation. This chapter, therefore, addresses such questions as: Does the professional discipline of the treatment clinician make a difference in the efficacy of the intervention? Are physicians, nurses, dentists, psychologists, and health educators all effective in delivering interventions? Similarly, are minimal interventions, such as clinician advice to quit smoking, effective or are more intensive interventions required? Does the duration of an intervention in weeks or the number of treatment sessions substantially influence efficacy? Which screening strategies result in the reliable identification of smokers? Are pharmacologic interventions effective, and if so, which ones? In short, which treatments or assessments are efficacious and how should they be implemented?

The panel examined the relation between outcomes and 12 major assessment or treatment characteristics or strategies. These 12 characteristics or strategies, and the categories within each, are listed in Table 3. Type of outcome varied across the different strategies being analyzed. For instance, in the analysis of strategies for screening for tobacco use, one outcome was the percent of smokers identified, whereas in the analysis of treatment strategies, the outcome was long-term smoking cessation (cessation for 5 months or more). The panel analyzed treatment or assessment strategies that seemed rationally related to efficacy and that constituted distinct approaches that exist in current clinical practice.

The panel chose categories within strategies according to three major concerns. First, some categories reflected generally accepted dimensions or taxonomies. An example of this is the categorical nature of the clinician types (physician, psychologist, and so on). Second, information on the category had to be available in the published literature. Many questions of theoretical interest had to be abandoned simply because the requisite information was not available. Third, the category had to occur with sufficient frequency to permit meaningful statistical analysis. For example, the cut-points of some continuous variables (e.g., Intensity of Person-to-Person Contact, Duration of Treatment) were determined so that relevant studies were apportioned appropriately for statistical analysis. Information on the coding of articles according to these dimensions is located in the technical report.

In ideal circumstances, the panel could evaluate each category by consulting randomized controlled trials relevant to the category in question. Unfortunately, with the exception of pharmacologic interventions, very few or no randomized controlled trials are specifically designed to address the effects of the various

Table 3. Analyzed treatment and assessment strategies

Strategies analyzed	Categories
Screen for tobacco use	No screening system in place Screening system in place
Advice to quit	No advice to quit Physician advice to quit
Specialized assessment	Nicotine dependence Psychiatric comorbidity Motivation Readiness to change Self-efficacy Environmental risk Stress
Clinician interventions	No clinician/self-administered Nonmedical health care provider (e.g., psychologist, counselor, social worker, graduate student) Nonphysician medical health care provider (e.g., dentist, nurse, health counselor, pharmacist) Physician
Format	No contact Self-help/self-administered (e.g., pamphlet, audiotape, video, mailed information, computer program) Individual counseling/contact Group counseling/contact
Self-help materials	No self-help intervention Pamphlets/booklets/manuals Video Audio Referral to 12-step program, support group, etc. List of community programs Hotline/helpline Computer program
Intensity of person-to-person clinical contact	No person-to-person intervention Minimal contact (longest session ≤ 3 min in duration) Brief counseling (longest session > 3 min and ≤ 10 min in duration) Counseling/psychosocial intervention (longest session > 10 min)

(Table continues on next page)

Table 3. (continued)

Strategies analyzed	Categories
Content of the intervention	No person-to-person intervention or minimal contact General—problem-solving/coping skills/relapse prevention/stress management approach Negative affect/depression component Weight/diet/nutrition component Exercise/fitness component Extratreatment social support component Intratreatment social support intervention Contingency contracting/instrumental contingencies Aversive smoking Cue exposure/extinction Cigarette fading/smoking reduction prequit Relaxation/breathing Motivation Quit day Hypnosis Acupuncture
Duration of the intervention/ number of person-to-person treatment sessions	Duration of person-to-person treatment in weeks Number of person-to-person treatment sessions
Pharmacologic interventions	No pharmacotherapy Transdermal nicotine replacement Nicotine gum Other nicotine replacement Clonidine Antidepressants Anxiolytics/benzodiazepines Other pharmacotherapies
Followup assessment and procedures	Followup cessation intervention Motivational intervention
Reimbursement for smoking cessation treatment	Paid services via health insurance/managed care Reimbursement for clinicians

categories within these treatment or assessment strategies. Moreover, strategy categories are frequently confounded with one another. For example, comparisons among clinicians are almost always confounded with the content, format, and intensity of the interventions. Psychologists tend to deliver relatively intensive, psychosocial interventions, often in a group format, whereas physicians tend to deliver brief advice to individuals. More intensive interventions may result in higher cessation rates, such that psychologists appear to be more effective in promoting smoking cessation than do physicians, when in fact, the intensity of the intervention rather than the type of clinician may result in higher cessation rates. Therefore, direct, unconfounded comparisons of categories within a particular strategy were often impossible. These strategies were nevertheless analyzed because of their clinical importance and because it was possible to

reduce confounding by careful selection of studies and by statistical control of confounding factors.

Panel meta-analyses were used as the primary source of data for evaluating most strategies. For two topics, however, pharmacotherapies and interventions for pregnant smokers, high-quality published meta-analyses already existed and were the primary source of data. Individual articles from these analyses were evaluated whenever necessary. Details of the meta-analytic techniques can be found in the technical report.

Some meta-analyses were conducted to evaluate strategies with respect to the population under study and the type of outcome data used in the study. The relative efficacy of various treatment characteristics was largely unaffected by differences in the population under study (i.e., all-comers vs. self-selected analyses) and the type of outcome data (i.e., intent-to-treat vs. other studies and studies with vs. without biochemical confirmation).

The following sections of Chapter 3 address the 12 treatment and assessment strategies outlined in Table 3. For each strategy analyzed, background information, clinical recommendations, and the evidentiary basis for those recommendations are provided.

Screen for Tobacco Use

Recommendation: All patients should be asked if they use tobacco and should have their tobacco-use status documented on a regular basis. (Strength of Evidence = A)

Recommendation: Clinic screening systems such as expanding the vital signs to include smoking status, or the use of smoking status chart stickers, are essential for consistent assessment and documentation of smoking. (Strength of Evidence = B)

The panel conducted meta-analyses to determine the impact of systems that screen for smoking on two outcomes: the rate of smoking cessation intervention by clinicians and the rate of cessation by patients who smoke.

Identifying Smokers: Impact on Clinical Intervention

Nine studies met selection criteria and were analyzed using a random-effects meta-analysis to assess the impact of screening systems on the rate of smoking cessation intervention by clinicians. The results of this meta-analysis are shown in Table 4. Implementing clinic systems designed to increase the assessment and documentation of smoking status markedly increases the rate at which clinicians intervene with their patients who smoke.

Identifying Smokers: Impact on Smoking Cessation

Three studies met selection criteria and were analyzed using a random-effects meta-analysis to assess the impact of identifying smokers on actual

Table 4. Impact of having a smoking status identification system in place on rates of clinician intervention with their patients who smoke (*n* = 9 studies)

Screening system	Number of arms	Estimated odds ratio (95% C.I.)	Estimated intervention rate (95% C.I.)
No screening system in place to identify smoking status (reference group)	9	1.0	38.5
Screening system in place to identify smoking status	9	3.1 (2.2–4.2)	65.6 (58.3–72.6)

rates of smoking cessation. The results of this meta-analysis are shown in Table 5. These results suggest that having a clinic system in place that identifies smokers results in higher rates of smoking cessation, although this finding was not statistically significant and was based on a small number of studies.

Evidence. The following statements support the above recommendations:

- Screening systems that systematically identify and document smoking status result in higher rates of smoking cessation interventions by clinicians. (Strength of Evidence = A)
- Screening systems that systematically identify and document smoking status appear to result in higher quit rates among patients who smoke. (Strength of Evidence = C)

Strategy 1 for the Primary Care Clinician and Strategy 1 for Health Care Administrators, Insurers, and Purchasers detail an approach for including tobacco-use status as a new vital sign. This approach is designed to produce consistent assessment and documentation of tobacco use. Evidence from randomized controlled trials shows that this approach increases the probabili-

Table 5. Impact of having a smoking status identification system in place on the rates of cessation among patients who smoke (*n* = 3 studies)

Screening system	Number of arms	Estimated odds ratio (95% C.I.)	Estimated cessation rate (95% C.I.)
No screening system in place to identify smoking status (reference group)	3	1.0	3.1
Screening system in place to identify smoking status	3	2.0 (0.8–4.8)	6.4 (1.3–11.6)

ty that tobacco use is consistently assessed and documented (Fiore, Jorenby, Schensky, et al., 1995; Robinson, Laurent, and Little, 1995).

Advice To Quit Smoking

Recommendation: All *physicians* should strongly advise every patient who smokes to quit. (Strength of Evidence = A)

Recommendation: All *clinicians* should strongly advise their patients who smoke to quit. Although studies have not independently addressed the impact of advice to quit by all types of nonphysician clinicians, it is reasonable to believe that such advice is effective. (Strength of Evidence = C)

Nine studies met selection criteria for assessing the efficacy of clinician advice to quit smoking. For the purpose of this analysis, advice was defined as clinical intervention lasting 3 minutes or less. Seven of these studies examined the impact of physician advice, a number sufficient to assess this variable using meta-analytic techniques. The meta-analysis was unable to address the impact of advice to quit by other nonphysician clinicians, because only two studies addressed this issue and were limited to pregnant patients. Results of the meta-analysis are shown in Table 6. Given the large number of smokers who visit a clinician each year, the potential public health impact of universal advice to quit is substantial.

Evidence. The following statements support the above recommendations:

- Physician advice to quit smoking increases quit rates compared with the absence of such advice. (Strength of Evidence = A)
- Insufficient data exist to assess the efficacy of advice to quit smoking when the advice is given by nonphysician clinicians. However, it is likely that such advice is efficacious. Therefore, all clinicians should advise their patients who smoke to quit. (Strength of Evidence = C)

Specialized Assessment

Recommendation: Clinicians should routinely assess both the smoking status of all of their patients and the appropriateness of cessation interventions such as nicotine replacement therapy. (Strength of Evidence = A)

Recommendation: Cessation treatment is effective without specialized assessments. Clinicians, therefore, should intervene with every patient who smokes even if specialized assessments are not available. (Strength of Evidence = A)

Recommendation: Clinicians may engage in specialized assessments in order to gauge potential for successful quitting. (Strength of Evidence = C)

Every individual entering a health care setting should receive an assessment that determines his or her smoking status and interest in quitting. Such

Table 6. Efficacy of advice to quit by a clinician (n = 7 studies)

Advice	Number of arms	Estimated odds ratio (95% C.I.)	Estimated cessation rate (95% C.I.)
No advice to quit (reference group)	9	1.0	7.9
Physician advice to quit	10	1.3 (1.1–1.6)	10.2 (8.5–12.0)

an assessment is a necessary first step in treatment. In addition, every patient should be assessed for physical or medical conditions that may affect the use of planned treatments (e.g., nicotine replacement therapy).

The clinician may also wish to perform specialized assessments of individual and environmental attributes that provide information for tailoring treatment. Specialized assessments refer to the use of formal instruments (e.g., questionnaires, clinical interviews, or physiologic indices such as carbon monoxide, serum nicotine/cotinine levels, and/or pulmonary function) that may be associated with cessation outcome. Some of the variables targeted in specialized assessments that are associated with differential cessation rates are listed in Table 7.

Several considerations should be kept in mind regarding the use of specialized assessments. First, there was little strong or consistent evidence that a smoker's status on a specialized assessment predicted the relative efficacy of the various interventions. The one exception is that persons high in nicotine dependence may benefit more from 4 mg as opposed to 2 mg of nicotine gum (see section in Chapter 3, Smoking Cessation Pharmacotherapy). More

Table 7. Variables associated with lower cessation rates[a]

Variable	Examples
High nicotine dependence	Smoker reports severe withdrawal during previous quit attempts
Psychiatric comorbidity	Depression, schizophrenia, alcoholism, other chemical dependency
Low motivation	Smoker reports low motivation to quit
Low readiness to change	Smoker reports not being ready to quit
Low self-efficacy	Smoker reports perceived inability to quit
Environmental risks	Other smokers in the home/workplace
High stress level	Stressful life circumstances and/or recent, major life change (e.g., divorce, job change)

[a] Although these variables are associated with relatively lower cessation rates, cessation treatment nevertheless remains effective in the presence of such variables.

importantly, the panel found that, regardless of their standing on specialized assessments, all smokers have the potential to benefit from cessation interventions. Therefore, delivery of cessation interventions should not depend on specialized assessments. Finally, little consistent research evidence shows how treatment should be tailored based on the results of these assessments. However, the panel recognizes that some effective interventions such as general problem solving (see section in Chapter 3, Content of Smoking Cessation Interventions) entail treatment tailoring based on a systematic assessment of individual patient characteristics.

The reviewed evidence suggested that treatment is effective despite the presence of risk factors for relapse (e.g., severe previous withdrawal, depression, other smokers in the home), but quit rates in smokers with these characteristics tend to be lower than rates in those without these characteristics.

Interventions

Type of Clinician

Recommendation: Smoking cessation interventions delivered by a variety of clinicians and health care personnel increase cessation rates. Clinician involvement in smoking cessation interventions should be based on factors such as access to smokers, level of training, and interest rather than on membership in a specific professional discipline. (Strength of Evidence = A)

Recommendation: All health care personnel and clinicians should repeatedly and consistently deliver smoking cessation interventions to their patients. Smoking cessation interventions should be delivered by as many clinicians and types of clinicians as is feasible given available resources. (Strength of Evidence = A)

There were 41 studies that met selection criteria for analyses examining the effectiveness of various types of providers of smoking cessation interventions. These analyses compared the efficacy of interventions delivered by specific types of providers and by multiple providers with interventions where there was no provider (e.g., where there was no intervention or intervention consisted of self-help materials only). Please note that "multiple providers" refers to the number of different types of providers, not the number of total providers regardless of type. The latter information was rarely, if ever, available from the study reports. Results are shown in Table 8.

Evidence. The following statements support the above recommendations:

- Smoking cessation interventions delivered by any single type of health care provider or by multiple providers increase cessation rates relative to interventions where there is no provider (e.g., self-help interventions). Results are consistent across diverse provider groups, with no clear advantage to any single provider type. (Strength of Evidence = A)

Table 8. Efficacy of and estimated cessation rates for interventions delivered by various types of providers (n = 41 studies)

Type of provider	Number of arms	Estimated odds ratio (95% C.I.)	Estimated cessation rate (95% C.I.)
No provider (reference group)	38	1.0	8.2
Multiple providers	14	3.8 (2.6–5.6)	25.5 (18.1–32.7)
Nonmedical health care provider (psychologist, social worker, counselor)	23	1.8 (1.5–2.2)	14.1 (12.0–16.3)
Physician provider	36	1.5 (1.2–1.9)	12.0 (9.6–14.3)
Nonphysician medical health care provider (dentist, nurse, health counselor, pharmacist)	20	1.4 (1.1–1.8)	11.5 (9.0–14.0)

- Smoking cessation interventions delivered by the following types of providers or clinicians have been shown to increase cessation rates relative to interventions where there is no provider: physician provider (e.g., primary care physician, cardiologist), nonphysician medical health care provider (e.g., dentist, nurse, health counselor, pharmacist), and nonmedical health care provider (e.g., psychologist, social worker, counselor). (Strength of Evidence = A)
- Smoking cessation interventions delivered by multiple types of providers markedly increase cessation rates relative to those produced by interventions where there is no provider. (Strength of Evidence = A)

Treatment Formats

Recommendation: To be most effective, smoking cessation interventions should include either individual or group counseling/contact. (Strength of Evidence = A)

Twenty-five studies met selection criteria and were included in the analysis comparing different types of formats for smoking cessation interventions. Results of this analysis are shown in Table 9.

Evidence. The following statements support the above recommendation:

- Smoking cessation interventions delivered by means of self-help materials appear to increase cessation rates relative to no intervention.

Table 9. Efficacy of and estimated cessation rates for various formats (n = 25 studies)

Format	Number of arms	Estimated odds ratio (95% C.I.)	Estimated cessation rate (95% C.I.)
No intervention (reference group)	23	1.0	7.6
Self-help	8	1.2 (1.0–1.6)[a]	9.3 (7.3–11.4)
Individual counseling	26	2.2 (1.9–2.4)	15.1 (13.6–16.5)
Group counseling	15	2.2 (1.6–3.0)	15.3 (11.4– 19.2)

[a] Actual 95% lower confidence estimate equals 0.97.

However, their impact is smaller and less certain than that of individual or group counseling. (Strength of Evidence = B)

- Smoking cessation interventions delivered by means of individual counseling (involving person-to-person contact) increase cessation rates relative to no intervention. (Strength of Evidence = A)
- Smoking cessation interventions delivered by means of group counseling/contact increase cessation rates relative to no intervention. (Strength of Evidence = A)

There is insufficient evidence to assess telephone counseling/contact. Telephone counseling/contact was defined as proactive clinician-initiated telephone calls. (Compare with "hotline/helpline" [Table 10], which involves patient-initiated telephone calls.)

Efficacy of Self-Help Treatment Alone

Recommendation: Where feasible, smokers should be provided with access to support through a telephone hotline/helpline as a self-help intervention. (Strength of Evidence = B)

Types of Self-Help Intervention. In general, smoking cessation interventions delivered by means of self-help materials may increase cessation rates relative to no intervention (Curry, 1993). However, their impact is smaller and less certain than that of individual or group counseling.

Twelve studies met selection criteria for evaluations of specific types of self-help materials. These studies involved self-help treatments used by themselves (with no non-self-help treatment modality). To estimate the effect of various types of self-help,we included all 12 studies in a single meta-analysis using a random-effects model (Table 10). In this analysis, the various types of self-help interventions were compared with a control condition or reference group in which subjects received no treatment.

Table 10. Efficacy of and cessation rates for various types of self-help formats when used alone (n = 12 studies)

Self-help format	Number of arms	Estimated odds ratio (95% C.I.)	Estimated cessation rate (95% C.I.)
No self-help (reference group)	8	1.0	7.9
Hotline/helpline	3	1.4 (1.1–1.8)	11.1 (8.7–13.4)
Video- or audiotapes	5	1.3 (0.6–2.9)	10.9 (3.6– 18.2)
List of community programs	2	1.1 (0.8–2.5)	8.8 (6.9–10.8)
Pamphlets/booklets/ manuals	22	1.0 (0.8–1.2)	8.1 (6.7–9.5)

Evidence. The following statements support the above recommendation:

- Written self-help materials (pamphlets/booklets/manuals) when used alone do not increase cessation rates relative to no self-help materials. (Strength of Evidence = A)
- Videotapes and audiotapes when used alone do not increase cessation rates relative to no self-help materials. However, these methods deserve further examination because very few studies addressed these types of self-help materials. (Strength of Evidence = B)
- Provision of a list of community programs when used alone does not increase cessation rates relative to no self-help materials. (Strength of Evidence = B)
- Hotlines/helplines (patient-initiated telephone calls for cessation counseling or aid) when used alone increase smoking cessation rates relative to no self-help materials. (Strength of Evidence = B)

No randomized clinical trials that addressed the efficacy of computer programs for smoking cessation met our selection criteria. Further research should be done on such innovative approaches to self-help (e.g., computerized, personalized interventions) (Strecher, Kreuter, Den Boer, et al., 1994).

Multiple Types of Self-Help Materials. An additional random-effects model assessed the efficacy of multiple types of self-help interventions versus no self-help, as shown in Table 11. These results are based on the 12 self-help studies, 6 of which contained at least one treatment arm in which subjects received multiple types of self-help materials (e.g., audiocassette, television program).

Evidence. The results suggest an increasing effect with an increase in the number of types of self-help interventions. However, the estimate for combining three different types of self-help materials is based on a single study. (Strength of Evidence = C)

Table 11. Efficacy of multiple types of self-help materials (n = 12 studies)

Number of types of self-help materials	Number of arms	Estimated odds ratio (95% C.I.)	Estimated cessation rate (95% C.I.)
No self-help (reference group)	8	1.0	7.9
One type	15	1.0 (0.9–1.3)	8.1 (6.7–9.6)
Two types	7	1.2 (0.9–1.6)	9.6 (7.0–12.1)
Three types[a]	1	1.9 (1.2–2.9)	14.5 (8.9–19.1)

[a] Based on a single study.

Intensity of Person-to-Person Clinical Intervention

Recommendation: There is a strong dose–response relationship between the intensity of person-to-person contact and successful cessation outcome. Intensive interventions are more effective and should be used when resources permit. (Strength of Evidence = A)

Recommendation: Every smoker should be offered at least a minimal or brief intervention whether or not the smoker is referred to an intensive intervention. (Strength of Evidence = B)

Fifty-six studies met selection criteria for comparisons among various intensity levels of person-to-person contact. Whenever possible, intensity was defined based on the amount of time the clinician spent with a smoker in a single contact. Minimal-contact interventions were defined as 3 minutes or less, brief counseling was defined as greater than 3 minutes to less than or equal to 10 minutes, and counseling/psychosocial interventions were defined as greater than 10 minutes. Intense interventions could involve multiple patient–clinician contacts. These levels of person-to-person contact were compared with a no-contact reference group involving study conditions where subjects received no person-to-person contact (e.g., self-help–only conditions). Results are shown in Table 12.

Evidence. The following statements support the above recommendations:

- As the intensity level of person-to-person contact increases, efficacy also increases. (Strength of Evidence = A)
- Smoking cessation interventions utilizing counseling/psychosocial interventions (sessions lasting more than 10 minutes) markedly increase cessation rates relative to no-contact interventions. (Strength of Evidence = A)
- Smoking cessation interventions utilizing brief counseling (sessions lasting 3–10 minutes) increase cessation rates over no-contact interventions. (Strength of Evidence = A)

Table 12. Efficacy of and cessation rates for various intensity levels of person-to-person contact (*n* = 56 studies)

Level of contact	Number of arms	Estimated odds ratio (95% C.I.)	Estimated cessation rate (95% C.I.)
No contact (reference group)	49	1.0	8.8
Minimal contact (≤ 3 min)	14	1.2 (1.0–1.5)[a]	10.7 (8.9–12.5)
Brief counseling (> 3 to ≤ 10 min)	26	1.4 (1.2–1.7)	12.1 (10.0–14.3)
Counseling (> 10 min)	60	2.4 (2.1–2.7)	18.7 (16.8–20.6)

[a] Actual 95% lower confidence estimate equals 1.03.

- Smoking cessation interventions utilizing minimal contact (sessions lasting less than 3 minutes) increase cessation rates over no-contact interventions. (Strength of Evidence = B)

Content of Smoking Cessation Interventions

Recommendation: Smoking cessation interventions should help smokers recognize and cope with problems encountered in quitting (problem solving/skills training) and should provide social support as part of treatment. (Strength of Evidence = B)

Recommendation: Smoking cessation interventions that use some type of aversive smoking procedure (rapid smoking, rapid puffing, other aversive smoking) increase cessation rates and may be used with smokers who desire such treatment or who have been unsuccessful using other interventions. (Strength of Evidence = B)

Primary Content Types. Thirty-nine studies met selection criteria for analyses examining the effectiveness of interventions utilizing various types of content. Results are shown in Table 13.

Evidence. Three specific content categories yield statistically significant increases in cessation rates relative to no contact (e.g., untreated control conditions). These categories follow:

1. Smoking cessation interventions including content on general problem solving (problem solving/skills training/relapse prevention/stress management) increase cessation rates. (Strength of Evidence = B)
2. Smoking cessation interventions including a supportive component administered during a smoker's direct contact with a clinician (intratreatment social support) increase cessation rates. Please note

that this refers only to support delivered during direct contact with a clinician and does not refer to a social support component implemented outside of this contact, such as attempting to increase social support in the smoker's environment. (Strength of Evidence = B)

3. Smoking cessation interventions including aversive smoking procedures (rapid smoking, rapid puffing, other smoking exposure) increase cessation rates. (Strength of Evidence = B)

The strength of evidence for the various content categories did not warrant an "A" rating for several reasons. First, smoking cessation interventions rarely used a particular content in isolation. Second, various types of content tended to be correlated with other treatment characteristics. For instance, some types of content were more likely to be delivered using a greater number of sessions across longer time periods. Third, it must be noted that all of these contents were being compared with no-contact/control conditions. Therefore, the control conditions in this meta-analysis did not control for nonspecific or placebo effects of treatment. This further restricted the ability to attribute efficacy to particular contents, per se.

Smoking cessation counseling interventions that included two content areas (general problem solving/skills training and intratreatment social support) were significantly associated with higher smoking cessation rates. General Strategies 1 and 2 outline elements of problem solving and supportive treatments to help the clinician using these treatment components. It must be noted, however, that these two treatment labels are nonspecific and include heterogeneous treatment elements. The third content area associated with superior outcomes was aversive smoking. This involves sessions of guided smoking where the patient smokes intensively, often to the point of discomfort or malaise. Some aversive smoking techniques, such as rapid smoking, may constitute a health risk and should be conducted only with appropriate medical screening and supervision. Aversive smoking interventions have largely been replaced by nicotine replacement strategies.

Other Content Types—Negative Affect, Cue Exposure, Hypnosis, Acupuncture. The content areas of acupuncture, hypnosis, negative affect, and cue exposure were examined separately because too few studies met selection criteria for inclusion in the primary meta-analysis (reported in Table 13). The efficacy of treatments directed at reduction of negative affect (three studies) and treatments utilizing cue exposure (four studies) was assessed through a direct review of relevant studies.

Psychiatric comorbidity and negative affect are risk factors for relapse. Preliminary but insufficient evidence suggested that cessation rates can be improved by treatments specifically addressing these issues.

Cue exposure treatment is intended to reduce smoking motivation through repeated exposure to smoking cues without the opportunity to smoke. None of the four cue exposure studies found this treatment superior to comparison treatments. However, these studies all suffered from method-

Table 13. Efficacy of and cessation rates for various types of content relative to no-contact arms (*n* = 39 studies)

Content category	Number of arms	Estimated odds ratio (95% C.I.)	Estimated cessation rate (95% C.I.)
No contact (reference group)	25	1.0	8.8
Aversive smoking	9	2.1 (1.0–4.2)[a]	17.5 (7.6–27.2)
Intratreatment social support	21	1.8 (1.4–2.5)	15.2 (11.3–19.1)
Problem solving/ skills training	57	1.6 (1.2–2.2)	13.7 (10.3–17.1)
Quit day	30	1.3 (0.9–2.0)	11.5 (7.4–15.7)
Extratreatment social support	16	1.3 (0.8–2.0)	11.2 (7.0–15.5)
Motivation	40	1.1 (0.9–1.5)	9.8 (7.5–12.2)
Weight/diet/nutrition	17	1.1 (0.8–1.6)	9.8 (6.6–13.0)
Exercise/fitness	8	1.1 (0.6–1.8)	9.6 (4.8–14.3)
Contingency contract	13	1.0 (0.7–1.6)	9.1 (5.6–12.7)
Relaxation/ breathing	15	0.8 (0.5–1.3)	7.5 (4.3–10.7)
Cigarette fading	18	0.7 (0.4–1.1)	6.4 (3.6–13.3)

[a] Actual 95% lower confidence estimate equals 1.04.

ological problems and were based on small samples. Hence, at present it would be premature to evaluate cue exposure/extinction interventions.

Separate meta-analyses were conducted for the content categories of hypnosis and acupuncture. Only three acceptable studies examined hypnosis. Because the studies were of poor quality and their results were inconsistent, the evidence was insufficient to assess the effectiveness of hypnosis.

Similarly, evidence was inadequate to support the efficacy of acupuncture as a smoking cessation treatment. The acupuncture meta-analysis comparing "active" acupuncture with "control" acupuncture revealed no difference in efficacy between the two types of procedures, and the odds ratio for active acupuncture was actually smaller than that of control acupuncture. These results suggest that any effect of acupuncture might be produced by factors such as positive expectations about the procedure.

The six studies included in the analysis of acupuncture were examined individually in order to explore acupuncture efficacy further. Of these six studies, five involved nonacupuncture control conditions. Two of these showed acupuncture to be more effective than control conditions, and three showed no

General strategy 1. Common elements of problem-solving/ skills-training smoking cessation treatments

Problem-solving treatment component	Examples
Recognition of danger situations—Identification of events, internal states, or activities that are thought to increase the risk of smoking or relapse.	■ Being around other smokers ■ Being under time pressure ■ Getting into an argument ■ Experiencing urges or negative moods ■ Drinking alcohol
Coping skills—Identification and practice of coping or problem-solving skills. Typically, these skills are intended to cope with danger situations.	■ Learning to anticipate and avoid danger situations ■ Learning cognitive strategies that will reduce negative moods ■ Accomplishing lifestyle changes that reduce stress, improve quality of life, or produce pleasure ■ Learning cognitive and behavioral activities that distract attention from smoking urges
Basic information—Provision of basic information about smoking and successful quitting.	■ The nature/timecourse of withdrawal ■ The addictive nature of smoking ■ The fact that any smoking (even a single puff) increases the likelihood of full relapse

difference. Therefore, active acupuncture was not consistently more effective than either placebo/control acupuncture or nonacupuncture control conditions. The panel concluded that there was relatively little evidence available regarding acupuncture and that the existing evidence was inconclusive.

Person-to-Person Treatment: Duration and Number of Sessions

Recommendation: In general, the greater the number of weeks over which person-to-person counseling or treatment is delivered, the more effective it is. Therefore, the duration of smoking cessation interventions should last as many weeks as is feasible given available resources. (Strength of Evidence = A)

Recommendation: Person-to-person treatment delivered over four to seven sessions appears especially effective in increasing cessation rates. Therefore, if available resources permit, clinicians should strive to meet at least four times with quitting smokers. (Strength of Evidence = A)

Duration of Treatment. Fifty-five studies met selection criteria for the analysis addressing the duration of smoking cessation interventions.

General strategy 2. Common elements of supportive smoking cessation treatments

Supportive treatment component	Examples
Encourage the patient in the quit attempt.	■ Note that effective cessation treatments are now available. ■ Note that half of all people who have ever smoked, have now quit. ■ Communicate belief in patient's ability to quit.
Communicate caring and concern.	■ Ask about how patient feels about quitting. ■ Directly express concern and willingness to help. ■ Be open to the patient's expression of fears of quitting, difficulties experienced, and ambivalent feelings.
Encourage the patient to talk about the quitting process.	**Ask about:** ■ Reasons the patient wants to quit ■ Difficulties encountered while quitting ■ Success the patient has achieved ■ Concerns or worries about quitting
Provide basic information about smoking and successful quitting.	■ The nature/timecourse of withdrawal ■ The addictive nature of smoking ■ The fact that any smoking (even a single puff) increases the likelihood of full relapse

Duration of treatment was categorized as less than 2 weeks, 2 weeks to less than 4 weeks, 4 weeks to 8 weeks, and greater than 8 weeks. Less than 2 weeks was used as the reference group. Results are shown in Table 14.

Because the duration of treatment was associated with the intensity of person-to-person contact (length of treatment sessions), an additional analysis examined the effect of duration after controlling for intensity of person-to-person contact. The trend for increasing efficacy with increasing duration remained after controlling for the intensity of person-to-person contact, but only the longest duration showed a significant effect (data not shown).

Evidence. The efficacy of a smoking cessation intervention increases with longer duration of treatment. The duration of treatment independently contributes to the efficacy of smoking cessation interventions over and above the contribution of the intensity of person-to-person contact. (Strength of Evidence = A)

Number of Treatment Sessions. Fifty-five studies involving at least some person-to-person contact met selection criteria for the analysis addressing the impact of number of treatment sessions. The number of treatment sessions

Table 14. Efficacy of and cessation rates for various durations of person-to-person treatment (*n* = 55 studies)

Duration	Number of arms	Estimated odds ratio (95% C.I.)	Estimated cessation rate (95% C.I.)
< 2 w (reference group)	101	1.0	10.4
2 to < 4 w	14	1.6 (1.3–2.0)	15.6 (12.9–18.3)
4–8 w	12	1.6 (1.2–2.1)	16.1 (12.4–19.7)
> 8 w	15	2.7 (2.2–3.2)	23.8 (20.6–27.1)

was categorized as one or fewer sessions, two to three sessions, four to seven sessions, and greater than seven sessions. One or fewer sessions was used as the reference group. Results are shown in Table 15.

Because number of treatment sessions was associated with the intensity of person-to-person contact (length of treatment sessions), an additional analysis that examined the effect of the number of sessions after controlling for intensity of person-to-person contact was also conducted. Only four to seven sessions remained statistically significant after controlling for the intensity of person-to-person contact.

Evidence. Multiple treatment sessions increase smoking cessation rates over those produced by one or fewer sessions. The evidence suggests that four to seven sessions may be the most effective range. These results also suggest that the number of treatment sessions, at least four to seven sessions, contributes to the efficacy of smoking cessation interventions over and above the contribution of the intensity of person-to-person contact. (Strength of Evidence = A)

Smoking Cessation Pharmacotherapy

Evaluation of various pharmacotherapies for smoking cessation was conducted using several sources of information. For transdermal nicotine and nicotine gum, several high-quality published meta-analyses were available.

Table 15. Efficacy of and cessation rates for number of person-to-person treatment sessions (*n* = 55 studies)

Number of sessions	Number of arms	Estimated odds ratio (95% C.I.)	Estimated cessation rate (95% C.I.)
≤ 1 session (reference group)	96	1.0	10.4
2–3 sessions	15	2.0 (1.6–2.4)	18.8 (15.8–21.9)
4–7 sessions	25	2.5 (2.2–2.9)	22.6 (19.9–25.3)
> 7 sessions	12	1.7 (1.2–2.5)	16.7 (11.4–22.0)

For clonidine, sources of information were an existing published meta-analysis, a meta-analysis conducted by guideline staff, and examination of individual studies. For all other pharmacotherapies, the source of information was examination of individual studies.

Recommendation: Patients should be encouraged to use nicotine replacement therapy (patch or gum) for smoking cessation except in the presence of special circumstances (see General Strategies 3 and 5). (Strength of Evidence = A)

Recommendation: Transdermal nicotine (the nicotine patch) is an efficacious smoking cessation treatment that patients should be encouraged to use. The nicotine patch is effective across diverse settings and populations and when used with a variety of psychosocial interventions. (Strength of Evidence = A)

Recommendation: Nicotine gum is an efficacious smoking cessation treatment that patients should be encouraged to use. (Strength of Evidence = A)

Transdermal Nicotine (the nicotine patch). Five meta-analyses of the efficacy of the nicotine patch have been published (Fiore, Smith, Jorenby, et al., 1994; Gourlay, 1994; Po, 1993; Silagy, Mant, Fowler, et al., 1994; Tang, Law, and Wald, 1994). The primary results of these meta-analyses are summarized in Table 16. Suggestions regarding clinical use of the nicotine patch are provided in General Strategies 3 and 4. General Strategy 4 suggests criteria for the use of nicotine replacement therapy.

Evidence. The following statements are based on published meta-analyses and panel opinion:

- Transdermal nicotine approximately doubles 6- to 12-month abstinence rates over those produced by placebo interventions. Five meta-analyses have concluded that the nicotine patch is a highly effective aid to smoking cessation. (Strength of Evidence = A)
- Transdermal nicotine is consistently more efficacious than placebo treatment regardless of the intensity of any adjuvant psychosocial interventions. However, intensive psychosocial interventions increase absolute abstinence rates among individuals given either placebo or active patch treatment. (Strength of Evidence = A)
- Patients are more likely to comply with transdermal nicotine instructions than with nicotine gum instructions. (Strength of Evidence = C)

Nicotine Gum. More than 50 studies on the efficacy of nicotine gum have been published, making nicotine gum by far the most extensively investigated pharmacologic treatment for smoking cessation. This body of research has now been summarized by four major meta-analyses (Cepeda-Benito, 1993; Lam, Sze, Sacks, et al., 1987; Silagy, Mant, Fowler, et al.,

Table 16. Summary of nicotine patch meta-analyses efficacy results (*n* = 5 meta-analyses)

Meta-analysis	Followup timepoint	Number of trials	Efficacy measure[a]
Po (1993)	6 mo	8	O.R. = 2.3
Gourlay (1994)	6 mo	6	O.R. = 2.2
Tang, Law, and Wald (1994)	12 mo	6	S.I. = 9%
Silagy, Mant, Fowler, et al. (1994)	12 mo	9	O.R. = 2.1
Fiore, Smith, Jorenby, et al. (1994)	6 mo	16	O.R. = 2.6

[a] For all of the meta-analyses, the increase in cessation was reported using the odds ratio (O.R.) statistic, with the exception of the Tang meta-analysis, which used a success increment (S.I.) (active abstinence rate–control abstinence rate). All meta-analyses used an active versus placebo patch comparison.

1994; Tang, Law, and Wald, 1994). Primary results of the three most recent nicotine gum meta-analyses are summarized in Table 17.

Evidence. The following statements are based on published meta-analyses and panel opinion:

- Nicotine gum improves smoking cessation rates by approximately 40–60 percent compared with control interventions through 12 months of followup.

  Three meta-analyses found the gum to be efficacious in assisting smokers to quit, and this improvement is observed in both self-referred and unselected populations. (Strength of Evidence = A)

- Nicotine gum is consistently more efficacious than control interventions regardless of the intensity of any adjuvant psychosocial intervention, although efficacy is greater when combined with an intensive psychosocial intervention. (Strength of Evidence = B)

- The 4-mg gum is more efficacious than the 2-mg gum as an aid to smoking cessation in highly dependent smokers. (Strength of Evidence = B)

Although nicotine chewing gum is an efficacious smoking cessation treatment, problems with compliance, ease of use, social acceptability, and unpleasant taste have been noted by investigators. Because transdermal nicotine replacement is not associated with these problems, the patch may be more acceptable for most smokers. General Strategy 4 contains guidelines for the differential recommendation of the nicotine patch and nicotine gum.

General strategy 3. Suggestions on the clinical use of the nicotine patch

Patient selection	Appropriate as a primary pharmacotherapy for smoking cessation. For suggestions regarding use in special populations, see General Strategy 4.
Precautions	*Pregnancy*— Pregnant smokers should first be encouraged to attempt cessation without pharmacologic treatment. The nicotine patch should be used during pregnancy only if the increased likelihood of smoking cessation, with its potential benefits, outweighs the risk of nicotine replacement and potential concomitant smoking. Similar factors should be considered in lactating women. *Cardiovascular diseases*— Although not an independent risk factor for acute myocardial events, the nicotine patch should be used only after consideration of risks and benefits among particular cardiovascular patient groups: those in the immediate (within 4 weeks) postmyocardial infarction period, those with serious arrhythmias, and those with severe or worsening angina pectoris. *Skin reactions*— Up to 50% of patients using the nicotine patch will have a local skin reaction. Skin reactions are usually mild and self-limiting, but may worsen over the course of therapy. Local treatment with hydrocortisone cream (5%) or triamcinolone cream (.5%) and rotating patch sites may ameliorate such local reactions. In less than 5% of patients do such reactions require the discontinuation of nicotine patch treatment.
Dosage	Treatment of 8 weeks or less has been shown to be as efficacious as longer treatment periods (Fiore, Smith, Jorenby, et al., 1994). Based on this finding, the following treatment schedules are suggested as reasonable for most smokers. Clinicians should consult the package insert for other treatment suggestions. Finally, clinicians should consider individualizing treatment based on specific patient characteristics, such as previous experience with the patch, amount smoked, degree of addictiveness, etc.[a]

Brand	Duration	Dosage
Nicoderm	4 weeks	21 mg/24 hours
and Habitrol	then 2 weeks	14 mg/24 hours
	then 2 weeks	7 mg/24 hours
Prostep	4 weeks	22 mg/24 hours
	then 4 weeks	11 mg/24 hours
Nicotrol	4 weeks	15 mg/16 hours
	then 2 weeks	10 mg/16 hours
	then 2 weeks	5 mg/16 hours

Prescribing instructions	*No smoking* while using the patch. *Location*— At the start of each day, the patient should place a new patch on a relatively hairless location between the neck and waist. *Activities*— No restrictions while using the patch. *Time*— Patches should be applied as soon as patients waken on their quit day.

[a] These dosage recommendations are based on a review of the published research literature and do not necessarily conform to packet insert information.

General strategy 4. Clinical guidelines for prescribing nicotine replacement products

Who should receive nicotine replacement?	Available research shows that nicotine replacement generally increases rates of smoking cessation. *Therefore, except in the presence of serious medical precautions, the clinician should encourage the use of nicotine replacement with patients who smoke.* Little research is available on the use of nicotine replacement with light smokers (e.g., those smoking 10–15 cigarettes/day or less). If nicotine replacement is to be used with light smokers, a lower starting dose of the nicotine patch or nicotine gum should be considered.
Should nicotine replacement therapy be tailored to the individual smoker?	Research does not support the tailoring of nicotine patch therapy (except with light smokers as noted above). Patients should be prescribed the patch dosages outlined in General Strategy 3. Research supports tailoring nicotine gum treatment. Specifically, 4-mg gum, as opposed to 2-mg gum, can be used with patients who are highly dependent on nicotine (e.g., those smoking more than 20 cigarettes/day, those who smoke within 30 minutes of awakening, and those who report that it is difficult to refrain from smoking where it is forbidden; see Heatherton, Kozlowski, Frecker, et al., 1991). Clinicians may also recommend the higher gum dosage if patients request it or have failed to quit using the 2-mg gum.
Should patients be encouraged to use the nicotine patch or nicotine gum?	Although both pharmacotherapies are efficacious, nicotine patch therapy is preferable for routine clinical use. This preference is based on the following comparisons with nicotine gum therapy: ■ Nicotine patch therapy is associated with fewer compliance problems that interfere with effective use. ■ Nicotine patch therapy requires less clinician time and effort to train patients in its effective use. The following factors support the use of nicotine gum: ■ Patient preference. ■ Previous failure with the nicotine patch. ■ Contraindications specific to nicotine patch use (e.g., severe skin reactions).

Most side effects of gum use are relatively mild and transient, and many can be resolved by simply correcting the user's chewing technique. Some patients may desire to continue nicotine replacement therapy for periods longer

Table 17. Summary of nicotine gum meta-analyses[a] (n = 3 meta-analyses)[b]

Meta-analysis	Percent abstinent (12 mo)		Odds ratio (95% C.I.)
	Active gum	Control[c]	
Cepeda-Benito (1993)	16.9	12.5	1.4 (1.4–1.4)[e]
Tang, Law, and Wald (1994)	17.9	12.8	1.5 (1.4–1.5)
Silagy, Mant, Fowler, et al. (1994)	18.2[d]	10.6	1.6 (1.5–1.8)

[a] In general, these meta-analyses reported treatment outcome effects as a function of control variables such as counseling intensity, patient recruitment methods, gum dosage, and nicotine dependence. One clear finding was that nicotine gum effect sizes are larger when gum is used in the context of intensive psychosocial therapy than when used with brief therapy. For ease of presentation, only overall effect sizes from each analysis are tabled. In cases where no overall value was presented in the original report, average effect sizes were estimated from data provided.

[b] Data from Lam, Sze, Sacks, et al. (1987) are omitted because this older meta-analysis included only nine nicotine gum studies, which were included in the later meta-analyses.

[c] Control groups are a mixture of placebo and no-gum conditions.

[d] This estimate includes data from seven studies involving the 4-mg gum and thus may be biased upward.

[e] (1.41–1.43).

than usually recommended. For instance, studies suggest that when patients are given free access to nicotine gum, 15–20 percent of successful abstainers continue to use the gum for a year or longer (Hajek, Jackson, and Belcher, 1988; Hughes, Wadland, Fenwick, et al., 1991). Although weaning should be encouraged, continued use of nicotine replacement is clearly preferable to a return to smoking with respect to health consequences. This is because, unlike smoking, nicotine replacement products do not (a) contain nonnicotine toxic substances (e.g., "tar"), (b) produce dramatic surges in blood nicotine levels, and (c) produce strong dependence (Henningfield, 1995). Suggestions regarding the clinical use of nicotine gum are provided in General Strategy 5.

Other Nicotine Replacement Interventions. Two new nicotine replacement interventions, a nicotine nasal spray and a nicotine inhaler, have been developed and tested. Published data on these products are limited, but studies demonstrate a significant benefit compared with placebo interventions (Hjalmarson, Franzon, Westin, et al., 1994; Sutherland, Stapleton, Russell, et al., 1992; Tonnesen, Norregaard, Mikkelsen, et al., 1993). At present, these products are not licensed for prescription use in the United States, and there are limited data regarding their use. Therefore, the panel drew no conclusions about their efficacy and made no recommendations regarding their use. *[As this guideline went to press, nicotine nasal spray was approved for use in the United States by the FDA.]*

General strategy 5. Suggestions for the clinical use of nicotine gum

Patient selection	Appropriate as a primary pharmacotherapy for smoking cessation. For suggestions regarding use in special populations, see General Strategy 4.
Precautions	*Pregnancy*—Pregnant smokers should first be encouraged to attempt cessation without pharmacologic treatment. Nicotine gum should be used during pregnancy only if the increased likelihood of smoking cessation, with its potential benefits, outweighs the risk of nicotine replacement and potential concomitant smoking. *Cardiovascular diseases*—Although not an independent risk factor for acute myocardial events, nicotine gum should be used only after consideration of risks and benefits among particular cardiovascular patient groups: those in the immediate (within 4 weeks) postmyocardial infarction period, those with serious arrhythmias, and those with severe or worsening angina pectoris. *Side effects*—Common side effects of nicotine chewing gum include mouth soreness, hiccups, dyspepsia, and jaw ache. These effects are generally mild and transient, and can often be alleviated by correcting the patients' chewing technique (see *Prescribing instructions* below).
Dosage	Nicotine gum is available in 2-mg and 4-mg (per piece) doses. Patients should be prescribed the 2-mg gum except in special circumstances outlined in General Strategy 4. The gum is most commonly prescribed for the first few months of a quit attempt. Clinicians should tailor the duration of therapy to fit the needs of each patient. Patients using the 2-mg strength should use not more than 30 pieces/day, whereas those using the 4-mg strength should not exceed 20 pieces/day. (Information on tailoring the dose of nicotine gum is presented in General Strategy 4.)
Prescribing instructions	*No smoking* while using the gum. *Chewing technique*—Gum should be chewed slowly until a "peppery" taste emerges, then "parked" between cheek and gum to facilitate nicotine absorption through the oral mucosa. Gum should be slowly and intermittently "chewed and parked" for about 30 minutes. *Absorption*—Acidic beverages (e.g., coffee, juices, soft drinks) interfere with the buccal absorption of nicotine, so eating and drinking anything except water should be avoided for 15 minutes before and during chewing. *Scheduling of dose*—Patients often do not use enough gum to get the maximum benefit: they chew too few pieces per day and they do not use the gum for a sufficient number of weeks. Instructions to chew the gum on a fixed schedule (at least one piece every 1–2 hours) for at least 1–3 months may be more beneficial than ad lib use.

Over-the-Counter Nicotine Replacement Therapy. The FDA approved nicotine gum for over-the-counter (OTC) use in April 1996, and the nicotine patch may be approved for OTC use by the end of 1996. Although the OTC status of these medications will no doubt increase their availability, this does not reduce the clinician's essential responsibility to intervene with smokers. Once OTC nicotine replacement products are available, the clinician will also continue to have specific responsibilities regarding these products, such as encouraging their use when appropriate, providing counseling, and offering instruction on appropriate use. In addition, the clinician may advise patients regarding the use of an OTC product versus a non-OTC product such as a new nicotine replacement treatment or antidepressant therapy.

Clonidine. Evidence for the efficacy of clonidine as a smoking cessation intervention was derived from an examination of individual studies, a published meta-analysis, and a fixed-effect meta-analysis conducted by guideline staff that examined clonidine use in women only. The use of a fixed-effects model, opposed to a random-effects model, is a departure from the typical guideline analytic strategy. The fixed-effects meta-analysis was used because of the very small number of studies available for analysis and the different statistical assumptions of the two models (see the technical report).

Evidence. There is little support for the use of clonidine either as a primary or as an adjunctive pharmacologic treatment for smoking cessation. (Strength of Evidence = B)

Seven clinical trials on clonidine were identified in the initial literature review, but only two fulfilled selection criteria for meta-analysis. Based on these two studies, the guideline meta-analysis suggested that clonidine may be effective with female patients (odds ratio = 3.0, 95 percent C.I. = 1.5–5.9). However, no recommendations were made with respect to clonidine because of the following concerns. First, of the seven trials examining the effectiveness of clonidine for smoking cessation, only two provided adequate long-term followup information. Second, only three of the seven clonidine studies presented results by gender, and only two of these three met meta-analytic selection criteria. Thus, the success of clonidine among women may be the reason for the presentation of results by gender in these studies; that is, there may be a selection bias. Finally, side effects are common with clonidine use, and as many as 25 percent of patients may discontinue clonidine therapy for this reason.

Antidepressants. Smoking is significantly more prevalent among individuals with a history of depression, and these individuals have more difficulty quitting smoking than do smokers without a history of depression (Anda, Williamson, Escobedo, et al., 1990; Breslau, Kilbey, and Andreski, 1992; Glassman, Helzer, Covey, et al., 1990). Some trials have investigated the use of antidepressants for smoking cessation, but no published articles met selection criteria for review. Because of a paucity of data, the panel drew no conclusions about antidepressant therapy for smoking cessation.

Anxiolytics/Benzodiazepines. A few trials have evaluated anxiolytics as a treatment for smoking cessation. Individual trials of propranolol (a beta-blocker) and diazepam did not reveal a beneficial effect for these drugs compared with control interventions. Only one study using an anxiolytic (buspirone) revealed evidence of efficacy in smoking cessation. Because of a lack of data, no conclusion was drawn regarding the efficacy of anxiolytics in smoking cessation.

Silver Acetate. The three randomized clinical trials of silver acetate that met selection criteria revealed no beneficial effects for smoking cessation.

Evidence. The use of silver acetate as either a primary or an adjunctive treatment for smoking cessation was not supported. (Strength of Evidence = B)

Followup Assessment and Procedures

Recommendation: All patients who receive an intervention should be assessed for abstinence at the completion of treatment or during subsequent clinic visits. (1) for abstinent patients, all should receive relapse prevention treatment (see section in Chapter 4, Relapse Prevention). (2) For patients who have relapsed, assess their willingness to quit (Strength of Evidence = C):

- **If willing to quit, provide or arrange an additional intervention (see section in Chapter 3, Interventions).**
- **If not willing to quit at the current time, provide an intervention designed to promote the motivation to quit (see section in Chapter 4, Promoting the Motivation to Quit).**

All patients should be assessed with respect to their smoking status at least at the completion of treatment. Additional assessments within the first 2 weeks of quitting should also be considered (Kenford, Fiore, Jorenby, et al., 1994). Abstinent patients should receive relapse prevention treatment (see General Strategy 8) including reinforcement for their decision to quit, congratulations on their success at quitting, and encouragement to remain abstinent. Clinicians should also inquire about current and future threats to abstinence and provide appropriate suggestions for coping with these threats.

Patients who have relapsed should be assessed for their willingness to quit. Patients who are currently motivated to make another quit attempt should be provided with an intervention (see section in Chapter 3, Interventions). Clinicians may wish to increase the intensity of psychosocial treatment at this time or refer the patient to a smoking cessation specialist/program for a more intensive treatment if the patient is willing. In addition, nicotine replacement should be offered to the patient. If the previous cessation attempt included nicotine replacement, the clinician should review whether the patient used these medications in an effective manner and consider use of another form (see General Strategies 3 and 5).

Patients who are unwilling to quit at the current time should receive a brief intervention designed to promote the motivation to quit (see General Strategy 6).

Reimbursement for Smoking Cessation Treatment

Recommendation: Smoking cessation treatments (both pharmacotherapy and counseling) should be provided as paid services for subscribers of health insurance/managed care. (Strength of Evidence = C)

Recommendation: Clinicians should be reimbursed for delivering effective smoking cessation treatments. (Strength of Evidence = C)

Primary care clinicians frequently cite insufficient insurance reimbursement as a barrier to the provision of preventive services such as smoking cessation treatment (Henry, Ogle, and Snellman, 1987; Orleans, Schoenbach, Salmon, et al., 1989). Insurance coverage has been shown to increase rates of cessation services utilization and therefore increase rates of quitting. For example, the presence of prepaid or discounted prescription drug benefits increases patients' receipt of nicotine gum, the duration of gum use (Johnson, Hollis, Stevens, et al., 1991), and smoking cessation rates (Cox and McKenna, 1990; Hughes, Wadland, Fenwick, et al., 1991). In addition, an 8-year insurance industry study found that reimbursing physicians for provision of preventive care resulted in reported increases in exercise, seat belt use, and weight loss, as well as decreased alcohol use and a trend (because of small sample size) toward decreased smoking (Logsdon, Lazaro, and Meier, 1989).

4 Promoting the Motivation To Quit and Preventing Relapse

Promoting the Motivation To Quit

Recommendation: For patients not willing to initiate a quit attempt at the time of their health care visit, clinicians should engage in a brief intervention designed to promote motivation to quit. (Strength of Evidence = C)

Enhancing the motivation to quit requires some initial steps described in detail earlier in this guideline. Specifically, patients entering a health care setting should have their smoking status assessed regularly. As a result of a systematic, institutionalized assessment of smoking status, clinicians should advise all smokers to quit and assist those willing to make a quit attempt.

Despite receiving a clinician's advice to quit smoking, many patients are not willing to make a commitment to quit. These patients may be uninformed, concerned about the effects of quitting, or demoralized because of previous relapse. Such patients may respond to a motivational intervention. Motivational interventions are characterized by the "4 Rs": relevance, risks, rewards, and repetition. Clinical components of the 4 Rs are shown in General Strategy 6. Finally, some patients may be discouraged by previous relapses. These patients should be informed that most smokers make repeated cessation attempts before achieving long-term abstinence.

Relapse Prevention

Recommendation: When clinicians encounter a recent quitter, they should reinforce the patient's decision to quit, review the benefits of quitting, and assist the patient in resolving any residual problems arising from quitting. (Strength of Evidence = C)

Although most relapse occurs early in the quitting process (Kenford, Fiore, Jorenby, et al., 1994), some relapse occurs months or even years after the quit date (Hatziandreu, Pierce, Lefkopoulou, et al., 1990). Therefore, clinicians should engage in relapse prevention interventions designed to reduce the long-term risks of relapse (Brandon, Tiffany, and Baker, 1986). Interventions should be delivered to former smokers who no longer consider themselves actively engaged in the quitting process. (For information on how to reduce relapse risk among those actively engaged in quitting, see General Strategies 1 and 2.)

Relapse prevention interventions can be delivered by means of either prearranged telephone calls or clinic visits, or any time the clinician encounters an ex-smoker. It is vital that a systematic, institutionalized mechanism be in place to identify ex-smokers, because that is a necessary first step in delivering relapse prevention messages.

General strategy 6. Components of clinical interventions designed to enhance motivation to quit smoking: the "4 Rs"

Relevance	Motivational information given to a patient has the greatest impact if it is relevant to a patient's disease status, family or social situation (e.g., having children in the home), health concerns, age, gender, and other important patient characteristics (e.g., prior quitting experience).
Risks	The clinician should ask the patient to identify the potential negative consequences of smoking. The clinician may suggest and highlight those that seem most relevant to the patient. The clinician should emphasize that smoking low-tar/low-nicotine cigarettes or use of other forms of tobacco (e.g., smokeless tobacco, cigars, pipes) will not eliminate these risks. Examples of risks follow: ■ *Acute risks:* Shortness of breath, exacerbation of asthma, impotence, infertility, increased serum carbon monoxide. ■ *Long-term risks:* Heart attacks and strokes, lung and other cancers (larynx, oral cavity, pharynx, esophagus, pancreas, bladder, cervix, leukemia), chronic obstructive pulmonary diseases (chronic bronchitis and emphysema). ■ *Environmental risks:* Increased risk of lung cancer in spouse and children; higher rates of smoking by children of smokers; increased risk for SIDS, asthma, middle ear disease, and respiratory infections in children of smokers.
Rewards	The clinician should ask the patient to identify the potential benefits of quitting smoking. The clinician may suggest and highlight those that seem most relevant to the patient. Examples of rewards follow: ■ Improved health ■ Food will taste better ■ Improved sense of smell ■ Save money ■ Feel better about yourself ■ Home, car, breath will smell better ■ Can stop worrying about quitting ■ Set a good example for kids ■ Have healthy babies and children ■ Not worry about exposing others to smoke ■ Feel better physically ■ Freedom from addiction ■ Perform better in sports
Repetition	The motivational intervention should be repeated every time an unmotivated patient visits the clinic setting.

Relapse prevention interventions can be divided into two categories: minimal practice and prescriptive interventions.

Minimal Practice

Minimal relapse prevention interventions should be part of every primary care encounter with a patient who has recently quit (General Strategy 7).

General strategy 7. Components of *minimal practice* relapse prevention interventions

1. Every ex-smoker undergoing relapse prevention should receive congratulations, encouragement, and a statement of concern on the part of the clinician that the patient remain abstinent.
2. The clinician should encourage the patient's active discussion of the topics listed below. The clinician should ask the patient open-ended questions designed to initiate the patient's problem solving on these topics (e.g., How has stopping smoking helped you?):
   - The benefits, including potential health benefits, the patient may derive from cessation.
   - Any success the patient has had in quitting (duration of abstinence, reduction in withdrawal, etc.).
   - The problems encountered or anticipated in maintaining abstinence (e.g., depression, weight gain).
   - Anticipated problems or threats to maintaining abstinence.

Because most relapse occurs within the first 3 months after quitting, relapse prevention is especially appropriate during this period (DHHS, 1994). Relapse prevention activities can easily be incorporated into cessation treatments such as problem-solving counseling (see General Strategy 1).

Prescriptive Interventions

These relapse prevention components are individualized based on information obtained about problems the patient has encountered in maintaining abstinence (General Strategy 8). These more intensive relapse prevention interventions may be delivered through primary care or through a specialized clinic or program.

General strategy 8. Components of *prescriptive* relapse prevention interventions

During relapse prevention, an inquiry about problems encountered in maintaining abstinence might lead the clinician to make recommendations or offer treatment designed to address specific problems reported by the patient. Specific problems likely to be reported by patients and potential responses follow:

Weight gain—The clinician might make dietary, exercise, or lifestyle recommendations, or might refer the patient to a specialist or program. The patient can be reassured that some weight gain after quitting is common and that significant dietary restrictions soon after quitting may be counterproductive.

Negative mood or depression—If significant, the clinician might prescribe appropriate medications or refer the patient to a specialist.

Prolonged withdrawal symptoms—If the patient reports prolonged craving or other withdrawal symptoms, the clinician might consider extending nicotine replacement therapy.

Lack of support for cessation—The clinician might schedule followup phone calls with the patient, help the patient identify sources of support within his/her environment, or refer the patient to an appropriate organization that offers cessation counseling or support.

5 Special Populations and Topics

Background

Many factors could potentially affect the choice, delivery, and efficacy of cessation interventions. This possibility raises numerous questions. For instance, should interventions be tailored or modified on the basis of gender, age, or hospitalization status? Should pregnant smokers receive nicotine replacement therapy? Do smoking cessation interventions work with smokeless tobacco users? How do cessation and intervention affect weight, and should treatment be modified with those effects in mind? These special issues are considered in this chapter. It is important to note that many health care specialties can have a key role in addressing these issues (e.g., obstetrics and family practice for pregnant smokers; gynecology and family practice for preconceptional counseling and general health maintenance; pediatrics for children and adolescents; internal medicine (including cardiology, pulmonology, and oncology) and family practice for hospitalized patients; and dentistry and orthodonture for smokeless tobacco users).

Gender

Recommendation: The same smoking cessation treatments are effective for both men and women. Therefore, the same interventions can be used with both sexes. (Strength of Evidence = B)

One important question regarding quitting smoking is whether men and women should receive different cessation interventions. Smoking cessation clinical trials reveal that the same treatments benefit both men and women. Moreover, epidemiologic studies do not show a consistent gender difference in quit attempts and success rates. Few studies have examined programs specifically tailored to one gender, however. Although research suggests that women benefit from the same interventions as do men, women may face different stressors and barriers to quitting that may be addressed in treatment. These include greater likelihood of depression, weight control concerns, and issues surrounding child care.

Evidence. There is no consistent evidence of gender differences in response to smoking cessation treatments. (Strength of Evidence = B)

Racial and Ethnic Minorities

Recommendation: Members of racial and ethnic minorities should be provided smoking cessation treatments shown to be effective in this guideline. (Strength of Evidence = B)

Recommendation: Whenever possible, smoking cessation treatments should be modified or tailored to be appropriate for the ethnic or racial populations with which they are used. (Strength of Evidence = C)

Ethnic and racial minority groups in the United States—African Americans, American Indians/Native Americans, Alaskan Natives, Asian and Pacific Islanders, Hispanics—experience higher mortality in a number of disease categories compared with the white majority. For example, African Americans experience substantial excess mortality from cancer, cardiovascular disease, and infant death, all of which are directly affected by tobacco use (CDC, 1987). American Indians and Alaskan Native subgroups have some of the highest documented rates of infant mortality caused by sudden infant death syndrome (Coultas, Gong, Grad, et al., 1994). Therefore, there is a critical need to deliver effective smoking intervention to ethnic and racial minorities.

There are well-documented differences between racial and ethnic minorities and the white majority in smoking patterns and in smoking and quitting prevalence (Orleans, Schoenbach, Salmon, et al., 1989; Stotts, Glynn, and Baquet, 1991). In addition, smoking prevalence and patterns vary substantially among minority subgroups (Coultas, Gong, Grad, et al., 1994). Racial and ethnic minorities also differ from whites in awareness of health effects of smoking (Brownson, Jackson-Thompson, Wilkerson, et al., 1992) and a sense of fatalism that may affect disease prevention efforts. On the other hand, both nicotine addiction and desire to quit appear to be prevalent across all racial and ethnic groups (Orleans, Schoenbach, Salmon, et al., 1989; Royce, Hymowitz, Corbett, et al., 1993; Stotts, Glynn, and Baquet, 1991).

Few studies have examined interventions specifically tailored to particular ethnic or racial groups, and there is no consistent evidence that tailored cessation programs result in higher quit rates in these groups. Moreover, smoking cessation interventions developed for the general population have been effective with racial and ethnic minority participants. Therefore, clinicians who see minority group patients should offer them treatments identified as effective in this guideline. Clinicians should remain sensitive, however, to individual differences and health beliefs that may affect treatment acceptance and success (see section in Chapter 3, Specialized Assessment).

Because of the small amount of research on this topic, there is currently little support for the obligatory tailoring of cessation treatments for minority populations. Logically, however, tailoring may be necessary at times for effective intervention. For instance, cessation counseling or self-help materials must be conveyed in a language understood by the smoker. Additionally, culturally appropriate models or examples may increase the smoker's acceptance of treatment. Certainly, practices with multiethnic or multiracial populations should make culturally appropriate materials available whenever resources permit.

Among subgroups of racial and ethnic minorities, some smoke at exceptionally high rates and suffer high rates of smoking-attributable morbidity

and mortality (Coultas, Gong, Grad, et al., 1994; Sugarman, Warren, Oge, at al., 1992). Yet, there is relatively little extant research on optimal interventions or on the specific barriers or impediments to successful cessations for these populations (e.g., relatively low educational attainment, inadequate access to medical care). These are important topics for future research.

Evidence. The following statements support the above recommendations:

- Smoking cessation treatments identified as effective in this guideline increase smoking cessation rates among members of ethnic and racial minorities. (Strength of Evidence = B)
- Smoking is especially prevalent among some racial and ethnic minority subgroups and results in mortality and morbidity. (Strength of Evidence = A)
- Although little research has been done on the effectiveness of treatment tailoring for ethnic and racial minority populations, some types of tailoring such as the use of language-appropriate materials should increase treatment effectiveness. (Strength of Evidence = C)

Pregnancy

Recommendation: Pregnant smokers should be strongly encouraged to quit throughout pregnancy. Because of the serious risks of smoking to the pregnant smoker and fetus, pregnant smokers should be offered intensive counseling treatment. (Strength of Evidence = A)

Recommendation: Minimal interventions should be used if more intensive interventions are not feasible. (Strength of Evidence = C)

Recommendation: Motivational messages regarding the impact of smoking on both the pregnant smoker and fetus should be given. (Strength of Evidence = C)

Recommendation: Nicotine replacement should be used during pregnancy only if the increased likelihood of smoking cessation, with its potential benefits, outweighs the risk of nicotine replacement and potential concomitant smoking. (Strength of Evidence = C)

Smoking in pregnancy imparts risks to both the woman and the fetus. Many women are motivated to quit during pregnancy, and health care professionals can take advantage of this motivation by reinforcing the notion that cessation will be best for the fetus, with postpartum benefits for both mother and children. On the other hand, clinicians should be aware that some pregnant women may try to hide their smoking status.

Quitting smoking prior to conception or early in the pregnancy is most beneficial, but health benefits result from cessation at any time. Therefore, a pregnant woman who still smokes should continue to be encouraged and helped

to quit. Women who quit smoking during pregnancy have a high rate of relapse in the postpartum period. Relapse is common in the postpartum period even among women who have maintained total abstinence from tobacco for 6 or more months during pregnancy. Relapse postpartum may be decreased by continued emphasis on the relationship between maternal smoking and poor health outcomes (sudden infant death syndrome, respiratory infections, asthma, and middle ear disease) in infants and children. General Strategy 9 outlines clinical factors to address when counseling pregnant women about smoking.

No clinical trials have assessed the benefits and risks of nicotine replacement therapy as an aid to smoking cessation in pregnant women. In a review of this topic, Benowitz (1991) concluded that, for pregnant women, the benefits of nicotine replacement therapy outweigh the risks of both continued smoking and nicotine replacement itself. Benowitz limited this conclusion, however, to those pregnant women who cannot stop without replacement therapy and suggested that benefits would be the greatest for heavy smokers.

To assess the effectiveness of smoking cessation during pregnancy, the panel used both a published meta-analysis (Mullen, Ramirez, and Groff, 1994) and a meta-analysis conducted by panel staff (Table 18). The meta-analysis conducted by panel staff was based on six studies evaluating the effectiveness of smoking cessation counseling in pregnant smokers. The effectiveness of counseling interventions in these studies was compared with either "no treatment" or "usual care" conditions. The latter usually consisted of a recommendation to stop smoking that was often supplemented by provision of self-help material or referral to a stop-smoking program. Because of the small number of studies available for analysis, only the impact of counseling (greater than 10 minutes of person-to-person contact) was examined in the meta-analysis. Less intense interventions, such as those involving "minimal contact" or "brief counseling" (see subsection in Chapter 3, Intensity of Person-to-Person Clinical Intervention), were not examined because of a lack of relevant studies. Both the panel meta-analysis and the published meta-analysis yielded essentially the same finding—smoking cessation interventions during pregnancy are effective and should be used to benefit both the woman and the fetus.

Evidence. The following statements support the above recommendations:

- A published meta-analysis and a meta-analysis conducted by panel staff (n = 14 studies) suggest that counseling interventions during pregnancy increase quit rates above those of pregnant women who do not receive such interventions. (Strength of Evidence = A)

- Because of the small number of studies examining minimal counseling in pregnant smokers, no focused statistical tests were possible on this topic. However, the panel concluded that minimal counseling has a beneficial effect and should be used if more intensive counseling is not feasible. (Strength of Evidence = C)

General strategy 9. Clinical issues when assisting a pregnant patient in smoking cessation

Clinical issues	Rationale
Quit early in pregnancy if possible.	Early quitting provides the greatest benefit to the fetus.
Quit anytime during pregnancy.	Fetus benefits even when quitting later in pregnancy.
Stress early benefits to quitting.	Both woman and fetus will benefit immediately.
Provide pregnancy-related motivational messages.	These are associated with higher quit rates.
Be alert to patients' minimizing or denying tobacco use.	Minimizing or denying smoking is common among pregnant women who smoke.
Assess for relapse and use relapse prevention.	Postpartum relapse rates are high even if a woman maintains abstinence throughout pregnancy (see General Strategies 6 and 7). Relapse prevention may start during pregnancy.

Table 18. Efficacy of counseling intervention with pregnant smokers

Level of contact	Number of arms	Estimated odds ratio (95% C.I.)	Estimated cessation rate (95% C.I.)
No contact/usual care (reference group)	11	1.0	7.9
Counseling	8	2.0 (1.3–2.9)	14.7 (9.8–19.5)

Hospitalized Smokers

Recommendation: For every hospitalized patient, the following steps should be taken: (a) ask each patient on admission if he/she smokes and document smoking status; (b) for current smokers, list smoking status on the admission problem list and as a discharge diagnosis; (c) assist all smokers with quitting during the hospitalization, using treatments identified as effective in this guideline, including nicotine replacement therapy if appropriate; and (d) provide advice and assistance on how to remain abstinent after discharge. (Strength of Evidence = C)

It is vital that hospitalized patients attempt to quit smoking, because smoking may interfere with their recovery. Among cardiac patients, second

heart attacks are more common in those who continue to smoke (Multiple Risk Factor Intervention Trial Research Group, 1990). Lung, head, and neck cancer patients who are successfully treated, but who continue to smoke, are at elevated risk for a second cancer (Browman, Wong, Hodson, et al., 1993). Smoking negatively affects bone and wound healing (Jones, 1985).

Every hospital in the United States must now be smoke free if it is to be accredited by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO). As a result, hospitalized patients may be particularly motivated to make a quit attempt for two reasons. First, the illness resulting in hospitalization may have been caused or exacerbated by smoking, highlighting the patient's personal vulnerability to the health risks of smoking. Second, motivation may be enhanced during hospitalization because the smoker is temporarily housed in a smoke-free environment. For these reasons, clinicians should use hospitalization as an opportunity to promote smoking cessation in their patients who smoke (Hurt, Lauger, Offord, et al., 1991; Stevens, Glasgow, Hollis, et al., 1993). Patients in long-term care facilities should also receive cessation interventions identified as efficacious in this guideline.

Specifically, clinicians and hospital administrators should collaborate to ensure that systems are in place that identify the smoking status of all patients admitted to a hospital and that provide at least a brief clinical intervention to every hospitalized patient who smokes.

Finally, smokers may experience nicotine withdrawal symptoms during a hospitalization. Clinicians should consider providing temporary nicotine patch therapy during a hospitalization to reduce such symptoms.

Efficacy of Inpatient Hospital Smoking Cessation Treatment

Five studies met selection criteria for analyses examining the effectiveness of inpatient hospital smoking cessation treatment compared with usual care. Because of the limited number of studies, no attempt was made to separate the level or type of treatment. Results are shown in Table 19.

Evidence. Smoking cessation interventions among hospitalized patients increase rates of smoking cessation. (Strength of Evidence = A)

Smokers With Psychiatric Comorbidity

Recommendation: Smokers with comorbid psychiatric conditions should be offered smoking cessation treatments identified as effective in this guideline. (Strength of Evidence = C)

Recommendation: Although it is not necessary to assess for psychiatric comorbidity prior to initiating smoking treatment, such assessment may be helpful in that it allows the clinician to prepare for an increased likeli-

Table 19. Efficacy of inpatient smoking cessation treatment (n = 5 studies)

Type of treatment	Number of arms	Estimated odds ratio (95% C.I.)	Estimated cessation rate (95% C.I.)
No inpatient smoking cessation treatment (reference group)	5	1.0	18.0 (10.1–27.5)
Inpatient smoking cessation treatment provided	5	1.4 (1.1–1.7)	23.1 (19.2–27.0)

hood of smoking relapse or for exacerbation of the comorbid condition in response to nicotine withdrawal. (Strength of Evidence = C)

The term "psychiatric comorbidity" refers to the co-occurrence of smoking with another psychiatric disorder. Psychiatric comorbidity is important to the assessment and treatment of smokers for several reasons:

- Psychiatric disorders are more common among smokers than in the general population. For instance, as many as 30–50 percent of patients seeking smoking cessation services may have a history of depression, and 20 percent or more may have a history of alcohol abuse or dependence (Brandon, 1994; Glassman, Stetnes, Walsh, et al., 1988; Hall, Munoz, Reus, et al., 1993; also cf. Breslau, 1995; Breslau, Kilbey, and Andreski, 1994).
- Smoking cessation or nicotine withdrawal may exacerbate a patient's comorbid condition. For instance, smoking cessation may elicit or exacerbate depression among patients with a prior history of affective disorder (Glassman, 1993; Glassman, Covey, Dalack, et al., 1993).
- As noted in the Specialized Assessment section in Chapter 3, smokers with psychiatric comorbidities have heightened risk for relapse to smoking after a cessation attempt (Brandon, 1994; Glassman, Covey, Dalack, et al., 1993; Hall, Munoz, Reus, et al., 1993).

Although psychiatric comorbidity places smokers at increased risk for relapse, there is also evidence that such smokers can be helped by smoking cessation treatments (Breckenridge, 1990; Burling, Marshall, and Seidner, 1991; Hall, Munoz, and Reus, 1994; Hartman, Jarvik, and Wilkins, 1989; Hartman, Leong, Glynn, et al., 1991). There is currently too little evidence to determine whether smokers with psychiatric comorbidity benefit more from specialized or tailored cessation treatments than from standard treatments (e.g., Hall, Munoz, and Reus, 1994; Zelman, Brandon, Jorenby, et al., 1992). Even though some smokers may experience exacerbation of a comorbid condition upon quitting smoking, most evidence suggests that cessation entails little adverse impact. For instance, patients in inpatient psychiatric

units are able to stop smoking with few adverse effects (e.g., little increase in aggression, or nonadherence to treatment; Hurt, Eberman, Slade, et al., 1993; Resnick, 1993). Additionally, there is little evidence that patients with other chemical dependencies relapse to other drug use when they stop smoking (Hurt, Eberman, Slade, et al., 1993). Finally, stopping smoking may affect the pharmacokinetics of certain psychiatric agents (e.g., Hughes, 1993). Therefore, clinicians may wish to monitor closely the actions or side effects of psychiatric medications in smokers making a quit attempt.

Weight Gain After Smoking Cessation

Recommendation: The clinician should inform smokers that they are likely to gain weight when they stop smoking. The clinician should recommend that smokers not take strong measures (e.g., strict dieting) to counteract weight gain during a quit attempt. Moreover, ex-smokers should wait until they are confident that they will not return to smoking before trying to reduce their weight. (Strength of Evidence = C)

Recommendation: For smokers who are greatly concerned about weight gain, the clinician may prescribe or recommend nicotine gum, which has been shown to delay weight gain after quitting. (Strength of Evidence = A)

Key facts about smoking, smoking cessation, and weight gain follow:

- The majority of smokers who quit smoking gain weight. Most will gain fewer than 10 pounds, but there is a broad range of weight gain, with as many as 10 percent of quitters gaining as much as 30 pounds (Williamson, Madans, Anda, et al., 1991).
- Women tend to gain slightly more weight than men, and for both sexes, African Americans, people under age 55, and heavy smokers (those smoking more than 25 cigarettes/day) are at elevated risk for major weight gain (Emont and Cummings, 1987; Williamson, Madans, Anda, et al., 1991).
- For many smokers, especially women, concerns about weight or fears about weight gain are motivators to start smoking or continue smoking (Gritz, Klesges, and Meyers, 1989; Klesges and Klesges, 1988; Klesges, Meyers, Klesges, et al., 1989).
- Weight gain that follows smoking cessation is a negligible health threat compared with the risks of continued smoking (DHHS, 1990; Williamson Madans, Anda, et al., 1991).
- No experimentally validated strategies or treatments are effective in preventing postcessation weight gain. In fact, some evidence suggests that attempts to prevent weight gain (e.g., strict dieting) may undermine the attempt to quit smoking (Hall, Tunstall, Vila, et al., 1992; Perkins, 1994; Pirie, McBride, Hellerstedt, et al., 1992).

- Nicotine replacement—in particular, nicotine gum—appears to be effective in delaying postcessation weight gain. Moreover, there appears to be a dose–response relation between gum use and weight suppression (i.e., the greater the gum use, the less weight gain occurs). However, once nicotine gum use ceases, the quitting smoker gains an amount of weight that is about the same as if she or he had never used gum (Emont and Cummings, 1987; Gross, Stitzer, and Maldonado, 1989; Nides, Rand, Dolce, et al., 1994).
- Postcessation weight gain appears to be caused both by increased intake (e.g., eating, alcohol consumption) and by metabolic adjustments. The involvement of metabolic mechanisms suggests that even if quitting smokers do not increase their caloric intake, they will still gain some weight (Hatsukami, LaBounty, Hughes, et al., 1993; Hofstetter, Schutz, Jequier, et al., 1986; Klesges and Shumaker, 1992; Moffatt and Owens, 1991; Schwid, Hirvonen, and Keesey, 1992).
- Once a quitting smoker relapses and begins smoking at precessation levels, he or she will usually lose some or all of the weight gained during the quit attempt (Moffatt and Owens, 1991; Noppa and Bengtsson, 1980; Stamford, Matter, Fell, et al., 1986).

The research evidence reviewed above illustrates why weight gain is an important impediment to smoking cessation. Many smokers (especially women) are very concerned about their weight and fear that quitting will produce weight gain. Many also believe that they can do little to prevent postcessation weight except to return to smoking. These beliefs are especially difficult to address clinically because they are congruent with research findings; that is, the beliefs have some basis in fact.

Recommendations To Address Weight Gain

How should the clinician deal with concerns about weight gain? First, the clinician should neither deny the likelihood of weight gain nor minimize its significance to the patient. Rather, the clinician should inform the patient about the likelihood of weight gain and prepare the patient for its occurrence. However, the clinician should counter exaggerated fears about weight gain given the relatively moderate weight gain that typically occurs. Certain types of information may help prepare the patient for postcessation weight gain (see General Strategy 10).

Second, before and during the quit attempt the clinician should stress that quitting smoking is the patient's primary, immediate priority, and that the patient will be most successful in the long run if he or she does not take strong measures (e.g., strict dieting) to counteract weight gain during a quit attempt (see General Strategy 10).

Third, during the quit attempt, the clinician should offer to help the patient address weight gain (either personally or via referral) once the patient

General strategy 10. Clinician statements to help a patient prepare for, and cope with, postcessation weight gain

"The great majority of smokers gain weight once they quit smoking. However, even without special attempts at dieting or exercise, weight gain is usually limited to less than 10 lbs."

"There is evidence that smokers will gain weight once they quit smoking even if they do not eat more. Weight gain appears to be a natural part of quitting smoking."

"The amount of weight you will likely gain from quitting will be a minor health risk compared with the risks of continued smoking."

"Try to put your concerns about weight on the back burner. You are most likely to be successful if you first try to quit smoking, and then later take steps to reduce your weight. Tackle one problem at a time! After you have quit smoking successfully we can talk about how to reduce your weight."

"I know weight is important to you, and that you don't want to gain a lot of weight. However, temporarily—just until you are confident that you have quit smoking for good—let's focus on strategies to get you healthy rather than on weight. Think about eating plenty of fruit and vegetables, getting regular exercise, getting enough sleep, and not eating a lot of fats. Right now, this is probably the best thing you can do for both your weight and your smoking. Eat plenty of healthy foods—don't starve yourself!"

"While you may gain some weight after quitting smoking, compare the importance of this with the added years of healthy living you will gain, your better appearance (less wrinkled skin, whiter teeth), fresher breath, and good feelings about quitting."

has successfully quit smoking. Specifically, the clinician should recommend that intensive weight control strategies be avoided until the patient is no longer experiencing withdrawal symptoms and is confident that he or she will not return to smoking. Certainly, however, the patient should be encouraged to maintain or adopt a healthy lifestyle, including engaging in moderate exercise, eating plenty of fruits and vegetables, and limiting alcohol consumption.

Smokeless Tobacco Use

Recommendation: Smokeless tobacco (chewing tobacco and snuff) users should be identified and strongly encouraged to quit. (Strength of Evidence = C)

Recommendation: Smokeless tobacco users should be treated with the same psychosocial cessation interventions recommended for smokers. (Strength of Evidence = B)

Like cigarette smoking, the use of smokeless tobacco, such as chewing tobacco and snuff, produces addiction to nicotine and has serious health consequences. Consumption of smokeless tobacco products has increased in recent years (Glover and Glover, 1992; Marcus, Crane, Shopland, et al., 1989), especially among young males. Clinicians should offer quitting advice and assistance to their patients who use smokeless tobacco.

There is a need for smokeless tobacco information and assistance, but currently little research-based information is available on these topics. A small number of studies have evaluated both multicomponent and brief psychosocial interventions for smokeless tobacco cessation. Results of these evaluations suggest that the same cessation interventions that are effective with smokers are effective with smokeless tobacco users. Currently, there is little evidence on the effectiveness of pharmacologic treatments for smokeless tobacco use. However, nicotine replacement may help smokeless tobacco users just as it does smokers. This is an important area for further research.

Evidence. There is limited evidence that nonpharmacologic treatments used for smoking cessation are also effective in smokeless tobacco cessation. (Strength of Evidence = B)

Children and Adolescents: Primary Prevention of Tobacco Addiction

Recommendation: Clinicians should provide their pediatric and adolescent patients, and the parents of these patients, with a strong message regarding the importance of totally abstaining from tobacco use. (Strength of Evidence = C)

Recommendation: Cessation interventions shown to be effective with adults should be considered for use with children and adolescents. The content of these interventions should be modified to be developmentally appropriate. Nicotine replacement should be considered only when there is clear evidence of nicotine dependence and a clear desire to quit tobacco use. (Strength of Evidence = C)

The onset of tobacco use is a pediatric concern. Among adult daily smokers, 90 percent tried their first cigarette and 70 percent were daily users at or before age 18. Among high school seniors who had used smokeless tobacco, 79 percent had first done so by the ninth grade (DHHS, 1994). Young people begin to smoke or use tobacco for a variety of reasons related to social norms, advertising, peer pressure, parental smoking, and curiosity, but evidence suggests that nicotine addiction is established rapidly (CDC, 1995).

About three out of every four adolescent smokers have made at least one serious attempt to quit smoking and have failed (Moss, Allen, Giovino, et al., 1992). About 20 percent of high school seniors smoke daily (Green, 1979; Johnston, O'Malley, and Bachman, 1995). Among seniors who smoke daily and expect that they will not be smoking in 5 years, 73 percent are still smoking when surveyed 5–6 years after their senior year (DHHS, 1994).

Prevention of Tobacco Use

Efforts to prevent tobacco use should be conducted by many types of individuals and groups (e.g., parents, teachers, clergy, government officials,

medical societies) and in diverse venues (e.g., home, school, church, youth group). The clinician can target children and adolescents both inside and outside the clinical setting. In the clinical setting, discussion of tobacco-related issues should begin before the onset of adolescence, and preferably before entry into junior high school. These efforts should continue throughout high school. Patient charts should clearly reflect that tobacco has been discussed, and should indicate the smoking status of the patient and parents or caretakers. Clinical prevention activities are listed in General Strategy 11. Prevention strategies useful in more general settings can be found in the recent Institute of Medicine Report, "Growing Up Tobacco Free" (Lynch, Bonnie, and Institute of Medicine Committee on Preventing Nicotine

General strategy 11. Suggested interventions for clinicians to prevent the initiation of tobacco use

- Begin in the early elementary school grades to discuss tobacco use and its negative effects—especially the short-term negative effects.
- Ask the child if s/he has experimented with tobacco.
- Identify the advantages of not smoking, including those most appropriate for the patient's age and developmental stage.
- Discuss the fact that the child eventually will encounter peers who smoke, and discuss ways in which the child might resist peer pressure to try tobacco products.

For youngsters approaching middle school/junior high school age, provide the following information:

- Most kids don't smoke or use smokeless tobacco.
- All forms of tobacco (snuff, cigarettes, dip, etc.) are extremely addictive, and most teens who use tobacco are addicted to nicotine.
- Addiction to tobacco takes away one's independence.
- Smokeless tobacco is not a safe alternative to smoking, because it is addicting and causes oral cancer.
- Smoking makes a person smell bad, stains teeth and skin, causes shortness of breath, decreases athletic performance, ruins clothes, and is a major cause of fires and deaths.
- Smoking causes health problems in many young people, including chronic cough and sore throat.
- Smoking won't make a person rugged, sexy, "cool," or successful.
- Tobacco use is a gateway to other drug use, and addiction to nicotine may make a person more susceptible to trying other dangerous drugs.
- Tobacco is expensive—spending money on tobacco will mean less money for other things (e.g., books, clothes, make-up, music, movies, sports).
- There are other ways of being different without taking up a habit that is addicting and has such severe, long-term consequences.

Addiction in Children and Adults, 1994) and *Healthy People 2000: National Health Promotion and Disease Prevention Objectives* (DHHS, 1991).

Tobacco Use Cessation in Children and Adolescents

Little research evidence exists regarding either the effectiveness of psychosocial cessation interventions with children and adolescents or the safety and efficacy of pharmacological interventions with this population. Because there is no evidence that nicotine replacement is harmful for children and adolescents, clinicians should consider its use when nicotine dependence is obvious. However, because of the psychosocial and behavioral aspects of smoking in adolescents, clinicians should be confident of the patient's genuine nicotine dependence and desire to quit before instituting pharmacotherapy. Factors such as degree of dependence and body weight should be considered when selecting nicotine replacement therapy dosage.

Children and adolescents may benefit from community- and school-based intervention activities designed especially for these age groups. The messages delivered by these programs should be reinforced by the clinician (DHHS, 1994). Treatment of adolescents and children who smoke is an important research area. Along with clinical trials of interventions, studies of the "experimenters" or occasional tobacco users in this population are needed.

Evidence. Most adolescent tobacco users are addicted to nicotine and report they want to quit but are unable to do so; they experience relapse rates and withdrawal symptoms similar to those reported by adults. Little intervention research involves children and adolescent tobacco users. (Strength of Evidence = C)

References

Abrams DB, Orleans CT, Niaura RN, Goldstein MG, Prochaska JO, Velicer W. Treatment issues in smoking cessation: a stepped care approach. Tobacco Control 1993;2(suppl):17–34.

Abrams DB, Orleans CT, Niaura RN, Goldstein MG, Prochaska JO, Velicer W. Integrating individual and public health perspectives for treatment of tobacco dependence under managed health care: a combined stepped care and matching model. Ann Behav Med. In press.

American Medical Association. American Medical Association guidelines for the diagnosis and treatment of nicotine dependence: how to help patients stop smoking. Washington (DC): American Medical Association, 1994.

Anda RF, Remington PL, Sienko DG, Davis RM. Are physicians advising smokers to quit? The patient's perspective. JAMA 1987;257(14):1916–9.

Anda RF, Williamson DF, Escobedo LG, Mast EE, Giovino GA, Remington PL. Depression and the dynamics of smoking: a national perspective. JAMA 1990;264(12):1541–5.

Benowitz NL. Nicotine replacement therapy during pregnancy. JAMA 1991;22:3174–7.

Biener L, Abrams DB. The contemplation ladder: validation of a measure of readiness to consider smoking cessation. Health Psychol 1991;10(5):360–5.

Brandon SL, Tiffany ST, Baker TB. The process of smoking relapse. In: Tims F, Leukfeld C, editors. Relapse and recovery in drug abuse. National Institute on Drug Abuse Research Monograph 72. Rockville (MD): National Institute on Drug Abuse, 1986.

Brandon TH. Negative affect as motivation to smoke. Curr Directions Psychol Science 1994;3:33–7.

Breckenridge JS. Smoking by outpatients. Hosp Community Psychiatry 1990;41:454–5.

Breslau N. Psychiatric co-morbidity of smoking and nicotine dependence. Behav Genet 1995;25:95–101.

Breslau N, Kilbey MM, Andreski P. DSM-III-R nicotine dependence in young adults: prevalence, correlates and associated psychiatric disorders. Addiction 1994;89:743–54.

Breslau N, Kilbey NM, Andreski P. Nicotine withdrawal symptoms and psychiatric disorders: findings from an epidemiological study of young adults. Am J Psychiatry 1992;149(4):464–9.

Browman GP, Wong G, Hodson I, et al. Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med 1993;328:159–63.

Brownson RC, Jackson-Thompson TJ, Wilkerson JC, Davis JR, Owens NW, Fisher EB. Demographic and socioeconomic differences in beliefs about the health effects of smoking. Am J Public Health 1992;82:99–103.

Burling TA, Marshall GD, Seidner AL. Smoking cessation for substance abuse inpatients. J Subst Abuse Treat 1991;3:269–76.

Centers for Disease Control. Cigarette smoking-attributable mortality and years of potential life lost: United States, 1990. MMWR Morb Mortal Wkly Rep 1993a;42:645–9.

Centers for Disease Control. Physician and other health care professional counseling of smokers to quit: United States, 1991. MMWR Morb Mortal Wkly Rep 1993b;42:854–7.

Centers for Disease Control. Cigarette smoking among adults: United States, 1993. MMWR Morb Mortal Wkly Rep 1994;43:925–30.

Centers for Disease Control. Trends in smoking initiation among adolescents and young adults: United States, 1980-1989. MMWR Morb Mortal Wkly Rep 1995;44(28):521–5.

Centers for Disease Control. Cigarette smoking among blacks and other minority populations. MMWR Morb Mortal Wkly Rep 1987;36(25):405–7.

Cepeda-Benito A. A meta-analytic review of the efficacy of nicotine chewing gum in smoking treatment programs. J Consult Clin Psychol 1993;61:822–30.

Cohen SJ, Stookey GK, Katz BP, Drook CA, Christen AG. Helping smokers quit: a randomized controlled trial with private practice dentists. J Am Dent Assoc 1989;118:41–5.

Coultas DB, Gong H, Grad R, Handler A, McCurdy SA, Player R, Rhoades ER, Samet JM, Thomas A, Westley M. Respiratory diseases in minorities of the United States. Am J Respir Crit Care Med 1994;149:S93–S131.

Cox JL, McKenna JP. Nicotine gum: does providing it free in a smoking cessation program alter success rates? J Fam Pract 1990;31(3):278–80.

Cummings KM, Giovino G, Sciandra R, Koenigsberg M, Emont SL. Physician advice to quit smoking: who gets it and who doesn't. Am J Prev Med 1987;3(2):69–75.

Cummings SR, Rubin SM, Oster G. The cost-effectiveness of counseling smokers to quit. JAMA 1989;261(1):75–9.

Curry S. Self-help interventions for smoking cessation. J Consult Clin Psychol 1993;61:790–803.

Curry S, Wagner EH, Grothaus LC. Instrinsic and extrinsic motivation for smoking cessation. J Consult Clin Psychol 1990;58:310–16.

DerSimonian R, Laird N. Meta analysis in clinical trials. Control Clin Trials 1986;7:177–88.

Dix Smith M, McGhan WF, Lauger G. Pharmacist counseling and outcomes of smoking cessation. Am Pharm 1995;NS35(8):20–32.

Eddy DM. The economics of cancer prevention and detection: getting more for less. Cancer 1981;47(suppl):1200–9.

Eddy DM. Setting priorities for cancer control programs. J Natl Cancer Inst 1986;76:187–99.

Eddy DM. David Eddy ranks the tests. Harv Health Let 1992;11.

Eddy DM, Hasselblad V. FAST*PRO software for meta-analysis by the confidence profile method [manual for software]. San Diego (CA): Academic Press, 1992.

Emont SC, Cummings KM. Weight gain following smoking cessation: a possible role for nicotine replacement in weight management. Addict Behav 1987;12:151–5.

Fiore MC, Baker TB. Smoking cessation treatment and the good doctor club [editorial]. Am J Public Health 1995;85(2):161–3.

Fiore MC, Epps RP, Manley MW. Missed opportunity: teaching medical students about tobacco cessation and prevention. JAMA 1994;271(8):624–6.

Fiore MC, Jorenby DE, Schensky AE, Smith SS, Bauer RR, Baker TB. Smoking status as the new vital sign: effect on assessment and intervention in patients who smoke. Mayo Clin Proc 1995;70:209–13.

Fiore MC, Novotny TE, Pierce JP, Giovino GA, Hatziandreu EJ, Newcomb PA, Surawicz TS, Davis RM. Methods used to quit smoking in the United States: do cessation programs help? JAMA 1990;263:2760–5.

Fiore MC, Pierce JP, Remington PL, Fiore BJ. Cigarette smoking: the clinician's role in cessation, prevention, and public health. Disease-a-Month 1990;35(4).

Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. JAMA 1994;271:1940–7.

Frank E, Winkleby MA, Altman DG, Rockhill B, Fortmann SP. Predictors of physicians' smoking cessation advice. JAMA 1991;266:3139–44.

Gelb BD. Preventive medicine and employee productivity. Harv Bus Rev 1985;64(2):12–6.

Gilchrist V, Miller RS, Gillanders WR, Scheid DC, Logue EE, Iverson DC, Oprandi AM, Weldy DL, Krell MA. Does family practice at residency teaching sites reflect community practice? J Fam Pract 1993;37:555–63.

Glassman AH. Cigarette smoking: implications for psychiatric illness. Am J Psychiatry 1993;150:546–53.

Glassman AH, Covey LS, Dalack GW, Stetner F, Rivelli SK, Fleiss J, Cooper TB. Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin Pharmacol Ther 1993;54:670–9.

Glassman AH, Helzer JE, Covey LS, Gottler LB, Stetner F, Tipp JE, Johnson J. Smoking, smoking cessation, and major depression. JAMA 1990;264(12):1546–9.

Glassman AH, Stetnes F, Walsh BT, Raizman PS, Fleiss JL, Cooper TB, Covey LS. Heavy smokers, smoking cessation, and clonidine: results of a double-blind, randomized trial. JAMA 1988;259:2863–6.

Glover ED, Glover PN. The smokeless tobacco problem: risk groups in North America. In: Smokeless tobacco or health: an international perspective. Smoking and tobacco control monograph No. 2. US Department of Health and Human Services, Public Health Service, National Institutes of Health. Publication No. 92-3461. 1992.

Glynn TJ, Manley MW. How to help your patients stop smoking: a National Cancer Institute manual for physicians. Bethesda (MD): US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute. NIH Publication No. 90-3064, 1990.

Gourlay S. The pros and cons of transdermal nicotine therapy. Med J Aust 1994;160:152–9.

Green DE. Teenage smoking: immediate and long-term patterns. Washington (DC): National Institute of Education, 1979.

Gritz ER, Klesges RC, Meyers AW. The smoking and body weight relationship: implications for intervention and postcessation weight control. Ann Behav Med 1989;11:144–53.

Gross J, Stitzer ML, Maldonado J. Nicotine replacement: effects on postcessation weight gain. J Consult Clin Psychol 1989;57:87–92.

Group Health Association of America. HMO industry profile: 1993 edition. Washington (DC): Group Health Association of America, 1993.

Hajek P, Jackson P, Belcher M. Long-term use of nicotine chewing gum. JAMA 1988;260:2593–6.

Hall SM, Munoz RF, Reus VI, Sees KL. Nicotine, negative affect and depression. J Consult Clin Psychol 1993;61:761–7.

Hall SM, Munoz RF, Reus VI. Cognitive-behavioral intervention increases abstinence rates for depressive-history smokers. J Consult Clin Psychol 1994;62:141–6.

Hall SM, Tunstall CD, Rugg D, Jones RT, Benowitz N. Nicotine gum and behavioral treatment in smoking cessation. J Consult Clin Psychol 1985;53:256–8.

Hall SM, Tunstall CD, Vila KL, Duffy J. Weight gain prevention and smoking cessation: cautionary findings. Am J Public Health 1992;82:799–803.

Hartmann N, Jarvik M, Wilkins J. Reduction of cigarette smoking by the use of a nicotine patch. Arch Gen Psychiatry 1989;46:289.

Hartmann N, Leong GB, Glynn SM, Wilkins JN, Jarvik ME. Transdermal nicotine and smoking behavior in psychiatric patients. Am J Psychiatry 1991;148:374–5.

Hatsukami D, LaBounty L, Hughes J, Laine D. Effects of tobacco abstinence on food intake among cigarette smokers. Health Psychol 1993;12:499–502.

Hatziandreu EJ, Pierce JP, Lefkopoulou M, Fiore MC, Mills SL, Novotny TE, Giovano GA, Davis RM. Quitting smoking in the United States in 1986. J Natl Cancer Inst 1990;82(17):1402–6.

Hayward RA, Meetz HK, Shapiro MF, Freeman DE. Utilization of dental services: 1986 patterns and trends. J Public Health Dent 1989;49(3):147–52.

Heatherton TF, Kozlowski LT, Frecker RC, Fagerström K-O. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addiction 1991;86(9):1119–27.

Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med 1995;333:1196–203.

Henry RC, Ogle KS, Snellman LA. Preventive medicine: physician practices, beliefs, and perceived barriers for implementation. Fam Med 1987;19(2):110–3.

Herdman R, Hewitt M, Laschober M. Smoking-related deaths and financial costs: Office of Technology Assessment estimates for 1990. Congress of the United States. Office of Technology Assessment, 1993.

Hjalmarson A, Franzon M, Westin A, Wiklund O. Effect of nicotine nasal spray on smoking cessation: a randomized, placebo-controlled, double-blind study. Arch Intern Med 1994;154:2567–72.

Hofstetter A, Schutz Y, Jequier E, Wahren J. Increased 24-hour energy expenditure in cigarette smokers. N Engl J Med 1986;314:79–82.

Hollis JF, Lichtenstein E, Vogt TM, Stevens VJ, Biglan A. Nurse-assisted counseling for smokers in primary care. Ann Intern Med 1993;118:521–5.

Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley, 1989.

Hughes JR. Possible effects of smoke-free inpatient units on psychiatric diagnosis and treatment. J Clin Psychiatry 1993;54:109–14.

Hughes JR, Frances RJ. How to help psychiatric patients stop smoking. Psychiatr Serv 1995;46:435–45.

Hughes JR, Wadland WC, Fenwick JW, Lewis J, Bickel WK. Effect of cost on the self-administration and efficacy of nicotine gum: a preliminary study. Prev Med 1991;20:186–496.

Hurt RD, Dale LC, Offord KP, Bruce BK, McClain FL, Eberman KM. Inpatient treatment of severe nicotine dependence. Mayo Clin Proc 1992;67:823–8.

Hurt RD, Eberman KM, Croghan IT, Offord KP, Davis LJ Jr, Morse RM, Palmer MA, Bruce BK. Nicotine dependence treatment for patients undergoing inpatient treatment for other addictive disorders: a prospective intervention trial. Alcohol Clin Exp Res 1994;18(4):867–72.

Hurt RD, Eberman KM, Slade J, Karan L. Treating nicotine addiction in patients with other addictive disorders: In Orleans CT, Slade J, editors. Nicotine addiction: principles and management. New York: Oxford, 1993:310–26.

Hurt RD, Lauger GG, Offord KP, Bruce BK, Dale LC. An integrated approach to the treatment of nicotine dependence in a medical center setting. Clin Res 1991;39(2):636A.

Jaen CR, Stange KC, Nutting PA. Competing demands of primary care: a model for the delivery of clinical preventive services. J Fam Pract 1994;38:166–71.

Johnson RE, Hollis JF, Stevens VJ, Woodson GT. Patterns of nicotine gum use in a health maintenance organization. DICP Ann Pharmacother 1991;25:730–5.

Johnston LD, O'Malley PM, Bachman JG. National survey results on drug use from monitoring the future study, 1975-1994: vol. 1, secondary school students. Bethesda (MD): US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Drug Abuse. NIH Publication No. 95-4026, 1995.

Jones RM. Smoking before surgery: the case for stopping. Br Med J 1985;290:1763–4.

Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB. Predicting smoking cessation: who will quit with and without the nicotine patch. JAMA 1994;271:589–94.

Klesges RC, Klesges LM. Cigarette smoking as a dietary strategy in a university population. Int J Eat Disord 1988;7:413–9.

Klesges RC, Meyers AW, Klesges LM, LaVasque ME. Smoking, body weight, and their effects on smoking behavior: a comprehensive review of the literature. Psychol Bull 1989;106:204–30.

Klesges RC, Shumaker SA, editors. Proceedings of the national working conference on smoking and body weight. Health Psychol 1992;11(suppl):1–22.

Kottke TE, Solberg LI. Is it not time to make smoking a vital sign? Mayo Clin Proc 1995;70:303–4.

Kottke TE, Solberg LI, Brekke ML. Beyond efficacy testing: introducing preventive cardiology into primary care. Am J Prev Med 1990;6(suppl 1):77–83.

Kottke TE, Solberg LI, Brekke ML, Conn SA, Maxwell P, Brekke MJ. A controlled trial to integrate smoking cessation advice into primary care practice: doctors helping smokers, round III. J Fam Pract 1992;34:701–8.

Lam W, Sze PC, Sacks HS, Chalmers TC. Meta-analysis of randomized controlled trials of nicotine gum. Lancet 1987;2:27–30.

Lichtenstein E, Hollis JF. Patient referral to a smoking cessation program: who follows through? J Fam Pract 1992;34:739–44.

Logsdon DN, Lazaro CM, Meier RV. The feasibility of behavioral risk reduction in primary medical care. Am J Prev Med 1989;5:249–56.

Lynch BS, Bonnie RJ, editors. Institute of Medicine Committee on Preventing Nicotine Addiction in Children and Youths. Growing up tobacco free: preventing nicotine addiction in children and youths. Washington (DC): Natl Acad Press, 1994.

Marcus AC, Crane LA, Shopland DR, Lynn WR. Use of smokeless tobacco in the United States: recent estimates from the current population survey. Monogr Natl Cancer Inst 1989;8:17–24.

Mecklenburg RE, Christen AG, Gerbert B, Gift MC, et al. How to help your patients stop using tobacco: a National Cancer Institute manual for the oral health team 1990. US DHHS Public Health Service, National Institutes of Health, National Cancer Institute. NIH Publication No. 91–3191, 1991.

Moffatt RS, Owens SG. Cessation from cigarette smoking: changes in body weight, body composition, resting metabolism, and energy consumption. Metabolism 1991;40:465–70.

Moss AJ, Allen KF, Giovino GA, Mills SL. Recent trends in adolescent smoking, smoking-uptake correlates, and expectations about the future: advance data from Vital and Health Statistics, No. 221. Hyattsville (MD): National Center for Health Statistics, 1992.

Mullen PD, Ramirez G, Groff JY. A meta-analysis of randomized trials of prenatal smoking cessation interventions. Am J Obstet Gynecol 1994;171:1328–34.

Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. JAMA 1990;263:1795–1801.

National Cancer Institute. Tobacco and the clinician: interventions for medical and dental practice. NIH Publication No. 94-3693. Monogr Natl Cancer Inst 1994;5:1–22.

National Heart, Lung, and Blood Institute. How you can stop patients from smoking. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute. NIH Publication No. 91-2961, 1991.

Nelson DE, Emont SL, Brackbill RM, Cameron LL, Peddicord J, Fiore MC. Cigarette smoking prevalence by occupation in the United States. J Med 1994;36(5):516–25.

Nides M, Rand C, Dolce J, Murray R, O'Hara P, Voelker H, Connett J. Weight gain as a function of smoking cessation and 2-mg nicotine gum use among middle-aged smokers with mild lung impairment in the first 2 years of the lung health study. Health Psychol 1994;13:354–61.

Noppa H, Bengtsson C. Obesity in relation to smoking: a population study of women in Goteborg, Sweden. Prev Med 1980;9:534–43.

Ockene JK. Smoking intervention: the expanding role of the physician. Am J Public Health 1987;77:782–3.

Ockene JK, Kristeller J, Goldberg R, Amick TL, Pekow PS, Hosmer D, Quirk M, Kalan K. Increasing the efficacy of physician-delivered interventions: a randomized clinical trial. J Gen Intern Med 1991;6:1–8.

Orleans CT. Treating nicotine dependence in medical settings: a stepped-care model. In: Orleans CT, Slade J, editors. Nicotine addiction: principles and management. New York: Oxford University Press, 1993:145–61.

Orleans CT, Shoenbach VJ, Salmon MA, Strecher VJ, Kalsbeek W, Quade D, Brooks EF, Konrad TR, Blackmon C, Watts CD. A survey of smoking and quitting patterns among black Americans. Am J Public Health 1989;79:176–81.

Orleans CT, George LK, Houpt JL, Brodie KH. Health promotion in primary care: a survey of US family practitioners. Prev Med 1985;14:636–47.

Oster G, Huse DM, Delea TE, Colditz MB. Cost-effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking. JAMA 1986;256:1315–8.

Pederson LL. Compliance with physician advice to quit smoking: a review of the literature. Prev Med 1982;11:71–84.

Perkins KA. Issues in the prevention of weight gain after smoking cessation. Ann Behav Med 1994;16:46–52.

Pirie PL, McBride CM, Hellerstedt W, Jeffery RW, Hatsukami D, Allen S, Lando H. Smoking cessation in women concerned about weight. Am J Public Health 1992;82:1238–43.

Po ALW. Transdermal nicotine in smoking cessation: a meta-analysis. Eur J Clin Pharmacol 1993;45:519–28.

Prochaska JO, Goldstein MG. Process of smoking cessation: implications for clinicians. Clin Chest Med 1991;42(4):727–75.

Resnick, MP. Treating nicotine addiction in patients with psychiatric comorbidity. In: Orleans CT, Slade J, editors. Nicotine addiction: principles and management. New York: Oxford University Press, 1993;327–36.

Robinson MD, Laurent SL, Little JM Jr. Including smoking status as a new vital sign: it works. J Fam Pract 1995;40(6):556–63.

Royce JM, Hymowitz N, Corbett K, Hartwell TD, Orlandi MA. Smoking cessation factors among African Americans and whites. COMMIT Research Group. Am J Public Health 1993;83(2):220–6.

Russell MAH, Wilson C, Taylor C, Baker CD. Effect of general practioners' advice against smoking. Br Med J 1979;2:231–5.

Schwid SR, Hirvonen MD, Keesey RE. Nicotine effects on body weight: a regulatory perspective. Am J Clin Nutr 1992;55:878–84.

Scott CS, Neighbor WE. Preventive care attitudes of medical students. Soc Sci Med 1985;21:299–306.

Silagy C, Mant D, Fowler G, Lodge M. Meta–analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994;343:139–42.

Stamford BA, Matter S, Fell RD, Papanek P. Effects of smoking cessation on weight gain, metabolic rate, caloric consumption, and blood lipids. Am J Clin Nutr 1986;43:486–94.

Stevens VJ, Glasgow RE, Hollis JF, Lichtenstein E, Vogt TM. A smoking-cessation intervention for hospital patients. Med Care 1993;31(1):65–72.

Stotts RC, Glynn TJ, Baquet CR. Smoking cessation among blacks. J Health Care Poor Underserved 1991;2:307–19.

Strecher VJ, Kreuter M, Den Boer DJ, Kobrin S, Hospers HJ, Skinner CS. The effects of computer-tailored smoking cessation messages in family practice settings. J Fam Pract 1994;39(3):262–70.

Sugarman JR, Warren CW, Oge L, Helgerson SD. Using the Behavioral Risk Factor Surveillance System to monitor year 2000 objectives among American Indians. Pub Health Rep 1992;107:449–56.

Sutherland G, Stapleton JA, Russell MAH, Jarvis MJ, Hajek P, Belcher M, Fegerabend C. Randomized controlled trial of nasal nicotine spray in smoking cessation. Lancet 1992;340:324–9.

Tang JL, Law M, Wald N. How effective is nicotine replacement therapy in helping people to stop smoking? Br Med J 1994;308:21–6.

Tomar SL, Husten CG, Manley M. Do dentists and physicians advise tobacco users to quit? J Am Dent Assoc 1996;127:259–65.

Tonnesen P, Norregaard J, Mikkelsen K, Jorgensen S, Nilsson F. A double-blind trial of a nicotine inhaler for smoking cessation. JAMA 1993;269:1268–71.

US Department of Health and Human Services. Healthy People 2000, midcourse review and 1995 revisions. Washington (DC): US Department of Health and Human Services, Public Health Service, 1995.

US Department of Health and Human Services. Healthy People 2000: national health promotion and disease prevention objectives. Washington (DC): US Department of Health and Human Services, Public Health Service. DHHS Publication No. (PHS) 91–50212, 1991.

US Department of Health and Human Services. Preventing tobacco use among young people: a report of the Surgeon General. Atlanta (GA): US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1994.

US Department of Health and Human Services. Reducing the health consequences of smoking: 25 years of progress. A report of the Surgeon General. Atlanta (GA): US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. DHHS Publication No. (PHS) (CDC) 89–8411, 1989.

US Department of Health and Human Services. The health benefits of smoking cessation: a report of the Surgeon General. Atlanta (GA): US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. DHHS Publication No. (CDC) 90–8416, 1990.

US Department of Health and Human Services. The health consequences of smoking: nicotine addiction. A report of the Surgeon General. Atlanta (GA): US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office of Smoking and Health. DHHS Publication No. (PHS) (CDC) 88–8406, 1988.

Wechsler H, Levine S, Idelson RK, Rohman M, Taylor JO. The physician's role in health promotion. N Engl J Med 1983;308:97–100.

Wewers ME, Bowen JM, Stanislaw AE, Desimone VB. A nurse-delivered smoking cessation intervention among hospitalized postoperative patients—influence of a smoking-related diagnosis: a pilot study. Heart Lung 1994;23(2):151–6.

Williamson DF, Madans J, Anda RF, Kleinman JC, Giovino GA, Beyers T. Smoking cessation and severity of weight gain in a national cohort. N Engl J Med 1991;324:739–45.

Zelman DC, Brandon TH, Jorenby DE, Baker TB. Measures of affect and nicotine dependence predict differential response to smoking cessation treatments. J Consult Clin Psychol 1992;60:943–52.

Zhu SH, Stretch V, Balabanis M, Rosbrook B, Sadler G, Pierce JP. Telephone counseling for smoking cessation: effects of a single-session and multiple-session interventions. J Consult Clin Psychol 1996;64:1–10.

Glossary

All-comers. Individuals included in a smoking cessation study regardless of whether they sought to participate. For example, if cessation treatment was delivered to all smokers visiting a primary care clinic, the treatment population would be coded as "all-comers." Presumably, individuals who seek to participate in smoking cessation studies are more likely motivated to quit, and studies limited to these individuals may produce higher quit rates.

Anxiolytic. A pharmacologic agent used to reduce anxiety symptoms.

Aversive smoking. Several types of therapeutic techniques that involve smoking in an unpleasant or concentrated manner. These techniques pair smoking with negative associations or responses. Notable examples include rapid smoking, rapid puffing, focused smoking, and satiation smoking.

Biochemical confirmation. The use of assays of smoking-related biochemical compounds such as thiocyanate, cotinine, nicotine, and carboxyhemoglobin to verify smokers' reports of abstinence.

Cessation percentage. The percentage of smokers who achieve long-term abstinence from smoking. The major cessation measure for this guideline was the percentage of smokers in a group or treatment condition who were abstinent at a followup point that occurred at least 5 months after treatment.

Cigarette fading/smoking reduction prequit. Interventions that reduce the number of cigarettes smoked or nicotine intake prior to a patient's quit date. This may be accomplished through advice to cut down or by systematically restricting access to cigarettes. This category includes interventions using computers and/or devices to accomplish nicotine reduction prequit.

Clinician. A professional directly providing health care assistance.

Clinic screening system/system intervention. The strategies used in clinics and practices for the delivery of clinical services. Clinic screening system interventions involve changes in staff protocols designed to enhance the identification of and intervention with patients who smoke. Examples include affixing smoking status stickers to patients' charts, expanding the vital signs to include smoking, and incorporating smoking status items into patient questionnaires.

Clonidine. An alpha-2-adrenergic agonist typically used as an antihypertensive agent, but also used as a pharmacotherapy for smoking cessation. The Food and Drug Administration has not approved clonidine as a smoking cessation aid.

Contingency contracting/instrumental contingencies. Interventions where individuals earn rewards for cigarette abstinence and incur costs or unpleasant consequences for smoking. To receive this classification code, actual,

tangible consequences had to be contingent upon smoking or abstinence. Thus, simple agreements about a quit date, or other agreements between treatment providers and patients without specifiable consequences, were not included in this category. Deposits refunded based on study attendance and/or other incentives that are not contingent upon smoking abstinence or relapse did not receive this code.

Cue exposure/extinction. Interventions that repeatedly expose patients to smoking-related cues in the absence of nicotine reinforcement in an attempt to extinguish affective/motivational responding to such cues. This includes treatments where patients are encouraged to perform the smoking self-administration ritual, excepting inhalation.

Diazepam. A benzodiazepine anxiolytic.

Exercise/fitness component. Includes any intervention that contains a component related to exercise/fitness. The intensity of interventions falling within this category varied from the mere provision of information/advice about exercise/fitness to the classes.

Extratreatment social support component. Interventions or elements of an intervention wherein patients are provided with the tools to find social support on their own outside of treatment. This category is distinct from intratreatment social support, in which social support is delivered by treatment staff.

Formats. Refers to the context in which a smoking cessation intervention is delivered. May be either self-help, individual counseling, or group counseling.

Hotline/helpline. A telephone line dedicated to over-the-phone smoking intervention. A hotline/helpline treatment occurs when a hotline/helpline number is provided or a referral to a hotline/ helpline is made.

Intent-to-treat analysis. Treatment outcome analyses where abstinence percentages are based on all subjects randomized to treatment conditions, rather than on just those subjects who completed the intervention or who could be contacted at followup.

Intratreatment social support. Refers to an intervention component that provides support, help, or encouragement as part of the treatment.

Logistic regression. Statistical technique to determine the statistical association or relation between/among two or more variables, and where one of the variables, the dependent variable, is dichotomous (has only two levels of magnitude) (e.g., abstinent vs. smoking).

Meta-analysis. A statistical technique that estimates the impact of a treatment or variable across a set of related investigations.

Minimal contact. Minimal contact refers to interventions that involved very brief contact between clinicians and patients. It was coded based on the

length of contact between clinicians and patients (3 minutes or less). If that information was unavailable, it was coded based on the content of the contact between clinicians and patients.

Motivation. Includes interventions designed to bolster patients' resolve to quit through manipulations such as setting a quit date, use of a contract with a specified quit date, reinforcement correspondence (letters mailed from clinical/study staff after initial contact congratulating patient on decision to quit or on early success), providing information about the health risks of smoking, and so on.

Negative affect/depression component. Interventions in this category are designed to train patients to cope with negative affect after cessation. The intensity of the interventions in this category may vary from prolonged counseling to the simple provision of information about postquit mood and suggestions for dealing with it. To receive this code, interventions targeted depressed mood, not simply stress. Interventions aimed at teaching subjects to cope with stressors were coded as problem solving. When it was unclear whether an intervention was directed at negative affect/depression or at psychosocial stress, problem solving was the default code.

Nicotine replacement therapy. Refers to nicotine pharmacotherapy for smoking cessation. The two nicotine replacement therapy delivery systems currently approved for use in the United States are nicotine chewing gum and the nicotine patch.

Odds ratio. The odds of an outcome on one variable, given a certain status on another variable(s). This ratio expresses the increase in risk of a given outcome if the variable is present.

Oral mucosa. The mucous membranes that line the mouth.

Person-to-person intervention. In-person contact between a clinician and a patient(s) for the purpose of smoking intervention or assessment.

Primary care provider. Practitioner in one of the health professions (e.g., medicine, nursing, psychology, dentistry/oral health, physical and respiratory therapy) who provides health care services for problems other than smoking per se. Primary care providers are encouraged to identify smokers and to intervene with them, regardless of whether smoking cessation is the patient's presenting problem.

Problem solving/skills training. Refers to a smoking cessation intervention in which smokers are trained to identify and cope with events or problems that increase the likelihood of their smoking. For example, quitters might be trained to anticipate stressful events and to use coping skills such as distraction or deep breathing to cope with an urge to smoke. Related and similar interventions are coping skill training, relapse prevention, and stress management.

Purchaser. A corporation, company, or other consortium that purchases health care benefits for a group of individuals.

Propranolol. A beta-adrenergic blocker often used as an antihypertensive agent.

Quit day. The day of a given cessation attempt during which a patient tries to abstain totally from smoking. Also refers to a motivational intervention whereby a patient commits to quit tobacco use on a specified day.

Randomized controlled trial. For the purposes of this guideline, a study in which subjects are assigned to conditions on the basis of chance, and where at least one of the conditions is a control or a comparison condition.

Reference group. In meta-analyses, refers to the group against which other groups are compared.

Relaxation/breathing. Interventions in which patients are trained in relaxation techniques. Interventions using meditation, breathing exercises, and so on, fit this category. This category should be distinguished from the category of problem solving, which includes a much wider range of stress-reduction/management strategies.

Self-selected. Refers to a patient population that sought out or agreed to participate in a study of smoking cessation.

Serum cotinine. Blood levels of cotinine, nicotine's major metabolite. This is often used to estimate a patient's tobacco/nicotine self-administration prior to quitting, and to confirm abstinence self-reports during followup.

Serum nicotine. Blood levels of nicotine. This is often used to assess a patient's tobacco/nicotine self-administration prior to quitting, and to confirm abstinence self-reports during followup.

Silver acetate. Silver acetate reacts with cigarette smoke to produce an unpleasant taste and has been investigated as a deterrent to smoking.

Specialized assessments. Refers to assessment of patient characteristics such as nicotine dependence and motivation for quitting that may allow clinicians to tailor interventions to the needs of the individual patient.

Starter kits. Self-help materials and/or programs provided by a pharmaceutical company to assist patients in successfully quitting smoking while using a pharmaceutical agent.

Stepped-care. The practice of initiating treatment with a low-intensity intervention and then referring treatment failures to successively more intense interventions.

Transdermal nicotine. Refers to delivery of nicotine by diffusion through the skin. Often used as a synonym for "nicotine patch."

Treatment matching. Differential assignment of patients to treatments based on their pretreatment characteristics. Treatment matching is based on the notion that particular types of smokers are most likely to benefit from particular types of treatments.

Weight/diet/nutrition component. Any program dealing with weight issues. Interventions that teach nutrition/diet/weight management strategies, incorporate daily/weekly weight monitoring (for reasons other than routine data collection), require or suggest energy intake maintenance/reduction, and/or convey nutritional information/tips/counseling receive this code.

Contributors

Smoking Cessation Guideline Panel

Michael C. Fiore, MD, MPH
Panel Chair
Associate Professor, Department of Medicine
Director, Center for Tobacco Research and Intervention
University of Wisconsin Medical School
Madison, Wisconsin

Dr. Fiore completed medical school at Northwestern University and his internal medicine training at Boston City Hospital. His postgraduate education included a Masters of Public Health in Epidemiology from Harvard University and a fellowship in pulmonary medicine and occupational health at the University of Perugia in Italy. Dr. Fiore received additional training in epidemiology as an Epidemic Intelligence Service (EIS) Officer for the Centers for Disease Control, where he also completed a Preventive Medicine residency program. Dr. Fiore worked as a medical epidemiologist at the Office on Smoking and Health, where he contributed to a wide range of national research, educational, and policy projects to control the epidemic of tobacco-related diseases. Dr. Fiore is Director of the Center for Tobacco Research and Intervention at the University of Wisconsin Medical School and an Associate Professor in the Department of Medicine. At the University of Wisconsin, he is clinically active, treating patients both in internal medicine and for smoking cessation. He is also a consultant to the National Cancer Institute and continues to collaborate with the Office on Smoking and Health. Dr. Fiore is a nationally recognized expert on tobacco. He has written numerous articles, chapters, and books on cigarette smoking and is a coauthor of *Reducing the Health Consequences of Smoking: 25 Years of Progress–Report of the Surgeon General.*

William C. Bailey, MD
Professor of Medicine
Director, Lung Health Center
University of Alabama at Birmingham
Birmingham, Alabama

Dr. Bailey is clinically active in the treatment of patients with pulmonary disease. He is the Principal Investigator of research projects in the areas of asthma, tuberculosis, and smoking cessation and is the author of numerous articles, chapters, and books on these topics. In addition to his positions at the University of Alabama at Birmingham, he currently serves as the Tuberculosis Control Officer at the Veterans Affairs Medical Center in Birmingham. From 1989 to 1992, Dr. Bailey served as the Chairman of the

National Heart, Lung, and Blood Institute (NHLBI) Task Force on the Prevention of Asthma. He received the NHLBI Preventive Pulmonary Academic Award from 1989 through 1994.

Stuart J. Cohen, EdD
Director, Health Services Research Center
Professor, Departments of Public Health Sciences and Internal Medicine
Bowman Gray School of Medicine
Winston-Salem, North Carolina
Dr. Cohen received his doctorate in Educational Foundations/Psychology from the University of Rochester. For the past 18 years, he has received grants to improve the quality of ambulatory primary care from the National Institutes of Health, the Centers for Disease Control and Prevention, and the Agency for Health Care Policy and Research. In addition, a National Cancer Institute grant on developing methods to improve physician and dentist interventions in smoking cessation served as the basis for establishing the importance of having an office system include reminders for delivery of preventive services.

Sally Faith Dorfman, MD, MSHSA
Gynecologist, Public Health Consultant
Cornwall and New York, New York
Dr. Dorfman holds degrees in economics from Harvard/Radcliffe Universities, a master's degree in Health Services Administration and an M.D. from Stanford University, and trained in reproductive health epidemiology at the Centers for Disease Control and Prevention. She is board certified both in obstetrics and gynecology and in public health/general preventive medicine. Dr. Dorfman has consulted for state, regional, national, and international organizations and was Commissioner of Health for Orange County, NY, from 1988–1994. She also has published and presented extensively for professional and lay audiences, serves as reviewer for several peer review journals, and is the recipient of numerous honors and awards. Dr. Dorfman maintains a limited office-based practice of ambulatory gynecology in Manhattan, which is affiliated with Cornell University Medical Center.

Michael G. Goldstein, MD
Assistant Psychiatrist-in-Chief
The Miriam Hospital
Associate Professor, Psychiatry and Human Behavior
Brown University School of Medicine
Providence, Rhode Island
Dr. Goldstein is board certified in Internal Medicine and Psychiatry and currently serves as Medical Director of the Center for Behavioral and Preventive Medicine at The Miriam Hospital in Providence, Rhode Island. Dr. Goldstein's primary research interests include developing interventions to enhance the delivery of smoking cessation and other preventive services in primary care

settings. He has also received grant support to test combined behavioral and pharmacologic interventions for smoking cessation. Dr. Goldstein is a member of the Task Force on Nicotine Dependence of the American Psychiatric Association and serves as an Associate Editor of the *Annals of Behavioral Medicine.* He has published extensively in the areas of behavioral medicine, smoking cessation, and patient education and counseling.

Ellen R. Gritz, PhD
Professor and Chair
Department of Behavioral Science
University of Texas
M.D. Anderson Cancer Center
Houston, Texas
Dr. Gritz is a licensed psychologist and an established leader in cancer prevention and control research. She has published extensively on cigarette smoking behavior, including prevention, cessation, pharmacologic mechanisms, effects on weight, and special issues of women and other high risk groups, e.g., ethnic minorities, adolescents, and medical populations. Other areas of interest include adherence to cancer control regimens, chemoprevention, and psychosocial aspects of cancer. Dr. Gritz is an Associate Editor for *Cancer Epidemiology, Biomarkers & Prevention,* and serves on several editorial boards. She was the first recipient of the Joseph W. Cullen Memorial award for distinguished research in smoking.

Richard B. Heyman, MD
Chairman, Committee on Substance Abuse
American Academy of Pediatrics
Cincinnati, Ohio
A graduate of the Columbia University College of Physicians and Surgeons, Dr. Heyman practices pediatric and adolescent medicine and serves on the faculty of the Division of Adolescent Medicine at Children's Hospital Medical Center in Cincinnati, Ohio. He is a consultant to several adolescent chemical dependency programs and lectures widely in the area of substance abuse. As chairman of the Committee on Substance Abuse of the American Academy of Pediatrics, he is responsible for overseeing the creation of the Academy's educational programs and materials, as well as the development of policy in the area of alcohol, tobacco, and other drug abuse.

John Holbrook, MD
Professor of Medicine
University of Utah School of Medicine
University Hospital
Salt Lake City, Utah
Dr. Holbrook is a general internist who served as the Medical Director of the National Clearinghouse for Smoking and Health of the U.S. Department of

Health, Education, and Welfare. He was an editor for more than fifteen of the Reports of the Surgeon General on smoking and health. He has written the chapter on tobacco (nicotine addiction) in six editions of *Harrison's Principles of Internal Medicine*. He is active as a clinician, educator, and health care administrator in multiple aspects of smoking cessation.

Carlos Roberto Jaén, MD, PhD
Assistant Professor, Family Medicine,
and Social and Preventive Medicine
Director, Center for Urban Research in Primary Care
State University of New York at Buffalo
Buffalo, New York
Dr. Jaén is a family physician and epidemiologist. He is an Assistant Professor of Family Medicine, and of Social and Preventive Medicine, at the University of Buffalo. A Robert Wood Johnson Generalist Physician Faculty Scholar, his research activities focus on prevention, particularly of tobacco use, and on health issues affecting poor urban residents. The Center for Urban Research in Primary Care brings together scholars and community residents to evaluate and intervene on health issues affecting residents of central city communities. He has been a member of the New York State Public Health Council since 1995.

Thomas E. Kottke, MD, MSPH
Professor, Division of Cardiovascular Diseases
Department of Internal Medicine
Mayo Clinic and Foundation
Rochester, Minnesota
Dr. Kottke is a clinical cardiologist, epidemiologist, and health services researcher whose primary interest is describing, defining, and overcoming the barriers to the delivery of clinical preventive services. He has published widely on the evidence that clinical support systems are necessary for physicians and other health care professionals to provide preventive services to the patients they serve. Dr. Kottke was a member of the first United States Preventive Services Task Force.

Harry A. Lando, PhD
Professor, Division of Epidemiology
School of Public Health
University of Minnesota
Minneapolis, Minnesota
Dr. Lando has worked in the field of smoking cessation since 1969. He has published extensively in this area and was a scientific editor of the 1988 *Report of the Surgeon General: Nicotine Addiction.* His research has focused primarily on the development of effective multicomponent behavioral programs for smoking cessation. He has received numerous awards for his work and has consulted actively with Federal and voluntary agencies,

including the National Cancer Institute, the Centers for Disease Control, the American Cancer Society, the American Lung Association, the National Heart, Lung, and Blood Institute, and the National Institute on Drug Abuse.

Robert Mecklenburg, DDS, MPH
Dental Coordinator
National Cancer Institute
Smoking and Tobacco Control Program
Potomac, Maryland
Dr. Mecklenburg organized and manages dental affairs for the National Cancer Institute's Smoking and Tobacco Control Program. He chairs the National Dental Tobacco-Free Steering Committee and is vice-chairman of the World Dentistry Against Tobacco section of the Federation Dentaire Internationale. He chaired the committee on non-cancer oral effects of tobacco for the first Surgeon General's report on smokeless tobacco. He is the principal author of the NCI publications, *Tobacco Effects in the Mouth* and *How to Help Your Patients Stop Using Tobacco: A Manual for the Oral Health Team.* Dr. Mecklenburg has published and lectured widely in the United States and abroad about dental professionals' involvement in the creation of a tobacco-free society.

Patricia Dolan Mullen, DrPH
Professor and Deputy Director
Center for Health Promotion Research and Development
School of Public Health
University of Texas
Houston, Texas
Dr. Mullen received her doctorate in Public Health from the University of California at Berkeley. She has received many research grants to study smoking cessation during pregnancy. She has served on the Expert Panel on the Content of Prenatal Care and on numerous research advisory panels and boards for the National Institutes of Health, the Centers for Disease Control and Prevention, the American Cancer Society, and other national and international organizations, and was invited to write the section on smoking cessation during pregnancy for the 1997 *Surgeon General's Report on Women and Smoking.*

Louise M. Nett, RN, RRT
Research Associate
PSL/Health ONE
Clinical Research Division
Center for Health Sciences Education
Denver, Colorado
Ms. Nett currently is a research associate at the HealthONE Center for Health Sciences Education in Denver, Colorado, and focuses on the early detection of chronic obstructive lung disease and lung cancer and smoking cessation. Her early work focused on critical care, pulmonary rehabilitation, and oxygen

therapy. She is a member of the American Thoracic Society, the American Association for Respiratory Care, the Society for Research on Nicotine and Tobacco, and the American College of Chest Physicians. She is also active at the local level in Colorado. Ms. Nett has published and taught extensively and is the editor of the newsletter NICO-NOTES. She has received numerous awards and has consulted and lectured internationally.

Lawrence Robinson, MD, MPH
Deputy Health Commissioner
Philadelphia Department of Public Health
Philadelphia, Pennsylvania
As Deputy Commissioner for Health Promotion/Disease Prevention for the Philadelphia Department of Public Health, Dr. Robinson is responsible for development, planning, coordination, and evaluation of various programs delivering comprehensive medical, preventive, and health education services. He is a member of State and area antitobacco coalition groups and the Early Education Tobacco Prevention Project, chairman of the Philadelphia smoke-free task force, and clinical director of the Pro-Step nicotine patch program for city employees. He is also a board member of various groups, organizations, and agencies in the community.

Maxine L. Stitzer, PhD
Professor, Department of Psychiatry and Behavioral Sciences
Behavioral Biology Research Center
Johns Hopkins/Bayview Medical Center
Baltimore, Maryland
Dr. Stitzer received her Ph.D. in Psychology and training in psychopharmacology from the University of Michigan. At Johns Hopkins, she has developed a varied and extensive grant-supported research program focusing on both pharmacological and behavioral approaches to the treatment of substance abuse. Her many publications reflect active research interests in both illicit drug abuse and tobacco dependence. She has been president of the Division on Psychopharmacology and Substance Abuse of the American Psychological Association and currently serves on the Board of Directors of the College on Problems of Drug Dependence.

Anthony C. Tommasello, MS
Director, Office of Substance Abuse Studies
University of Maryland at Baltimore
School of Pharmacy
Baltimore, Maryland
Mr. Tommasello, a pharmacist, is an Associate Professor of Clinical Pharmacy at the University of Maryland School of Pharmacy, and Director, Office of Substance Abuse Studies, which he founded. He has worked in the

addiction field since 1973 and acquired advanced degrees in both pharmacology and epidemiology, specializing in drug abuse and addiction. He is active in clinical research and treatment in addictions and has created educational programs that have served as national models for pharmacists and other health and human service providers. He is the president of the Maryland Pharmacists' Rehabilitation Committee, which provides advocacy and treatment access for impaired pharmacists. He has published in the areas of general principles of assessment and treatment, methadone maintenance care, and adolescent drug abuse and addiction. Mr. Tommasello is a Ph.D. candidate in Policy Sciences at UMBC, where his focus has been on health policy analysis. His dissertation is entitled, "The Effects of State Policies on Addiction Intervention in the Health Professions: The Case of Pharmacy."

Louise Villejo, MPH, CHES
Director, Patient Education Office
Office of Public Affairs
M.D. Anderson Cancer Center
University of Texas
Houston, Texas

As the Director of the Patient Education Office at the M.D. Anderson Cancer Center, Ms. Villejo is responsible for the design, implementation, evaluation, and management of patient and family education programs. She has assisted in the writing, publication, and production of more than 100 patient education booklets and videotapes. For the past 10 years, she has served on the National Cancer Institute's Patient Education Committee and Network as well as on numerous other Federal and private advisory and planning boards and committees. Ms. Villejo's publications include articles on smoking cessation and cancer patient education.

Mary Ellen Wewers, PhD, RN
Associate Professor
Department of Adult Health and Illness Nursing
College of Nursing
Ohio State University
Columbus, Ohio

Dr. Wewers, an Adult Nurse Practitioner, has been conducting smoking cessation research since completing her Ph.D. in Nursing at the University of Maryland in 1986. She is funded by the National Institutes of Health to investigate reinforcement for nicotine in both human and animal models of dependence. Her clinical research has examined nurse-managed smoking cessation interventions. Dr. Wewers is Chair-elect of the Nursing Assembly of the American Thoracic Society and serves as Director of the Nursing Center for Tobacco Intervention at Ohio State University.

Consultants

Timothy Baker, PhD
Senior Scientific Consultant
Professor, Department of Psychology
Associate Director, Center for Tobacco Research and Intervention
University of Wisconsin Medical School
Madison, Wisconsin

Victor Hasselblad, PhD
Statistical Methodologist
Center for Health Policy Research and Education
Duke University
Durham, North Carolina

David L. Schriger, MD, MPH
Methodologist
Associate Professor
UCLA School of Medicine
Los Angeles, California

Project Staff

David W. Wetter, PhD
Project Director
University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Connie Kohler, DrPH
Project Co-Director
Department of Health Behavior
University of Alabama at Birmingham
School of Public Health
Birmingham, Alabama

Lisa D. Wetter
Project Manager
University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Kathleen Reardon
Sarah Trost
Project Co-Managers
Thomas M. Piasecki, MS
Fang-Ying Shi, MS
Project Research Associates
Center for Tobacco Research and Intervention
University of Wisconsin Medical School
Madison, Wisconsin

Additional Project Staff

Douglas Jorenby
Douglas Keehn
Lisa Rogers
Ann Schensky
Scott Woller
Center for Tobacco Research and Intervention
University of Wisconsin Medical School
Madison, Wisconsin

Federal Liaisons

Corinne Husten, MD, MPH
Medical Officer
Office on Smoking and Health
National Center for Chronic Disease Prevention and Health Promotion
Centers for Disease Control and Prevention
Atlanta, Georgia

Cathy Melvin, PhD, MPH
Chief, Program Services and Development Branch
Division of Reproductive Health
National Center for Chronic Disease Prevention and Health Promotion
Centers for Disease Control and Prevention
Atlanta, Georgia

Gary Giovino, PhD, MS
Chief, Epidemiology Branch
Office on Smoking and Health
National Center for Chronic Disease Prevention and Health Promotion
Centers for Disease Control and Prevention
Atlanta, Georgia

Marc Manley, MD, MPH
Chief, Public Health Applications Research Branch
National Cancer Institute
National Institutes of Health
Rockville, Maryland

Glen Bennett, MPH
Coordinator, Advance Technologies Applications in Health Education Programs
Office of Prevention, Education, and Control
National Heart, Lung, and Blood Institute
National Institutes of Health
Bethesda, Maryland

Jack E. Henningfield, PhD
Chief, Clinical Pharmacology Branch
Addiction Research Center
Intramural Research Program
National Institute on Drug Abuse
National Institutes of Health
Baltimore, Maryland

Debra Rothstein, PhD
Prevention Policy Advisor
Office of Disease Prevention and Health Promotion
Washington, DC

Canadian Government Liaison

Sylvie Stachenko, MD, MSC, FCFP
Director, Disease Prevention
Health Canada
Ottawa, Ontario, Canada

Article Reviewers

Jane Anderson
Julianne Brown
Denise Doyle
Thomas Piasecki
Kathleen Reardon
Fang-Ying Shi
Valerie Stromquist
Kathy Tiedje
Sarah Trost
Thomas Wodushek
Center for Tobacco Research and Intervention
University of Wisconsin Medical School
Madison, Wisconsin

AHCPR Staff

Douglas B. Kamerow, MD, MPH
Director, Office of the Forum for Quality and Effectiveness in Health Care

Ernestine W. Murray, RN, MAS
Panel Project Officer

Harriett V. Bennett
Public Affairs Specialist

Sandra Katz Cummings
Managing Editor

Contract Support

Technical Resources International, Inc.
Rockville, Maryland

Gail J. Herzenberg, MPA
Project Director

Cheryl Campbell
Panel Manager

Marcia Feinleib
Managing Editor

Joanna Taylor
Panel Editor

Peer Reviewers[a]

David B. Abrams, PhD
Professor and Director of Behavioral and Preventive Medicine
Brown University School of Medicine
Providence, Rhode Island

Karen Ahijevych, PhD, RN
Assistant Professor
Ohio State University College of Nursing
Columbus, Ohio

Norman B. Anderson
Associate Director
National Institutes of Health
Bethesda, Maryland

Michele Bloch, MD, PhD
Chair, Tobacco Control and Prevention Subcommittee
American Medical Women's Association
Alexandria, Virginia

Angela Boykin
Manager, Member Education and Wellness
Health Source North Carolina
Morrisville, North Carolina

Thomas H. Brandon, PhD
Assistant Professor of Psychology
State University of New York at Binghamton
Binghamton, New York

Richard L. Brown, MD, MPH
Assistant Professor
University of Wisconsin Medical School
Department of Family Medicine
Madison, Wisconsin

Blake Cady, MD, FACS
Chief, Surgical Oncology
Deaconess Hospital
Boston, Massachusetts

Deborah Caplan, MS, RN-CS
American Association of Occupational Health Nurses
Atlanta, Georgia

Moon S. Chen, Jr., PhD, MPH
Professor and Chair
Division of Health Behavior and Health Promotion
Ohio State University
Columbus, Ohio

Connie Conrad
Project Officer
Bureau of Policy and Development
Health Care Financing Administration
Baltimore, Maryland

David Coultas, MD
Associate Professor of Medicine
University of New Mexico School of Medicine
Albuquerque, New Mexico

Susan J. Curry, PhD
Investigator
Center for Health Studies
Group Health Cooperative of Puget Sound
Seattle, Washington

Jane Delgado, PhD
President and Chief Executive Officer
National Coalition of Hispanic Health and Human Services Organizations
Washington, District of Columbia

[a] These individuals provided peer review. Their participation does not necessarily imply endorsement of the guideline.

Harriet de Wit, PhD
Associate Professor
Department of Psychiatry
University of Chicago
Chicago, Illinois

Paul Fischer, MD
University Family Medicine
Augusta, Georgia

Erica Frank, MD, MPH
Assistant Professor
Emory University School of Medicine
Atlanta, Georgia

Jacquelyn L. Fried, MS, RDH
Associate Professor
Department of Dental Hygiene
University of Maryland Dental School
Baltimore, Maryland

Michael J. Geboy, PhD
Director, Cooperative Health Education Program
Veterans Affairs Medical Center
Prescott, Arizona

Sam P. Giordano, MBA, RRT
Executive Director
American Association for Respiratory Care
Dallas, Texas

Elbert D. Glover, PhD
Director, Tobacco Research
Mary Babb Randolph Cancer Center
Professor, Behavioral Medicine and Psychiatry
Robert C. Byrd Health Sciences Center
West Virginia University
Morgantown, West Virginia

Thomas J. Glynn, PhD
Acting Associate Director, Cancer Control Science Program
National Institutes of Health
Bethesda, Maryland

Debra Haire-Joshu, PhD, RN
Research Associate Professor of Medicine
Washington University School of Medicine
St. Louis, Missouri

Dorothy K. Hatsukami, PhD
Professor
Department of Psychiatry
University of Minnesota
Minneapolis, Minnesota

James G. (Gil) Hill
Director, Office of Substance Abuse
American Psychological Association
Washington, District of Columbia

Felicia Hodge, DrPH
Director
Center for American Indian Research and Education
University of California, Berkeley
Berkeley, California

Freddie Ann Hoffman, MD
Deputy Director, Medicine Staff Office of Health Affairs
Food and Drug Administration
Rockville, Maryland

Jack E. Hollis, PhD
Senior Investigator
Kaiser Permanente
Center for Health Research
Portland, Oregon

Thomas P. Houston, MD
Director
Department of Preventive Medicine and Environmental Health
American Medical Association
Chicago, Illinois

Richard D. Hurt, MD
Professor of Medicine
Director, Nicotine Dependence Center
Mayo Clinic
Rochester, Minnesota

Denise A. James
Program Manager
Fox Chase Cancer Center
Cheltenham, Pennsylvania

Martin J. Jarvis, MPhD
Principal Scientist
Imperial Cancer Research Fund
Health Behaviour Unit
London, England

Rhys B. Jones, DDS, MS
President
American Association of Public Health Dentistry
Cedar Rapids, Iowa

Robert C. Klesges, PhD
Professor of Psychology and Preventive Medicine
University of Memphis
Memphis, Tennessee

D. H. Klevan, MD, FACP
Health Partners Como Clinic
St. Paul, Minnesota

Jamie Kotch
Manager
Health Programs and Information
Harvard Pilgrim Health Care
Brookline, Massachusetts

Donald S. Kwalick, MD, MPH
Nevada State Health Officer
Nevada Division of Health
Carson City, Nevada

Edward Lichtenstein, PhD
Research Scientist
Oregon Research Institute
Eugene, Oregon

Jonathan T. Lord, MD
Senior Advisor for Clinical Affairs
Office of the President
American Hospital Association
Chicago, Illinois

Francis J. Mallon, Esq.
Chief Executive Officer
American Physical Therapy Association
Alexandria, Virginia

Betty J. Merriman
Director, Patient and Family Education
American Cancer Society
Atlanta, Georgia

Abby Millhauser, MS, NCC
Program Supervisor
Community Counseling and Resource Center
Cockeysville, Maryland

Edwin A. Mirand, MD
Vice President and Dean
Roswell Park Cancer Institute and SUNY at Buffalo
Buffalo, New York

Mildred S. Morse, JD
Director
National Smoking Cessation Campaign for African American Women
Silver Spring, Maryland

Alan R. Nelson, MD
Executive Vice President
American Society of Internal Medicine
Washington, District of Columbia

Raymond Niaura, PhD
Associate Professor
Department of Psychiatry
Brown University School of Medicine
Providence, Rhode Island

Don M. Nielsen, MD
Associate Medical Director
for Quality
Kaiser Permanente Medical Care
Program
Oakland, California

Judith K. Ockene, PhD
Professor of Medicine
Director, Division of Preventive
and Behavioral Medicine
University of Massachusetts
Medical School
Worcester, Massachusetts

C. Tracy Orleans, PhD
Director
Tobacco Control Research
Fox Chase Cancer Center
Princeton, New Jersey

Kenneth A. Perkins, PhD
Associate Professor of Psychiatry
Western Psychiatric Institute
and Clinic
University of Pittsburgh
Medical Center
Pittsburgh, Pennsylvania

Stephen Rennard, MD
Chief, Pulmonary and Critical
Care Medicine
University of Nebraska Medical
Center
Omaha, Nebraska

Barbara K. Rimer, DrPH
Professor
Duke University Medical Center
Durham, North Carolina

M. Diane Roberts, DrPH
Dean
College of Health Professionals
Wichita State University
Wichita, Kansas

William A. Robinson, MD, MPH
Chief Medical Officer
Health Resources and Services
Administration
Rockville, Maryland

Patricia A. Rowell, PhD, RN
Senior Policy Fellow
American Nurses Association
Washington, District of Columbia

Linda Sarna, RN, DNSc, FAAN
Assistant Professor
American Cancer Society
Professor of Oncology Nursing
School of Nursing
University of California,
Los Angeles
Los Angeles, California

Manuel Schydlower, MD
Professor
Department of Pediatrics
Texas Tech
University Health Sciences Center
El Paso, Texas

Saul Shiffman, PhD
Professor of Psychology
University of Pittsburgh
Pittsburgh, Pennsylvania

John Slade, MD
Associate Professor
University of Medicine and
Dentistry of New Jersey and the
St. Peter's Medical Center
New Brunswick, New Jersey

Leif I. Solberg, MD
Clinical Director of Research
Group Health Foundation
HealthPartners
Bloomington, Minnesota

Rodman D. Starke, MD
Senior Vice President
Science and Medicine
American Heart Association
Dallas, Texas

Jane W. Swanson, MS, RN, CNAA
Director, Ambulatory Nursing
National Naval Medical Center
Bethesda
Bethesda, Maryland

C. Barr Taylor, MD
Professor of Psychiatry
Stanford Medical Center
Stanford, California

Earl S. Ward, Jr., PharmD
Associate Dean for Health and
Administrative Services
Professor, Department of Pharmacy
Practice
Mercer University School of
Pharmacy
Atlanta, Georgia

Kenneth E. Warner, PhD
Richard D. Remington Collegiate
Professor of Public Health
Department of Health Management
and Policy
School of Public Health
University of Michigan
Ann Arbor, Michigan

C. Edwin Webb, PharmD, MPH
Vice President
Professional Affairs and Health
Policy
American Association of Colleges
of Pharmacy
Alexandria, Virginia

Gregory J. Westerbeck
Director of Medical Marketing
SmithKline Beecham Consumer
Healthcare
Washington, District of Columbia

Attachment

National Network of Tobacco Prevention and Control Contacts[a]

National Cancer Institute
Office of Cancer Communications
Building 31, Room 10A24
Bethesda, MD 20892
Telephone: 1-800-4-CANCER

Office on Smoking and Health
National Center for Chronic Disease Prevention and Health Promotion
Centers for Disease Control and Prevention
Mail Stop K-50
4770 Buford Highway, NE
Atlanta, GA 30341-3742
Telephone (770) 488-5705

ALABAMA
Mobile County Health Department
Bureau of Health Promotion
Administrative Services
P.O. Box 2867
Mobile, AL 36652
Telephone (334) 690-8186
FAX (334) 432-7443

Federal Express Address:
251 N. Bayou St.
Mobile, AL 36603

ALASKA
Manager, Health Promotion Program
Division of Public Health
Department of Health and Social Services
P.O. Box 110614
Juneau, AK 99811-0614
Telephone (907) 465-3140
FAX (907) 465-2770

Federal Express Address:
333 Willoughby St., Rm. 713
Juneau, AK 99801

ARKANSAS
Director
Office of Tobacco Control and Prevention
4815 W. Markham St.
Little Rock, AR 72205
Telephone (501) 661-2783
FAX (501) 661-2082

ARIZONA
Program Director
Tobacco Use Prevention and Control Program
Office of Health Promotion and Education
1400 W. Washington St.
Phoenix, AZ 85007
Telephone (602) 542-7234
FAX (602) 542-0141

CALIFORNIA
California Department of Health Services
744 P St.
P.O. Box 942732
Sacramento, CA 94234-7320
Telephone (916) 322-4787
FAX (916) 327-5424

COLORADO
ASSIST Project Manager
Colorado Department of Health
4300 Cherry Creek Dr., S.
Denver, CO 80222-1530

[a] If there is difficulty reaching any of the State contacts, please call the Office on Smoking and Health (770-488-5705).

Telephone (303) 692-2515
FAX (303) 782-0095

CONNECTICUT
Health Program Supervisor
Department of Public Health and Addiction Services
150 Washington St.
Hartford, CT 06106
Telephone (203) 566-6618
FAX (203) 566-1217

DELAWARE
Prevention Coordinator
Department of Health and Social Services
P.O. Box 637
Dover, DE 19903
Telephone (302) 739-4724
FAX (302) 739-6617

Federal Express Address:
Jessie Cooper Bldg.
Federal and Water Streets
Dover, DE 19901

DISTRICT OF COLUMBIA
Public Health Educator
Department of Human Services
2nd Floor
800 Ninth Street, SW
Washington, DC 20024
Telephone (202) 645-5556
FAX (202) 645-0526

FLORIDA
Program Administration
HRS Health Promotion and Wellness
Building 2-HSH, Room 321
1317 Winewood Blvd.
Tallahassee, FL 32399-0700
Telephone (904) 487-3220
FAX (904) 488-6495

GEORGIA
Tobacco Prevention Program Manager
Department of Human Resources
Tobacco Prevention Education Program
2 Peachtree St., 6th Fl.
Atlanta, GA 30303
Telephone (404) 657-2570
FAX (404) 657-6631

GUAM
Health Educator Administrator
Department of Public Health and Social Services
P.O. Box 2816
Agana, Guam 96910
Telephone (671) 734-7129
FAX (671) 734-5910

HAWAII
Department of Health
952 N. King St., Bay 06
Honolulu, HI 96817
Telephone (808) 832-5951
FAX (808) 832-5955

IDAHO
Health Promotion Coordinator
Idaho Department of Health and Welfare
P.O. Box 83728
450 W. State St.
Boise, ID 83720-0036
Telephone (208) 334-4936
FAX (208) 334-6573

ILLINOIS
Chief Public Health Educator
Illinois Department of Public Health
Division of Health Promotion
535 W. Jefferson St.
Springfield, IL 62761
Telephone (217) 785-2060
FAX (217) 782-1235

INDIANA
Director, ASSIST Project
Division of Health Education
Indiana Department of Health
1330 W. Michigan St.
P.O. Box 1964
Indianapolis, IN 46206-1964
Telephone (317) 633-0267
FAX (317) 633-0776

Federal Express Address:
Drop P.O. Box

IOWA
Director, Division of Substance Abuse and Health Promotion
Iowa Department of Public Health
Lucas State Office Bldg.
Des Moines, IA 50319-0075
Telephone (515) 281-7248
FAX (515) 281-4535

KANSAS
Office of Chronic Disease and Health Promotion
Kansas Department of Health and Environment
900 S.W. Jackson St.
Topeka, KS 66612-1290
Telephone (913) 296-1233
FAX (913) 296-8059

KENTUCKY
Tobacco Control Coordinator
Kentucky Department for Health Services
275 E. Main St.
Frankfort, KY 40621
Telephone (502) 564-7243
FAX (502) 564-6533

LOUISIANA
Chronic Disease Control Program
Louisiana Department of Health and Hospitals
325 Loyola Ave., Rm. 414
New Orleans, LA 70112
Telephone (504) 568-7210
FAX (504) 568-2543

MAINE
ASSIST Project
Division of Health Promotion and Education
Maine Department of Human Services
151 Capitol St.
State House Station 11
Augusta, ME 04333
Telephone (207) 287-5180
FAX (207) 287-4631

MARIANA ISLANDS
Psychiatric Clinical Coordinator
Department of Public Health and Environmental Services
P.O. Box 409 CK
Saipan, MP 96950
Telephone 670-234-8950, ext. 2500
FAX 670-234-8930

MARSHALL ISLANDS
Director of Human Services
Alcohol and Substance Abuse
Ministry of Health and Environment
P.O. Box 16
Majuro, Republic of the Marshall Islands 96960
Telephone 011-692-625-3249
FAX 011-692-625-3432

MARYLAND
Division of Health Education
Department of Health and Mental Hygiene
201 W. Preston St.
Baltimore, MD 21201
Telephone (410) 225-1362
FAX (410) 333-7903

MASSACHUSETTS
Office for Nonsmoking and Health
Massachusetts Department of Public Health
250 Washington St., 4th Fl.
Boston, MA 02111
Telephone (617) 624-5900
FAX (617) 624-5922

MICHIGAN
ASSIST Project Director
Chief, Tobacco Section
Michigan Department of Public Health
3423 N. Logan St.
P.O. Box 30195 - CHP
Lansing, MI 48909
Telephone (517) 335-8380
FAX (517) 335-9648

Federal Express Address:
Drop P.O. Box

MICRONESIA
Secretary, Department of Health
FSM National Government
Palikir Station, PS 70
Palikir, Pohnpei FSM 96941
Telephone 011-691-320-2619
FAX 011-691-320-5263/2785

MINNESOTA
ASSIST Project Manager
Minnesota Department of Health
717 Delaware St., S.E.
P.O. Box 9441
Minneapolis, MN 55440-9441
Telephone (612) 623-5623
FAX (612) 623-5775

MISSISSIPPI
Coordinator
Tobacco Prevention
Mississippi State Department of Health
P.O. Box 1700
Jackson, MS 39215-1700
Telephone (601) 960-7828
FAX (601) 354-6278

Federal Express Address:
2423 N. State St.
Jackson, MS 39216

MISSOURI
Project Manager, ASSIST
Tobacco Control Coordinator
Missouri Department of Health
101 Park DeVille Dr.
Columbia, MO 65203
Telephone (314) 876-3260
FAX (573) 446-8777

MONTANA
Health Services Manager
Department of Health and Environmental Sciences
1400 Broadway
Cogswell Bldg., Rm. C314
Helena, MT 59620
Telephone (406) 444-4488
FAX (406) 444-2606

NEBRASKA
Health Promotion and Education
Nebraska Department of Health
301 Centennial Mall South
P.O. Box 95007
Lincoln, NE 68509-5007
Telephone (402) 471-2101
FAX (402) 471-6446

Federal Express Address:
Drop P.O. Box

NEVADA
Tobacco Control Coordinator
Nevada Department of Human Resources
505 E. King St., Rm. 304

Carson City, NV 89710
Telephone (702) 687-4800
FAX (702) 687-4988

NEW HAMPSHIRE
Bureau of Health Promotion
New Hampshire Division of Public Health Services
Health and Welfare Bldg.
6 Hazen Dr.
Concord, NH 03301-6527
Telephone (603) 271-6892
FAX (603) 271-6116

NEW JERSEY
Coordinator
ASSIST Project—Tobacco Program
New Jersey Department of Health
CN 362, 129 Hanover St.
Trenton, NJ 08625-0369
Telephone (609) 984-1310
FAX (609) 292-3816

NEW MEXICO
Program Manager
Tobacco Use Prevention/ASSIST
2329 Wisconsin, N.E., Suite A
Albuquerque, NM 87110
Telephone (505) 841-8335
FAX (505) 841-8333

NEW YORK
Program Manager
Tobacco Control Program, ASSIST Project
New York State Department of Health
Corning Tower Bldg.
Empire State Plaza, Rm. 515
Albany, NY 12237-0620
Telephone (518) 474-1515
FAX (518) 473-2853

NORTH CAROLINA
Manager
Division of Adult Health, ASSIST Project
North Carolina Department of Environment, Health, and Natural Resources
P.O. Box 27687
Raleigh, NC 27611-7687
Telephone (919) 733-1676
FAX (919) 733-0488

Federal Express Address:
1330 St. Mary's St.
Raleigh, NC 27611-7687

NORTH DAKOTA
Coordinator
Tobacco Prevention and Control Program
600 E. Boulevard Ave., Judicial Wing, 2nd Fl.
Bismarck, ND 58505-0200
Telephone (701) 328-3138
FAX (701) 328-1412

OHIO
Chief
Bureau of Chronic Diseases, Prevention Branch
Ohio Department of Health
246 N. High St.
P.O. Box 118
Columbus, OH 43266-0118
Telephone (614) 466-2144
FAX (614) 644-7740

Federal Express Address:
Drop P.O. Box

OKLAHOMA
Health Information Section
Oklahoma State Department of Health
1000 N.E. 10th St.
Oklahoma City, OK 73117-1299
Telephone (405) 271-5601
FAX (405) 271-2865

OREGON
Chronic Disease
Oregon Department of Human Resources
800 N.E. Oregon St.
Portland, OR 97232
Telephone (503) 731-4025
FAX (503) 731-4082

PENNSYLVANIA
Director
Tobacco and Control Program
Pennsylvania Department of Health
P.O. Box 90, Rm. 1003
Harrisburg, PA 17108
Telephone (717) 783-5900
FAX (717) 783-5498

Federal Express Address:
Tobacco Control Program
Health and Welfare Bldg., Rm. 1003
Commonwealth Ave. and Forster St.
Harrisburg, PA 17120

PALAU
Minister of Health
Ministry of Health
P.O. Box 6027
Koror, Republic of Palau 96940
Telephone 011-680-488-2813
FAX 011-680-488-1725

PUERTO RICO
SAMPSF, Preventive Medicine
Puerto Rico Department of Health
P.O. Box 70184
San Juan, PR 00936
Telephone (809) 274-5645
FAX (809) 274-7863

RHODE ISLAND
ASSIST Project
Rhode Island Department of Health
Cannon Bldg., 3 Capitol Hill, Rm. 103
Providence, RI 02908-5097
Telephone (401) 277-3329
FAX (401) 861-5751

SAMOA
Associate Director, Public Health Nursing
Department of Health
Pago Pago, American Samoa 96799
Telephone 011-684-4606/5318
FAX 011-684-633-5379

SOUTH CAROLINA
ASSIST Project, Center for Health Promotion
South Carolina Department of Health and Environmental Control
2600 Bull St.
Columbia, SC 29201
Telephone (803) 734-4446
FAX (803) 253-4001

SOUTH DAKOTA
South Dakota Department of Human Services
Division of Alcohol and Drugs
3800 E. Hwy. 34; Hillsview Plaza
Pierre, SD 57501
Telephone (605) 773-3123
FAX (605) 773-5483

TENNESSEE
Tennessee Department of Health
Health Promotion/Disease Control
Tennessee Tower Bldg., 13th Floor
312 8th Ave., N.
Nashville, TN 37247-5201
Telephone (615) 741-7366
FAX (615) 532-8478

TEXAS
Office of Smoking and Health
Texas Department of Health
1100 W. 49th St.

Austin, TX 78756-3199
Telephone (512) 458-7402
FAX (512) 458-7618

UTAH
Statewide Risk Reduction
Utah Department of Health
288 N. 1460, W.
Salt Lake City, UT 84116-0660
Telephone (801) 538-6270
FAX (801) 538-6036

VERMONT
Tobacco Control Coordinator
Health Promotion/Epidemiology Division
Vermont Department of Health
P.O. Box 70
Burlington, VT 05402
Telephone (802) 865-7783l
FAX (802) 863-7425

VIRGIN ISLANDS
Virgin Islands Department of Social and Health Services
Charles Harword Complex, Rm. E-25
Christiansted, St. Croix, VI 00820
Telephone (809)774-7700
FAX (809)774-4701

VIRGINIA
Virginia Department of Health
1500 E. Main St.
P.O. Box 2448, Suite 245
Richmond, VA 23218-2448
Telephone (804) 786-3551
FAX (804) 371-6152

WASHINGTON
ASSIST Project, Heart Disease and Cancer Prevention
Department of Social and Health Services
Airdustrial Park, 10, P.O. Box 47835
Olympia, WA 98504-7835
Telephone (206) 586-6082
FAX (206) 664-8779

Federal Express Address:
Drop P.O. Box

WEST VIRGINIA
Program Manager
ASSIST Project
West Virginia Department of Health and Human Resources
1411 Virginia St., E.
Charleston, WV 25301
Telephone (304) 558-0644
FAX (304) 558-1553

WISCONSIN
ASSIST Project
Wisconsin Division of Health
1400 E. Washington Ave., Rm. 240
Madison, WI 53703-3041
Telephone (608) 266-8322
FAX (608) 266-8925

WYOMING
Program Manager
Health Risk Reduction
Wyoming Department of Health
Hathaway Bldg, 4th Fl.
Cheyenne, WY 82002
Telephone (307) 777-5949
FAX (307) 777-5402

ASTHO HEADQUARTERS
Director, Tobacco Control Projects
415 Second St., N.E.
Suite 200
Washington, DC 20002
Telephone (202) 546-5400
FAX (202) 544-9349

Index

A

Abstinence, iii, 1, 2, 24, 70
Acupuncture, 48–50
Adolescents. *See also* Special populations
  smoking prevalence in, 5
  treatment of, 8, 77–79
"All-comers," 13, 16, 38, 91
Antidepressants, 59
Anxiolytics, 60, 91
Assessment
  followup, 60–61
  of smoking status, 6, 8, 35, 38–39, 40–42, 63
  specialized, 94
Aversive smoking, 27, 47–48, 91

B

Benzodiazepines, 60
Biochemical confirmation, 12, 16, 38, 91
Buspirone, 60

C

Cessation
  percentage, 14, 15, 91
Children
  smoking prevalence in, 5
  treatment of, 8, 77–79
Clonidine, 52, 59, 91
Community programs, 45
Cost-effectiveness, 27–28, 29
Counseling, 68, 70
  group, 27, 28, 43, 44, 92
  individual, 27, 28, 43, 44, 92
  telephone, 25, 44
Cue exposure/extinction, 48, 49, 92

D

Diazepam, 60, 92
Disability, 5, 6
Disease, smoking-related, 5, 69
Duration of treatment, 1, 14–15, 35, 50–52

E

Ethnic groups. *See* Special populations
Exercise, 61, 76, 92

F

Focused smoking. *See* Aversive smoking

G

Gender. *See* Special populations

H

Health care administrators, 1, 2, 6, 9, 20, 21, 26–33
Health care insurers, 1, 2, 6, 9, 20, 21, 26–33
Health care purchasers, 1, 2, 6, 9, 20, 21, 26–33
HMO. *See* Managed care
Hospital policies. *See* Institutional policies
Hospitalized smokers. *See* Special populations
Hotline/helpline, 44, 45, 92
Hypnosis, 48, 49

I

Identifying smokers, iii, 21, 35, 38, 39, 41, 63
Institutional policies, 29
Insurance coverage, 26–27, 29, 61
Intent-to-treat analysis, 11, 38, 92

L

Logistic regression, 12, 13, 92
Low-tar/low-nicotine cigarettes, 64

M

Managed care, 2, 26, 61
Minimal contact interventions, 47, 70, 92
Minimal practice interventions, 64–65
Minorities. *See* Special populations
Motivation to quit, iii, 3, 8, 48
Motivational intervention, 3, 19, 21, 63, 93
  during followup, 60–61
  for pregnant smokers, 69, 71

N

Nasal inhaler, 57
Nasal spray, iii, 57
Negative affect intervention, 48, 93
Nicotine gum, 16, 24, 27, 28, 32, 41, 52–54, 56–59, 61, 75
  chewing technique for, 58
  dosage for, 58
  precautions for, 58
  prescribing instructions for, 58
Nicotine patch, 16, 24, 27, 28, 32, 52–57, 59, 72, 93, 95
  dosage for, 55
  precautions for, 55
  prescribing instructions for, 55
Nicotine replacement therapy, iii, 1, 40, 41, 52–59, 67, 69, 71, 75, 77, 79
  clinical guidelines for, 56
  starter kits, 31, 94

O

Oral mucosa, 58, 93

P

Person-to-person intervention, 16, 35, 44, 46–47, 50–52, 70, 93
Pharmacotherapy, 12, 19, 52–60
  for adolescent and younger smokers, 79
  and health care administrators, insurers, and purchasers, 26–27, 29
  for smokeless tobacco users, 77
Placebo, 16, 48, 50, 53, 57
Pregnant smokers. *See* Special populations
Prescriptive interventions, 65–66
Prevalence, 1, 2, 5, 6
Primary care clinicians, 1, 2, 3, 6, 9, 19–22, 39, 61, 93
Problem-solving techniques, 2, 28, 42, 47, 48, 65, 93
Propranolol, 60, 94
Psychiatric comorbidity, 25, 27, 48, 72–74
Psychosocial interventions, 27, 28, 37, 46, 53, 54, 60, 79
Public health impact, 3, 40

Q

Quit
  date, 21, 24, 63
  day, 11, 94

R

Rapid puffing. *See* Aversive smoking
Rapid smoking. *See* Aversive smoking
Reimbursement, 1, 19, 20, 29–33, 61
Relapse, 24, 42, 48, 60, 63, 70, 71
  prevention, iii, 47, 60, 63–66, 71, 93

S

Satiation smoking. *See* Aversive smoking
Screening, 12, 35, 38–39, 48, 91
Self-help treatment, 12, 42, 43, 44–46, 68, 92, 94
Self-reported abstinence, 12
Serum cotinine, 41, 94
Serum nicotine, 41, 94
Silver acetate, 60, 94
Skills training, iii, 2, 23, 47, 48, 93
Smoke-free environment, 24, 72
Smokeless tobacco, 8, 64, 78
  users, 2, 67, 76–77
Smoking cessation specialists. See Tobacco cessation specialists

Social support, iii, 1, 47, 48, 92
Special populations
by age, 5, 8, 27, 77–79
by ethnicity, 8, 27, 67–69
by gender, 27, 67
by hospitalized patients, 8, 32, 70–72
by pregnancy, 12, 27, 38, 40, 55, 56, 67, 69–70, 71
by race, 8, 27, 67–69
Stepped care, 25, 94

T

Tobacco cessation specialists, iii, 1, 2, 6, 9, 23–26
Training for clinicians, 20
Transdermal nicotine. *See* Nicotine patch
Treatment matching, 25, 95

W

Weight gain, 8, 65, 66, 74–76
Withdrawal symptoms, 24, 56, 72, 73

Notes

*U.S.G.P.O.: 1996-399-922S

ISBN 0-16-048610-6

Availability of Guidelines

For each clinical practice guideline developed under the sponsorship of the Agency for Health Care Policy and Research (AHCPR), several versions are produced to meet different needs.

The *Clinical Practice Guideline* presents recommendations for health care providers with brief supporting information, tables and figures, and pertinent references.

The Quick Reference Guide for Smoking Cessation Specialists is a distilled version of the *Clinical Practice Guideline*, with summary points for ready reference on a day-to-day basis. The *Quick Reference Guide for Primary Care Clinicians* contains information from the *Clinical Practice Guideline* presented in an even more condensed version as a pocket guide for the busy clinician.

The *Consumer Version*, available in English and Spanish, is an information booklet for the general public to increase consumer knowledge and involvement in health care decisionmaking.

To order single copies of guideline products and the meta-analysis reference list or to obtain further information on their availability, call the AHCPR Publications Clearinghouse toll-free at 800-358-9295 or write to: AHCPR Publications Clearinghouse, P.O. Box 8547, Silver Spring, MD 20907.

Single copies of the *Clinical Practice Guideline* are available for sale from the Government Printing Office, Superintendent of Documents, Washington, DC 20402, with a 25-percent discount given for bulk orders of 100 copies or more. The quick reference guides and the *Consumer Version* in English and Spanish are also available for sale in bulk quantities only. Call (202) 512-1800 for price and ordering information.

The *Guideline Technical Report* contains complete supporting materials for the *Clinical Practice Guideline*, including background information, methodology, literature review, scientific evidence tables, recommendations for research, and a comprehensive bibliography. It is available from the Nati… …ervice, 5285 Port Royal Road, Springfield, VA 2… price and ordering information.

…ents and the meta-analysis references for … …nternet through the AHCPR Web site. Acc… …ing a Web browser, specifying URL http… …cking on "Clinical Practice Guidelines Onl…

(AI… Access for Clinical Practice Guidelines …) and copies of the *Quick Reference Guide for… …ersion* of each guideline are available thr… …ax-on-demand service that operates 24 ho… …PR's InstantFAX is accessible to anyone usi… …d with a touchtone telephone handset: Dial (3… …n press the facsimile machine's start button fo… …ntly available publications.

U.S. Department of Health and Human Services
Public Health Service
Agency for Health Care Policy and Research
2101 East Jefferson Street, Suite 501
Rockville, MD 20852

AHCPR Publication No. 96-0692
April 1996